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ABSTRACT 
Blood transfusion enhances graft survival in renal transplant 
recipients. The mechanisms involved are unclear, but suppression of 
cell- mediated immunity plays a central role. This has led to the 
suggestion that blood transfusion may cause immunosuppression in 
cancer patients and this could have a detrimental effect on their 
survival. 
A retrospective study of 314 patients who had bowel resection for 
colorectal cancer was performed. Transfused patients had a poorer 
five year survival rate, but this was probably related to the fact 
that over 90% of patients with low rectal carcinoma who had an 
abdomino -perineal resection were transfused. Subsequently, the 
patients who had abdomino -perineal resections were excluded to limit 
analysis to the 159 patients who had abdominal resections. The 
5 -year survival was 34% in those transfused, compared with 47% in 
those who were not, but this was not a significant difference. 
In the experimental research the aim was to establish a model of 
colonic cancer in which blood transfusion caused immunosuppression. 
Analysis of peripheral T cell subsets has been used to assess 
suppression of cell -mediated immunity. Subsets were counted using 
flow cytometry and monoclonal antibodies to T lymphocytes. There 
were no significant changes in subsets after transfusion with blood 
in normal rats. However, in older rats, transfusion with blood 
caused a significant increase in suppressor cells. 
Blood transfusion enhances growth of transplanted tumours in animals 
and recent evidence implicated macrophage prostaglandin E2 as a 
mediator of transfusion- mediated immunosuppression. The next 
objective was to study the influence of blood transfusion on the 
course of colonic carcinogeneis and the possible abrogating effects 
of indomethacin. This study confirmed that blood transfusion 
enhanced dimethylhydrazine carcinogenesis and suggested that treated 
rats with indomethacin, a prostaglandin synthetase inhibitor, at the 
time of transfusion may abrogate this effect. 
Using a rat peritoneal macrophage model, it was shown that blood 
transfusion increased prostaglandin E2 production by these cells in 
vitro. Allogeneic serum caused the greatest increase, while 
transfusion with stored allogeneic and syngeneic blood both caused 
an increase in prostaglandin E2 production. This suggests 
immunomodulation by factors associated with storage of blood in 
addition to a genetic effect. 
In conclusion, there is evidence that blood transfusion is 
associated with reduced survival of colorectal cancer patients, but 
this may be due to more advanced malignancy in transfused patients. 
Blood transfusion enhances colonic carcinogenesis in rats and this 
may be abrogated by indomethacin. Blood transfusion increased 
prostaglandin E2 production by macrophages and this supports the 
theory that transfusion associated immunosuppression may be mediated 
by this effect. 
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1. PREFACE 
The first aim of this research was to test the theory that blood 
transfusion has detrimental effects in colorectal cancer. A 
retrospective clinical study of patients undergoing surgery for 
colorectal cancer suggested that blood transfusion may be associated 
with poorer survival. The aim of the experimental work was to 
establish an animal model in which the effects of blood transfusion 
on colonic cancer could be studied. It was shown that blood 
transfusion enhanced colonic carcinogenesis. Enumeration of T cell 
subsets was used to assess changes in the immune system. In normal 
rats blood transfusion did not alter these, but in older rats blood 
transfusion changed the T cell subsets in a manner suggestive of 
immunosuppression. The blood transfusion effect may be mediated by 
a mechanism involving increased synthesis of prostaglandins by 
macrophages. This possibility was investigated, and evidence to 
support this theory was found in this experimental model. Increased 
prostaglandin synthesis was greater in stored rather than fresh 
blood irrespective of the histocompatibility of the transfused 
blood. 
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3. SYNOPSIS 
Blood transfusion enhances graft survival in renal transplant 
recipients. The mechanisms involved are unclear, but suppression of 
cell- mediated immunity may play a central role. This has led to the 
suggestion that blood transfusion may cause immunosuppression in 
cancer patients and this could have a detrimental effect on their 
survival. 
A retrospective study of 314 patients who had bowel resection for 
colorectal cancer was performed. Complete records were retrieved 
for 302 patients. Of these, 236 had potentially curative 
resections. In this group, transfused patients had a poorer five 
year survival rate, but this appeared to be due to a larger number 
of low rectal tumours treated by abdomino -perineal resections, and a 
higher incidnce of other adverse prognostic variables in the 
transfused group. 
The first aim of the experimental work was to establish a model of 
colonic cancer in which blood transfusion caused immunosuppression. 
Analysis of peripheral T cell subsets has been used to assess 
suppression of cell mediated immunity. The role of T cell subset 
analysis was studied in the dimethylhydrazine (DMH) colonic 
carcinogenesis model in rats. Subsets were counted using flow 
cytometry and monoclonal antibodies to T lymphocytes. Three weekly 
transfusions were given of allogeneic blood or saline. There were 
no significant changes in subsets and after transfusion with blood 
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in normal rats. In older rats, transfusion with blood caused a 
significant increase in suppressor cells. Subset changes were not 
seen in rats receiving DMH injections. Helper subsets were higher 
in rats with advanced malignancy compared with age- matched controls. 
Blood transfusion enhances growth of transplanted tumours in 
animals. The next objective was to study the influence of blood 
transfusion on the course of colonic carcinogenesis. Sprague Dawley 
rats were given 16 weekly injections of DMH. During week 8 they 
were randomly divided into two groups. Group 1 were given three 
weekly transfusions of blood from DA rats and Group 2 were given 
saline. All rats were killed at 28 weeks and rats transfused with 
blood had more large bowel tumours than those transfused with 
saline. Histological analysis was complicated by the close 
proximity of individual tumours and alterations to the experimental 
model were made in subsequent experiments to avoid this problem. 
An experiment was designed to examine the influence of blood 
transfusion on prostaglandin production by rat peritoneal 
macrophages. Allogeneic blood increased prostaglandin E2 production 
and this effect was larger in stored blood, but greatest in serum. 
Transfusion with stored syngeneic blood was also associated with 
increased prostaglandin synthesis. 
Macrophage prostaglandin production may be increased by blood 
transfusion and this potentially immunosuppressive effect may be 
reversed by indomethacin. Treating rats with indomethacin, a 
prostaglandin synthetase inhibitor, at the time of transfusion 
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probably reverses the enhancing effect on carcinogenesis. This 
experiment confirmed (by histopathology) that blood transfusion 
enhanced colon carcinogenesis. 
In conclusion, there is evidence that blood transfusion may have a 
detrimental effect on survival of colorectal cancer patients, 
although transfused patients seemed to have more advanced disease. 
Blood transfusion enhances DMH colonic carcinogenesis in rats, but 
it was not shown that this may be reversed with indomethacin. 
Allogeneic blood transfusion results in increased prostaglandin E2 
production by rat peritoneal macrophages and storage conditions of 
blood may contribute to this. 
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4.1. HISTORY OF BLOOD TRANSFUSION 
Blood transfusion dates back to 1490 when Pope Innocent VIII was 
given blood drained from the veins of a youth. It is said that the 
Pope died together with three youths who were the blood donors. The 
first successful blood transfusion is credited to Richard Lower in 
1667. Most blood transfusions which followed this ended in 
fatality. In 1900 Karl Landsteiner discovered blood groups. George 
Crile performed successful blood transfusion in 1907. However, 
there were still many deaths resulting from incompatible 
transfusion. The Rhesus factor was discovered in 1940 by 
Landsteiner and blood transfusion subsequently became safer. The 
anticoagulant properties of sodium citrate were recognised in 1914. 
The concept of the blood bank became a reality around the time of 
the Spanish Civil War. 
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4.2. BLOOD TRANSFUSION AND TRANSPLANTATION 
4.2.1. The transfusion "effect" 
Patients with chronic renal failure often develop anaemia. This is 
usually normocytic and normchromic in nature. This type of anaemia 
is particularly marked when the patients are treated with 
haemodialysis rather than peritoneal dialysis. Patients with renal 
failure can be maintained on haemodialysis for many years. Many of 
these patients will require blood transfusion for symptomatic relief 
of anaemia. In the early days of dialysis transfusions were given 
liberally. However, in 1966 Kissemeyer -Nielsen and colleagues 
reported two cases of hyperacute rejection of renal transplants. 
They found lymphocytotoxic antibodies in the preoperative serum of 
the recipients (Kissemeyer- Nielsen, 1966). It was said that these 
patients had been "heavily isoimmunised by blood transfusions" and 
they suggested that the pretransplant transfusions were responsible 
for the production of the lymphocytotoxic antibodies which were 
directed against the donor cells. This finding resulted in highly 
restrictive transfusion policies for potential renal transplant 
recipients. It also led to a greater use of lymphocyte crossmatches 
which are so important in renal transplantation today. It was 
subsequently confirmed that patients waiting for a renal transplant 
who have preformed lymphocytotoxic antibodies in their serum have a 
smaller chance of receiving a successful graft ( Opelz and Terasaki, 
1972). Opelz also studied cytotoxic antibodies in patients who were 
regularly transfused while on haemodialysis (Opelz et al, 1972). 
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Patients with no demonstrable cytotoxic antibodies for more than one 
year before transplantation had a significantly better graft 
survival than patients who had no cytotoxic antibodies for less than 
a year prior to transplantation. Cytotoxic antibodies only 
developed in half of the patients who received regular blood 
transfusions. They suggested that those patients who did not 
develop antibodies represented a group of "non- responders" who were 
more likely to accept a renal graft. 
In 1973, Gerhard Opelz and his co- workers reported retrospective 
studies on a group of 148 renal transplant recipients (Opelz et al, 
1973). They were surprised to find that 57 patients with a total of 
more than ten pre -transplant transfusions had the highest survival 
compared to patients not transfused (n =25) and transfused patients 
who received less than ten transfusions of blood (n =66). The 
one -year graft survival rate for the heavily transfused group was 
66% compared with 43% for the patients receiving one to ten 
transfusions and 29% for non -transfused patients. Several 
retrospective studies followed and these confirmed the beneficial 
effect of blood transfusion. There has only been one attempt to 
compare pretransplant transfusion with no transfusion using a 
prospective randomised trial protocol (Bucin et al, 1981). This 
confirmed a beneficial effect associated with transfusion. 
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4.2.2. Mechanisms 
Much research has been directed towards identifying the mechanisms 
involved in mediating the beneficial effects of blood transfusion on 
renal graft survival. Fifteen years have passed and the problem has 
not been solved. Multiple mechanisms may be involved because no one 
theory adequately explains all the known effects of blood 
transfusion. Some of this work will be reviewed to illustrate the 
theories which have been put forward. 
4.2.2a. Antiidiotypic antibodies 
Blood transfusion may induce donor -specific antibody directed 
against HLA -DR antigens (antiidiotypic antibodies) on the donor 
lymphocytes. This would enhance graft survival. Morris et al 
reported 14 successful renal transplants in the presence of a 
positive B- lymphocyte cross -match against donor tissue (Morris et 
al, 1978). These findings do not support the selection theory which 
suggests that blood transfusion induces alloantibodies and 
this only allows the patient to receive a kidney which is more 
likely to be accepted. This means that only non -responders would be 
selected because of their inability to produce lymphocytotoxic 
antibodies. 
Singal and Joseph (1982) tested sera from renal transplant 
recipients to study the effects of blood transfusions on the 
Page 18 
induction of antibodies directed against recognition sites on T 
lymphocytes. They found that blood transfusion induced antibodies 
capable of inhibiting proliferative responses in mixed lymphocyte 
culture against antigens present on the kidney donor. However, such 
antigens were not present in patients who had rejected the 
transplant. This suggested that these antibodies which were induced 
by transfusion may have been associated with prolonged graft 
survival. More recently Keown et al (1983) have shown that in a 
series of eighteen patients who had not previously been transplanted 
the incidence of cytotoxic antibodies to a T lymphocyte panel was 
only 2 %. These patients did not develop broadly reactive anti -HLA 
antibodies after transfusion. Within the first week after 
transfusion there was a significant decrease in the mixed lymphocyte 
culture response of the recipient after stimulation with donor or 
third party lymphocytes. However, this effect was transient and 
levels of response returned to normal two weeks after transfusion. 
In multiparous females and in patients sensitised by a previous 
graft which had been rejected, blood transfusion induced antibodies 
against T and B lymphocytes. In this group cytotoxic activity in 
mixed lymphocyte culture was increased. 
4.2.2b. Non -specific immunosuppression 
Non -specific immunosuppression by macrophages has been suggested 
(Keown and Descamps, 1979). They suggested that endocytosis of 
damaged red cells from the transfused blood impaired normal 
mononuclear phagocytic function. They postulated that endocytosis 
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might generate prostaglandin which could induce suppressor cells. 
Watson et al (1979) measured cell- mediated immunity by skin testing 
with dinitrochlorobenzene. The degree of skin reaction to this 
chemical is a measure of cell- mediated immune function. They found 
that patients with weak reactions had a higher graft survival after 
transplantation and that the weak responders had had more 
pretransplant transfusions. In fact the patients who were weak 
responders were more anaemic than strong responders so these 
findings could not support a theory which suggested that blood 
transfusion caused a general suppression of cell -mediated immunity. 
4.2.2c. Lymphocyte responses 
Another group assessed cell -mediated immunity by measuring the 
lymphocyte responses to mitogenic and antigenic stimulation (Fischer 
et al, 1980). Non -transfused prospective kidney transplant 
recipients were transfused with washed red cells. They found a 
reduced lymphocyte response after transfusion. A second transfusion 
led to a more pronounced and prolonged suppression of this response. 
Normal volunteers were given transfusions of autologous blood, but 
no suppression of cell mediated immunity was found. 
Kerman et al (1982) assessed cellular immunity by testing 
spontaneous lymphocyte blastogenesis, skin test antigen responses, 
lymphocyte response to alloantigen and mononuclear suppressor cell 
activity. Patients who received more than five pretransplant 
transfusions were found to be weak immune responders and have a 
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strong in vitro suppressor cell function. They suggested that these 
"traits" may explain the beneficial effect of transfusion on graft 
survival. 
4.2.2d. Suppressor cells 
A group in Cardiff showed that blood transfusion was associated with 
increased suppressor cell function in patients undergoing 
haemodialysis (Smith et al, 1983). This method involved Con -A 
lymphocyte stimulation before and after cell culture. Suppressive 
activity is lost during culture, but is retained if suppressor 
activity is high. Lenhard et al (1982) showed that blood 
transfusion suppressed the mixed lymphocytic reaction and increased 
the number of monocytes. The mixed lymphocytic reaction returned to 
normal after removal of the monocytes. They suggested that 
monocytes act as suppressor cells. They also found that T cell 
suppressor activity increased later on in the post- transfusion 
period suggesting that at least two immunoregulatory mechanisms may 
be induced by blood transfusion. 
Another theory suggests a two stage process (van Rood, 1983). 
Firstly there is a non -specific suppression of cytotoxic lymphocyte 
reactivity and induction of anti -HLA class I (A,B,C) antibodies. 
Then specific anti -HLA antibodies are produced which prevent 
activation of T lymphocytes by class I and class II (D,DR) in the 
donor blood. These antibodies may subsequently block host T 
lymphocyte activation in response to class I antigens on the graft. 
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This theory explains why transfusion with HLA- matched blood exerts 
no beneficial effect on graft survival (Albert et al, 1981). It 
must be noted that HLA typing at that time only allowed 
classification of class I antigens and HLA -D,DR typing could not be 
performed on the patients involved. 
4.2.2e. Clonal deletion theory 
Terasaki (1984) proposed the clonal deletion theory. This suggests 
that blood transfusion can exert a beneficial effect only in the 
presence of immunosuppressive therapy. Multiple blood transfusions 
will sensitise recipients to a wide range of antigen. After 
transplantation a rapid immune response is directed against 
previously encountered antigens present on the graft. However, the 
presence of immunosuppressive therapy at the time of grafting 
deletes the clones of reactive lymphocytes. 
4.2.3. Amount, type, and timing of the transfusion 
Do the amount, type and timing of blood transfusion influence the 
observed beneficial effect? Stiller et al (1978) reported that 
transfusion given on the day of transplantation improved graft 
survival in patients who had not been transfused previously and also 
in patients who had received pretransplant transfusions. This 
retrospective study also confirmed the beneficial effect of 
pretransplant transfusion on graft survival at one year (71% for 
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transfused and 40% for non -transfused). Corry et al (1980) found 
that transfusions given at the time of surgery had a beneficial 
effect, but other studies have failed to confirm this (Opelz and 
Terasaki, 1981). Hourmant et al (1979) demonstrated a small benefit 
in patients transfused within three months prior to transplantation 
compared with patients transfused at an earlier stage. 
Pretransplant transfusion usually consists of whole blood or packed 
red cells. Both types of blood improve graft survival. Packed 
cells possiby exert a greater effect than whole blood and frozen 
blood preparations do not influence graft outcome (Opelz and 
Terasaki, 1980). Leucocyte -free blood can be produced by filtering 
with cotton wool and it does not have an effect on graft survival 
(Persijn et al, 1979). The same report showed that leucocyte -poor 
blood (washed red cells) did exert a beneficial effect. Rapaport 
and Dausset (1983) have demonstrated that blood leucocyte extracts 
enhance skin allograft survival in humans. The leucocytes express 
HLA antigens whereas red blood cells do not (the situation differs 
in rats and mice where histocompatibility antigens are also present 
on red blood cells). 
The benefit on graft survival increases with the number of 
transfusions given (Opelz and Terasaki, 1978). This has been 
confirmed by several studies. Opelz reviewed data from 200 
transplant centres and was able to study nearly 7000 transplant 
recipients (Opelz, 1985). Patients who had received six to ten 
transfusions had the highest one year survival rates. However, 
patients who had received more than ten transfusions had a lower 
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graft survival rate. 
4.2.4 Live donor renal transplantation 
Salvatierra first reported the beneficial effects of donor specific 
transfusion in live -related donor renal transplants (Salvatierra et 
al, 1980). This study demonstrated a highly significant survival 
advantage for transfused recipients of a one HLA- haplotype matched 
live related donor kidney. Similar effects have been demonstrated by 
others (Glass et al, 1985). A hazard of donor specific transfusion 
is sensitisation with the appearance of anti -donor T lymphocyte 
antibodies which will contraindicate the intended transplantation. 
This may occur in up to 30% of cases, but anti -donor sensitisation 
can be abolished by concomitant administration of cyclosporin with 
donor specific transfusion prior to transplantation; however, donor 
specific transfusion may be associated with earlier rejection 
episodes (Sells et al, 1989). The situation is confused by the 
recent finding that when compared with random donor transfusions, 
donor specific transfusion may not have a superior beneficial effect 
(Opelz, 1989). This study also indicated that the transfusion effect 
present at one year after transplant was not seen at three years 
i.e. transfused and non -transfused patients had similar long -term 
graft survival rates. 
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4.2.5 Transfusion, transplantation and cyclosporin 
The latest update on the Collaborative Transplant Study published in 
1989 indicates that the influence of pretransplant transfusion on 
graft survival has been diminishing since 1984 (Opelz, 1989). This 
study includes 17,000 patients (90% were transfused) and still 
demonstrates a small significant beneficial effect associated with 
transfusion, but it would seem that the risks of sensitisation and 
disease transmission may now outweigh this small advantage 
(Anonymous, 1990). 
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4.3. BLOOD TRANSFUSION AND EXPERIMENTAL CANCER 
4.3.1. History 
Experimental evidence that blood transfusion influences tumour 
growth dates back to the early 1950's when Snell (1955) reported 
that blood transfusion enhanced the growth of tumour transplants in 
mice. 
4.3.2. Blood transfusion enhances tumour growth 
Previous work had shown that pretreatment with some tissue 
preparations could produce tolerance of tumour transplants in host 
mice when these tissues or their extracts were injected 
intraperitoneally (Snell, 1954; Kandutsch, 1959). The tissue 
preparations included tumour, spleen and kidney. The tumour used in 
the experiments was a mouse sarcoma. The recipient mice of the 
tumour graft were transfused with whole blood from the same strain 
of mouse used as a source of the sarcoma. Results were expressed as 
the proportion of mice dying from progressive tumour growth. 
Intravenous blood transfusion was the most effective regime and 
consisted of five transfusions. In this group of mice there were 
26/27 deaths. A second group of mice received five intraperitoneal 
injections of blood: 11/20 deaths occurred. Spleen and renal tissue 
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preparations, also syngeneic with the sarcoma, did not produce a 
similar effect. A control group had 0/19 deaths following tumour 
transplant. Therefore, in this sarcoma transplant model virtually 
complete tolerance to grafts of sarcoma (and early death) were 
obtained by donor specific whole blood transfusion. At the time it 
was known that whole blood could produce immunity to homografts and 
the authors concluded this paper with the statement, "the factors 
involved in the production of tolerance instead of immunity in this 
particular experimental situation are still largely obscure ". 
Workers from Sapporo, Japan used a rat model to investigate 
allogeneic blood transfusion and anti -tumour immunity in rats 
(Oikawa, 1977). Immunisation consisted of one 2 ml intravenous 
injection of donor blood given 7 days before tumour implantation. 
The tumour used was a fibrosarcoma induced by a subcutaneous 
injection of 3- methyl- cholanthrene in syngeneic rats. Inhibition of 
tumour growth was seen with four strains of allogeneic donor blood. 
However, some strains were associated with a more potent effect than 
others. White blood cells from one of the strains were treated with 
mitomycin C. This process did not appear to alter the inhibitory 
influence of blood transfusion on tumour growth. This ruled out a 
graft- versus -host reaction mediating the effect. It had been 
suggested that inhibition of tumour growth might be due to 
cross -reactive antigens between immunising cells and challenged 
tumours. The authors looked for cross -reactive antigens by 
cytotoxicity and immunofluorescent tests, but found none. They 
concluded that the mechanism of inhibition of tumour growth may be 
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due to a non- specific immunostimulation of the host by immunisation 
with alloantigens. 
After Opelz had published data on the beneficial effects of blood 
transfusion in renal transplant recipients in 1981 and Gantt had 
suggested that blood transfusion may enhance the growth of tumours 
in patients with cancer, Francis and Shenton (Newcastle) published a 
brief report on their animal experiments (Francis, 1981). 
They used three groups of five Wistar rats and transfused these rats 
prior to subcutaneous injection of a tumour homogenate derived from 
a methylcholanthrene- induced sarcoma. One group was transfused with 
two 2ml injections of whole blood three days apart, the blood being 
allogeneic for the recipient strain. The second group received 
similar transfusion with syngeneic blood while the third group 
received saline. They measured the growth of the tumour and then 
excised and weighed the tumour at 14 days. They took blood samples 
at intervals to measure peripheral blood lymphocyte responses to 
purified protein derivative of old tuberculin and 
phytohaemagglutinin. The plasma suppressive activity was also 
measured (Veitch, 1978). 
They reported that plasma suppressive activity was increased and 
that lymphocyte reactivity was reduced after transfusion with 
allogeneic blood, but not after syngeneic blood or saline 
transfusion. The rate of tumour growth and the final weight of the 
excised tumour were significantly greater in the group transfused 
with allogeneic blood than in the other two groups. There were no 
Page 28 
differences between the group transfused with syngeneic blood and 
the group transfused with saline. 
This work was also reported later elsewhere in abstract form 
(Francis, 1982a). Francis et al expanded their experimental groups 
to twelve rats in each and found similar results to those cited 
above (Francis, 1982b) . 
Hormini and co- workers (Okayama) investigated the influence of blood 
transfusion on transplanted tumours in mice (Hormini, 1983). The 
tumour transplants were a hepatoma originating in C3H /He mice and a 
lung carcinoma in Lewis mice. Suspensions of cells from these 
tumours were injected subcutaneously into various strains of mice 
which were either syngeneic or allogeneic with the strain from which 
the tumour cells were derived. Blood transfusion consisted of one 
0.3 ml intravenous injection of whole blood or saline or various 
blood components. These blood components were red cells, B 
lymphocytes, T lymphocytes, thymus cells and plasma. Tumour growth 
was determined by measurement of the diameters at intervals. They 
found that some, but not all of the allogeneic transfusions promoted 
tumour growth in the recipients. Recipients transfused with 
syngeneic blood showed no increase in tumour growth compared with 
rats transfused with saline. 
Components of allogeneic blood known to have positive effect on 
tumour growth were then transfused. The red cell only component 
did not accelerate tumour growth. T lymphocyte, thymus cell and B 
lymphocyte components greatly increased tumour growth. Plasma was 
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found to have the most potent effect. These findings are at 
variance with those of Jeekel. This can be explained partially by 
the fact that both animals and tumours used were different. 
A further series of experiments were reported in a Japanese journal 
by the same group from Okayama (Kagawa, 1984). However, the English 
abstract suggests that their findings were very similar to Hormini's 
results. 
Singh, Marquet, Jeekel et al (Rotterdam) used a rat model to 
investigate the effetcs of surgery and blood transfusion on the 
growth of established tumour metastases (Singh, 1987). They used a 
different tumour model to that previously studied (Jeekel, 1982). 
This new tumour was a "nonimmunogenic ", spontaneous sarcoma in BN 
rats. The tumour was maintained in cell culture and tumour cell 
suspensions were injected intravenously. This procedure resulted in 
pulmonary metastatic deposits which could be counted. The surgery 
comprised a small bowel resection under ether anaesthesia. Blood 
transfusion consisted of a single intravenous injection of 1m1 of 
syngeneic or allogeneic blood. This injection was given at either 
seven days before or seven days after injection with tumour cells. 
Syngeneic blood transfusions and surgery (alone or combined) had no 
effect on tumour growth. However, allogeneic blood transfusion 
significantly increased the number of lung deposits. This effect 
was even greater when allogeneic blood transfusion was combined with 
surgery. However, allogeneic blood did not exert this effect 
(described as the effect on the "take" of tumour cells) when given 
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seven days before tumour inoculation. Tumour take was increased by 
surgery (bowel resection) on the day of tumour inoculation, but 
surgery alone did not influence the growth of established 
metastases. 
The same group from Rotterdam assesed the effect of a single blood 
transfusion on the formation of lung metastases in rats (Marquet, 
1986). In rats with established metastases, allogeneic transfusion 
stimulated the growth of these tumour deposits. However, using 
different strains of rats they found that blood transfusion 
inhibited the development of new metastases. Further studies by 
this group demonostrated that surgical trauma increased the 
enhancing effect of allogeneic blood transfusion on development of 
lung metastases after injection of sarcoma cells (Marquet et al, 
1989). 
Clarke and Tarin (Oxford) studied the effect of blood transfusions 
on tumour metastases using a mouse model (Clarke, 1987). The 
subcutaneous growth rate and metastatic spread of syngeneic melanoma 
and fibrosarcoma were assessed. These tumours were maintained as 
cell lines in monolayer tissue culture. The harvested cell 
suspensions were injected subcutaneously and spontaneous lung 
metastases occurred. Blood transfusion consisted of one intravenous 
injection of 0.25m1 whole blood (allogeneic or syngeneic) 14 days 
prior to tumour inoculation. 
Compared with syngeneic blood and saline transfusion, allogeneic 
blood did not affect the growth rate of primary tumours, but did 
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increase and accelerate spontaneous metastasisation. However, this 
effect was not observed in one of the four strains of allogeneic 
blood used in the experimental groups. Similar increases in 
spontaneous metastases were seen when tumour graft recipients were 
transfused with allogeneic peripheral blood lymphocytes and 
splenocytes. This effect was again dependent on the strain of the 
allogeneic blood donor. 
This group reported further experiments which confirmed that the 
growth of the experimental UV -2237 metastases was augmented by 
transfsuion with certain strains of allogeneic blood given both 
before and after tumour inoculation (Clarke et al, 1989). Syngeneic 
blood, saline transfsuions (controls), and some strains of 
allogeneic blood did not cause this effect, however. 
Melanoma growth in a mouse model is influenced by blood transfusion 
(Francis et al, 1987). They used a transplantable B16 melanoma 
tumour in nude (athymic) mice. Normal mice and nude mice transfused 
with saline were compared with mice transfused with incompatible 
allogeneic blood. The growth rates of the transplanted tumours were 
assessed by measuring the tumour diameter at intervals and by 
weighing the excised tumour. In athymic mice there were no 
differences between the three groups. However, in normal 
immunocompetent mice allogeneic blood transfusion enhanced the rate 
of tumour engraftment and the tumours were also heavier and larger. 
The authors concluded that the blood transfusion effect depended on 
the presence of the thymus gland and that this, by implication, 
meant that cell- mediated immunity must be involved in the mechanism. 
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This group also reported in another series of experiments, which 
also used this model, that tumour weight and volume were increased 
by transfusion with allogeneic blood (Francis, 1986). This effect 
was seen only when blood was transfused before tumour cells were 
implanted. 
Waymack and Chance showed that allogeneic, but not syngeneic, 
transfusions increased the rate of tumour growth in rats implanted 
with a sarcoma when compared with the control group which had been 
transfused with saline (Waymack and Chance, 1988). These animals 
were followed until death, but there were no significant differences 
between survival times. 
Shirwadkar et al, using a fibrosarcoma pulmonoary metastases mouse 
model, found that the number of tumour cells injected influenced the 
allogeneic transfusion effect compared with syngeneic transfusions 
and a control transfusion of saline: higher numbers of pulmonary 
metastases occurred with lower numbers of tumour cells whereas 
higher numbers inhibited development of lung deposits (Shirwadkar et 
al, 1990). 
Parrott et al, demonstrated that blood transfusion enhanced growth 
of MC7 sarcoma in rats in a dose dependent manner and also that 
surgical trauma (sham laporotomy) exerted a synergistic effect on 
this (Parrott et al, 1990). Allogeneic washed cells and plasma also 
had similar effects, although they were less marked. 
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4.3.3. Blood transfusion does not enhance tumour growth 
Tsukada (1970) studied the effect of blood or blood component 
transfusion on the survival of rats transplanted with sarcoma and 
hepatoma cells. He demonstrated that blood from normal rats had an 
anti -transplantation effect. The transfused rats survived longer. 
The effect seemed to be due to leukocytes in the transfused blood. 
These effects were seen only when blood or blood components were 
transfused prior to tumour transplantation. 
Jeekel and colleagues (Rotterdam) reported further conflicting 
findings (Jeekel, 1982). They had already investigated the effects 
of transfusion in a rat heart transplant model and found that donor 
specific blood transfusion could lead to an indefinite survival of 
cardiac grafts (BN) in recipient (WAG) rats (Marquet, 1981). 
They transplanted two types of tumours in WAG rats (Marquet, 1982). 
The first was a radiation induced basal cell carcinoma and the 
second was a chemically induced carcinoma of the duodenum. Both 
these tumours were induced in BN rats. After subcutaneous 
implantation of the first tumour the doubling time was 2.5 days 
while the adenocarcinoma had a doubling time of 14 days. Blood 
transfusion consisted of a single intravenous injection of 1m1 of 
whole blood given 14 days before tumour implantation. The blood was 
either syngeneic (WAG) or allogeneic (BN) for the recipient rats. 
There were six experimental groups each containing eight rats. 
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Allogeneic (donor specific) blood transfusion caused a slight, but 
not statistically significant, inhibition of tumour growth in the 
basal cell carcinoma model. A much stronger inhibitory effect was 
found in the adenocarcinoma model. Isolated basal cell tumour cells 
were injected intravenously 14 days after transfusion in a third 
model. Allogeneic blood transfusion caused a reduction by half of 
the number of pulmonary metastatic nodules counted three weeks after 
inoculation. Syngeneic (WAG) blood did not affect transplanted 
tumour (BN) growth in the recipient (WAG) rats. The authors 
concluded that allogeneic transfusions can lead to a substantial 
reduction of tumour growth and that this observation may have 
important clinical implications. This situation can only be applied 
to clinical cases where patients have been exposed to blood products 
prior to developing cancer. This group of patients will include 
women who have been pregnant. The implication suggested by Jeekel 
cannot be applied to patients who already have cancer at the time of 
first exposure to blood transfusion, at operation for example. 
There were now several contradictory studies concerning the effect 
of blood transfusion on tumour growth. A group from Heidelberg 
attempted to clarify the situation by investigating five tumour 
models in the rat (three syngeneic, one allogeneic, and one 
autochthonous) using different transfusion regimes (Zeller, 1986). 
The autochthonous tumour was a fibrosarcoma induced by a single 6mg 
injection of benzo(a)pyrene in Sprague Dawley rats. Third party 
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blood (Lewis) was transfused according to three regimes:- i) five 
transfusions before tumour induction, ii) five transfusions after 
tumour induction and iii) five transfusions before and after tumour 
induction. A control group were transfused with saline at the same 
intervals as the latter group. The syngeneic tumours were 
ependymoma, neurinoma and adenocarcinoma of the stomach from BDIX 
rats. The blood donors for this group were Sprague Dawley rats. 
The allogeneic tumours were lymphomas from BDX rats transplanted to 
Sprague Dawley rats. The take rate, induction time, incidence and 
growth rate of these tumours were measured. T lymphocyte subsets 
and lymphocyte stimulation by Con -A were measured. The latter was 
reduced following blood transfusion, but no change was observed in 
the peripheral T lymphocyte subpopulations. 
Allogeneic or syngeneic blood transfusion did not influence tumour 
behaviour in the transplant tumour models. Allogeneic transfusion 
did not have an effect on the autochthonous chemically induced 
fibrosarcoma. This series of experiments involved large numbers of 
animals and the results are impressive. However, it should be noted 
that the transfusion protocols included five or ten transfusions. 
Possibly these were administered under general anaesthesia or some 
form of sedation. These and the general trauma of the procedures 
may have been enough to cause immunosuppression which may have 
masked more subtle changes related to the immunological effects of 
blood. 
Judson et al (1985) studied the effects of allogeneic blood 
transfusion before and after inoculation with a mammary carcinoma 
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cell line. There was no effect on survival if blood was given 
before tumour inoculation, but if the mice were transfused both 
before and after tumour inoculation, then this led to a prolonged 
survival. 
Transfused syngeneic blood did not affect growth or number of 
azoxymethane induced colonic tumours in rats compared with a saline 
transfused control (Carty et al, 1989). 
In an exentensive series of experiments involving a range of 
transplantable and autochthonous tumours (fibrosarcoma, ependymoma, 
neurinoma, adenocarcinoma and lymphoma), Lehhard et al could not 
demonstrate any effects of allogeneic and syngeneic transfusion on 
tumour growth compared with control rats which were transfused with 
saline (Lenhard et al, 1989). THey had demonstrated, however, that 
their transfusion regimes were associated with increased suppressor 
cell activity. 
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4.4. BLOOD TRANSFUSION AND COLONIC CANCER IN HUMANS 
In 1981, Gantt had noted the beneficial effect of blood transfusion 
on renal graft prognosis (Gantt, 1981). He suggested that patients 
who are transfused may be immunosuppressed "to the point where the 
malignant tumour has a better chance to survive ". He was aware that 
tumour antigens were similar to histocompatibility antigens and that 
the immunosuppression created by blood transfusions appeared to be 
non -selective for histocompatibilty antigens. 
Burrows and Tartter first drew attention to a possible detrimental 
effect of blood transfusion on survival and recurrence in colorectal 
cancer patients (Burrows, 1982). They reported a retrospective 
study of 122 patients who had undergone curative resections for 
primary colorectal cancer. Of these patients, 58 (48 %) received 
blood transfusion. The cumulative recurrence -free survival rates 
were lower in the transfused patients. The transfusion effect was 
also present when left and right colonic lesions were considered 
separately. The conclusion was that perioperative blood transfusion 
was associated with recurrence after curative colon cancer surgery. 
They suggested that blood transfusion should be avoided if possible, 
and that if transfusion was essential then leukocyte -free blood 
should be given "to avoid induction of a tolerant state" citing 
Fuller (1982). 
In response to this report, it was suggested that the observed 
difference in survival rates could be accounted for by difficulty of 
resection (Hodgson, 1982). This would be influenced by the location 
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of the tumour and by the skill and experience of the surgeon. The 
inference was that the tumours of patients requiring transfusion 
were more difficult to remove, and the operation involved more 
operative manipulation and bleeding than in the non -transfused 
group. This counter -argument has consistently been raised by 
critics of the hypothesis concerning the immunosuppressive effects 
of blood transfusion. However, subsequent retrospective studies 
have failed to address this critisism because there are no obvious 
prognostic factors which can identify a tumour which is difficult to 
resect. 
Again in response to Burrows and Tartter's paper, Opelz reviewed the 
records of the Denver Kidney Transplant -Tumor Registry (Opelz, 
1981). He found no evidence that non -specific immunosuppression by 
transfusions might lead to an increased risk of malignancies in 
kidney transplant recipients who had received plood transfusions 
compared with those who had not been transfused. 
The next retrospective study to be reported involved 206 patients 
(Agarwal, 1983). Of these 65% were transfused within a month before 
or after surgery. The recurrence rate was 48% in the transfused 
patients and only 10% in those not transfused. For these two groups 
the mean follow -up was 39 months and 46 months respectively. The 
same authors (Agarwal and Blumberg) of this abstract subsequently 
reported a retrospective study in the British Medical Journal. 
This study included the same patients, but the number analysed was 
now 197 (Blumberg, 1985). Recurrence or death due to recurrence was 
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observed in six of 68 (9 %) patients not transfused. In the 
transfused group recurrence occurred in 56 of 126 patients (43 %). 
These survival statistics were those at the end -point of the study. 
The five year recurrence -free survival was 90% and 50% 
approximately. No relationship was seen between the incidence of 
recurrence and the amount of blood transfused. This study is 
important because it was the first to use sophisticated statistical 
techniques to determine the relationship of transfusion rates with 
other variables. Using a multivariate stepwise logistic regression 
it was found that age, location of the tumour, duration of the 
operation and preoperative packed cell volume were the only factors 
tested which had a significant association with blood transfusion. 
Dukes' stage and year of operation were not associated. Tumour site 
was and of these (left, right and rectum) tumours in the rectum were 
associated with the highest incidence of transfusion while those in 
the left colon had the lowest association. 
A prospective study was performed in 1981 in Auckland, New Zealand 
(Frankish, 1985). This included 179 patients who underwent 
potentially curative surgery for colorectal cancer. Of these 59% 
were transfused and this group included significantly more rectal 
tumours and patients undergoing operations longer than two and a 
half hours. At 42 months the recurrence -free survival was 73.6% for 
transfused versus 70.4% for non -transfused patients. 
Another retrospective study used the Cox proportional hazards model 
to adjust the the two groups for differences in known prognostic 
variables (Nathanson, 1985). Between 1972 and 1977, 366 patients in 
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the Henry Ford Hospital, Detroit had curative resections for 
colorectal cancer. At 4000 days the transfused group had a survival 
rate of 43% compared with 56.5% in those not transfused. This was a 
significant difference when the logrank test was applied (p<0.005). 
However, after stage, age and sex had been adjusted for using Cox 
regression analysis, blood transfusion was not a significant 
prognostic variable. In fact the most significant prognostic 
variable in the study was the percentage of lymph nodes containing 
microscopic tumour deposits. They also found that patients with 
stage B2 tumours who were transfused had a better prognosis than 
non -transfused cases. 
Foster et al found a 68% five year survival rate for non -transfused 
compared with 51% for transfused patients in 129 patients who had 
curative resection for colorectal cancer (Foster, 1985). However, 
the logrank test failed to demonstrate a statistically significant 
difference between the two survival curves. 
Another group had been studying the effects of haemodilution on 
coagulation of blood (Blair, 1985). They had demonstrated that 
haemodilution led to a fall in haemoglobin and hypercoagulation. 
They subsequently showed that blood transfusion had an anticoagulant 
effect. It had previously been shown that anticoagulation prevented 
experimental circulating malignant cells becoming metastases 
(Hilgard, 1976). Consequently, 301 patients at St Mark's Hospital 
were studied. They reported that blood transfusion had no effect on 
survival in patients having curative resection of Dukes' A and B 
tumours. However, there was an apparent beneficial effect of blood 
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transfusion on the survival of patients with Dukes' stage C tumours. 
The five year survival for transfused patients being 65% (43/66) 
compared with 44% (14/32) for non -transfused patients. A simple chi 
squared test applied to these small numbers gave a significant 
difference (p<0.05). The other important point about this study is 
that blood transfusion was defined as blood given during the 
operation. This probably excludes a large number of patients who 
may have been susceptible to an immunosuppressive effect of blood 
transfusion giving either before or after surgery. 
The influence of tumour site on the transfusion effect was examined 
in 207 cases by separately analysing right, left and sigmoid 
colectomy operations (Ota, 1985). This study did not demonstrate a 
detrimental effect of blood transfusion on five and ten year 
survival. The five year survival was 77% (n =45) for non -transfused 
and 72% (n =162) for transfused patients. The ten year survival 
figures were 61% and 71% respectively. There was a trend which 
showed a lower survival rate as the amount of transfused blood 
increased, but this was not significant. 
Workers in Newcastle reported a series of 517 patients undergoing 
curative surgery for colorectal cancer (Parrott, 1986). They 
compared the recurrence and mortality rates in transfused and 
non - transfused groups of patients. The two groups were evenly 
matched for the major prognostic factors (age, sex, Dukes' stage and 
histological differentiation). The transfused group contained 
significantly more rectal tumours. Blood transfusion was given to 
72% of the patients. The transfused group had a mean operative 
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blood loss of 837 ml compared with 333 ml in the non -transfused 
group. Transfused patients had a significantly longer operation 
(2.37 versus 1.99 hours). The recurrence free -survival rates were 
60% for the transfused group and 76% for the non -transfused group. 
The logrank test suggested that this difference was highly 
significant. A similar trend was established when rectal lesions 
were excluded from the analysis. In this group of patients the 
probability of recurrent disease at five years was 20% greater in 
the transfused group. 
Francis, who was one of the first to demonstrate an experimental 
transfusion effect in a tumour model, reported a retrospective study 
of 87 patients (Francis, 1987). Of these 67% were transfused. The 
recurrence -free five year survival was 64% in transfused patients 
and 74% in patients not transfused. This was not a statistically 
significant difference using the logrank test. However, there was a 
significantly higher incidence of recurrence in those patients who 
received transfusion during surgery when compared with those who 
were transfused either before or after surgery. It was suggested 
that factors influencing the need for blood transfusion during 
operation had a greater effect on prognosis than blood transfusion 
as a separate prognostic variable. 
In an attempt to eliminate the epidemiological heterogeneity of 
colorectal tumours Creasy et al studied retrospectively 68 patients 
with sigmoid tumours (Creasy, 1987). The sigmoid colon was chosen 
because of the high frequency of tumours at this site and because 
about half of the patients with sigmoid tumours were transfused 
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(33/68). The five year recurrence -free survival was 53% for 
non -transfused patients and 28% for transfused patients. When the 
Cox proportional hazards regression analysis was applied it was 
found that histological stage and blood transfusion status were the 
only significant co- variants. In fact blood transfusion status was 
the most sensitive prognostic indicator fer recurrence. There was 
no association between increasing number of units transfused and 
increased risk of recurrence. However, the correspondence columns 
published brief contradictory results of another study of 99 
patients with sigmoid cancer (Kiff and Kingston, 1987). This was 
part of a prospective series of 525 patients who underwent curative 
resection for colorectal cancer. 
Bickel et al reported (briefly) a series of 188 colorectal cancer 
patients (Bickel, 1985). This study did not demonstrate a 
difference in survival statistics between transfused and 
non -transfused patients. 
A series of 281 patients was studied by a Canadian group (Corman, 
1986). Using Cox's regression analysis they found that the number 
of units of blood transfused had a strong influence on prognosis in 
patients with colorectal cancer, particularly colonic cancer. This 
blood transfusion effect was not observed when rectal tumours were 
studied separately. It was suggested that this was due to the small 
numbers of patients involved. The transfusion rate for the whole 
group was one of the highest with 84% of 236 patients being 
transfused. This group carried out further studies of rectal cancer 
which did not confirm these initial results (vide infra: Arnoux et 
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al, 1988). 
The most comprehensive retrospective study comes from the Large 
Bowel Cancer Project which is a collaborative study involving 94 
surgeons and 38 pathologists in 23 hospitals in the United Kingdom. 
In this project clinical data were collected prospectively, but the 
blood transfusion details had to be collected retrospectively. It 
appears that complete records were obtained in only a quarter of the 
total cases involved. Despite this, the series included 961 cases 
with complete data - the largest retrospective study to date 
(Cheslyn- Curtis et al, 1988, 1990). There was no survival advantage 
to patients in either group of transfused or non -transfused 
patients. Blood transfusion was more likely to be given for tumours 
in the rectum and rectosigmoid, Dukes' stage C and if there was some 
degree of tumour fixation. Of those patients who developed 
metastases, there were significant differences in the organs 
involved. Transfused patients tended to have a higher proportion of 
extra -hepatic metastases. This could be explained by the larger 
number of rectal tumours in the transfused groups. Tumours in this 
site may metastasise through the systemic venous circulation rather 
than entirely through the portal venous system. 
Beynon et al studied 519 patients with colorectal cancer (Beynon, 
1988). Recurrence was diagnosed in 214 patients; 179 of these 
patients had been transfused whilst 35 had not. The incidence of 
recurrence was significantly higher in transfused patients with an 
increased risk of both local and distant recurrence. The risk 
associated with transfusion was greatest if the patient had been 
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transfused during definitive surgery for colorectal cancer. 
Arnoux et al, studied 198 patients with rectal cancer, 96% of whom 
were transfused (Arnoux et al, 1988). It was found that the number 
of units transfused perioperatively had a detrimental effect on 
survival, and this was independent of the other analysed variables. 
Their data also indicated that the timing of transfusions may be 
important since peroperative transfusion had a greater prognostic 
significance than other transfusions. 
Stubbs et al, studied a group of 59 patients who had undergone 
curative surgery for colorectal cancer and who had been followed for 
five years with prospective data recording (Stubbs et al, 1988). 
The survival rate for transfused patients was 55% compared with 65% 
in non -transfused patients: this was not a significant difference, 
however. 
It had been suggested from animal studies that blood loss (as 
opposed to transfusion) enhanced development of metastases (Singh et 
al, cited in van Lawick van Pabst et al, 1988), however, this group 
showed that perioperative blood loss did not have prognostic 
significance in colorectal cancer patients. This study confirmed 
that perioperative blood transfusion was associated with poorer 
survival rates. 
Crowson et al, studied a group of 525 patients undergoing 
prospective follow -up after colorectal cancer surgery (Crowson et 
al, 1989). Perioperative blood transfusion had been given to 71% of 
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these patients, but this had no significant effect on outcome. 
Tiska -Rudman and colleagues (Zagreb) reported a detrimental effect 
of blood transfusion on survival in 312 patients with colorectal 
cancer (Tiska- Rudman et al, 1988). Follow -up was for 5 years, but 
over a third of the patients were lost. In transfused patients 64% 
developed metastatic disese, whereas in non -transfused patients no 
patient developed recurrence. However, non -transfused patients had 
a significantly better prognosis in terms of staging. 
Data were analysed from a prospective trial which compared two 
different resection techniques: three quarters of these patients had 
been transfused, but the 5 -year survival was the same (52 %) for both 
transfused and non -transfused (Vente et al, 1989). Wobbes' study 
was of 270 patients and showed a survival disadvantage associated 
with blood transfusion which was worse if two or more units of whole 
blood had been given (Wobbes et al, 1989). However, the transfused 
group in this study had a much higher proportion of rectal tumours 
and this could explain the observed differences. Onodera et al 
demonstrated that blood transfusion status was the strongest 
prognostic indicator equal with Dukes stage (Onodara et al, 1989). 
A small study of patients undergoing abdominoperineal resection for 
rectal cancer suggested that the need for blood transfusion in these 
cases was a significant risk factor for postoperative complications 
(Halpern et al, 1989). Hermanek et al, using multivariate analysis, 
showed no significant effects on survival of blood transfusion, but 
did find that administration of fresh frozen plasma had a highly 
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significant association with poorer survival. 
In a study of 520 patients with colorectal cancer, blood transfusion 
was significantly associated with an increased recurrence rate, but 
further analysis suggested that this could be explained by other 
variables such as emergency operations for obstruction and 
involvement of other structures with the primary tumour mass 
(Mecklin et al, 1989). 
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Table 4.1 
Influence of blood transfusion on survival in colorectal cancer 
patients 
Author n 
Year of % Survival 
%BT censor BT No BT p value 
Burrows, 1982 122 47 5 51* 84 <0.005 
Blumberg, 1985 129 43 5 57* 91 <0.0001 
Foster, 1985 146 45 5 51 68 N.S. 
Nathanson, 1985 366 54 10 43 56 <0.005 
Blair, 1985 98 ** 67 5 65 44 <0.05 
Frankish, 1985 174 59 3.5 74* 70 N.S. 
Ota, 1985 207 78 10 72 77 N.S. 
Bickel, 1985 180 53 5 N.S. 
Parrott, 1986 517 72 5 60 76 <0.005 
Corman, 1986 281 84 20 40 60 <0.02 
Francis, 1987 87 61 5 64* 74 <0.01 
Voogt, 1987 113 76 5 48 74 <0.01 
Creasy, 1987 68 * ** 49 5 28 53 <0.01 
Weiden, 1987 171 60 7 81* 73 N.S. 
Cheslyn- Curtis, 1990 961 61 8 N.S. 
Beynon, 1988 519 84 5 <0.001* 
Arnoux, 1988 198 96 decreased survival with more blood 
(continued on next page) 
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Table 4.1 (continued) 
Influence of blood transfusion on survival in colorectal cancer 
patients 




BT No BT p value 
Blumberg, 1986,88,89 197 65 5 65 97 <0.05 
Windle, 1987 141 6.5 <0.02 
Tiska -Rudman, 1988 312 80 5 64* 100 ? 
Stubbs, 1988 103 71 5 65 55 N.S. 
van Lawick, 1988 164 71 5 80 68 <0.05 
Crowson, 1989 525 71 5 N.S. 
Vente, 1989 212 73 5 52 52 N.S. 
Wobbes, 1989 270 68 5 57 72 <0.001 
Onodera, 1989 592 5 <0.001 
Klingler, 1989 282 81 5 N.S. 
Hermanek, 1989 ( ?A) 5 N.S. 
Mecklin, 1989 520 68 5 66 81* <0.001 
* Recurrence -free survival 
** Dukes stage C only * ** Sigmoid colon tumours only 
( ?A) - abstract only and data not included 
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The various retrospective studies are summarised in Table 4.1. 
Several points deserve attention. Of these studies, it should be 
noted that Blair found no transfusion effect in Dukes A and B cases, 
but found that transfused patients with Dukes C tumours had a 
significantly better prognosis despite the small numbers of cases 
studied, although this study considered transfusions given only 
during the operation. They postulated that blood transfusion had an 
anticoagulant effect and this mechanism protected patients from 
developing metastases from tumour emboli. Their finding is 
supported by another study which demonstrates a possible beneficial 
effect associated with blood transfusion in patients with stage C2 
colon cancer (Weiden et al, 1987). 
Clearly, there is a marked variation in the proportion of patients 
receiving transfusion. The reason for this is unclear, but it 
probably reflects different transfusion policies rather than 
differences between the various groups of patients. 
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Further evidence of an immunosuppressive effect of blood transfusion 
comes from a prospective trial of adjuvant 5- fluorouracil and 
levamisole in colorectal cancer (Windle, 1987). Following curative 
surgery for colorectal cancer 141 patients had been randomised to 
receive a six month course of chemotherapy alone or combined with 
the immunomodulating drug levamisole. A third group acted as 
controls. This trial was curtailed at an early stage of patient 
recruitment because of evidence of a possible detrimental effect on 
survival associated with levamisole. However, they were able to 
apply a series of Cox proportional hazards models using various 
factors as co- variants. This demonstrated that receipt of blood 
immediately before, during or within three days of surgery had a 
significant detrimental effect on survival (p= 0.0166). 
Another prospective study of colorectal cancer patients has been 
reported by Tartter et al (1986a). This showed a significant 
association of blood transfusion with postoperative infective 
complications. These infective complications included wound 
infections, pneumonia, urinary infections and intra- abdominal 
abscesses. Interestingly, patients with a preoperative haematocrit 
of less than 40% had a lower incidence of postoperative infections. 
The same group also analysed prospectively the indications for 
perioperative transfusion in another series of 123 patients 
undergoing surgery for colorectal cancer (Tartter, 1986b). They 
decided that if patients had a haemotocrit of greater than 36 %, then 
they did not require transfusion. Of the total, 41% were transfused 
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and by their criteria 28% of these patients received at least one 
unit of unnecessary blood. They concluded that overtransfusion 
resulted from excessive intraoperative transfusion and secondly it 
was due to the apparent practice of giving units of blood in pairs. 
They suggested that a greater use of haematocrit testing would 
reduce the amount of blood transfused unnecessarily. However, the 
major critisism of this proposal is that the haematocrit does not 
accurately reflect blood volume particularly during haemorrhage. 
Further studies by Tartter investigated the relationship of blood 
transfusion to malignancy in 354 patients with colorectal cancer 
matched by age and sex to a control group of patients who were 
undergoing hernia repair or cholecystectomy (Tartter, 1988). 
The incidence of previous transfusion was higher in the control 
group (17% versus 9 %). Of the cancer patients, previously 
transfused patients and non -transfused patients had similar 
preoperative clinical features. 
The amount of perioperative blood transfused was found to be an 
independent prognostic variable in a study consisting of 55 patients 
who had hepatic resections for colorectal liver metastases 
(Stephenson et al, 1988). It was calculated that for each 
additional unit of blood transfused the risk of disease recurrence 
and death was increased by 5% and 7% respectively. 
There has been one prospective study of pre- and post- transfusion 
immune status (Quintiliani et al, 1988). The study group included a 
total of 38 patients undergoing colorectal cancer surgery of whom 20 
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4.5. BLOOD TRANSFUSION AND NON- COLORECTAL CANCER IN HUMANS 
The possible detrimental effects of blood transfusion are not as 
obvious in other malignancies. Several have been studied including 
breast, lung, gastric, renal cancer and sarcoma. 
4.5.1. Breast 
Nowak reported a retrospective study of 81 patients who had surgery 
for breast cancer (Nowak, 1984). There was no significant 
difference in recurrence -free survival rates between those who 
received blood transfusions and those who did not. Subgroups based 
on age, nodal status, oestrogen receptor status and progesterone 
receptor status were analysed, but no detrimental effect was found 
to be associated with blood transfusion. Patients who were being 
treated with tamoxifen did have a reduced recurrence -free survival 
if they had been transfused. Of the 81 patients 50% were 
transfused. In the whole group the 5 year survival was 70% for the 
transfused group and 61.5% for the non -transfused group. Fifty 
patients received tamoxifen and of these 21 were transfused. The 
five year recurrence -free survival in this group (n =21) was 48% for 
transfused patients and was 80% for those not transfused. The Cox 
regression method gave a p value of 0.03 for the observed difference 
despite the small numbers involved. 
Block et al reported a small series of T1T2, node negative breast 
cancer and showed that metastatic disease developed in 21% of 
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were transfused. Age- matched controls numbered 24. They tested the 
following parameters: 
- peripheral blood lymphocyte counts 
- T and B cell counts 
- CD4 and CD8 numbers 
- proliferative response of lymphocytes to 
phytohaemagglutinin 
- serum IgG levels 
- interleukin -2 and interferon gamma synthesis by 
peripheral blood lymphocytes 
- Ig synthesis in culture by stimulated lymphocytes 
There was a significant increase in IL -2 and INF -gamma production in 
culture supernatants of the stimulated lymphocytes and also 
increased immunoglobulin synthesis in cancer patients whether or not 
they had been transfused. No significant differences in these 
immune function tests were found between transfused and non - 
transfused patients either before or after surgery. 
Hoh et al carried out a prospective study of immune function in 
patients undergoing surgery for colorectal cancer (Hoh et al, 1990). 
They measured the mitogenic activity of patient plasma using 
cultured fibroblasts as target cells. Transfused patients had a 
100% increase over preoperative levels. Banked blood plasma was 
also tested in this experimental in vitro system. Mitogenic 
activity increased with storage time over 28 days, with the greatest 
changes occurring from the end of the second week. 
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transfused and in 21% of non- transfused patients (Block et al, 
1984). 
Foster et al studied 226 patients with breast cancer who had a 
mastectomy (Foster, 1984). Of these, 29% were transfused. When 
compared with the non -transfused group, both groups were matched for 
age, clinical stage and number of lymph nodes bearing metastases. 
Interestingly, patients who were not transfused had slightly larger 
tumours as measured by the pathologist. At five years for patients 
who had transfusions and those who did not, both the percentage of 
all deaths (22% and 21 %, respectively) and deaths due to cancer (18% 
and 16 %, respectively) were similar. No effect was seen with 
increasing amounts of blood transfused. 
Tartter and Burrows did find that perioperative blood transfusion 
had a prognostic significance in their group of 169 patients 
undergoing mastectomy (Tartter, 1984). The five year recurrence - 
free survival was 51% for patients receiving blood and 65% for those 
not transfused. Both groups were comparable in age, clinical stage 
and proportion of radical mastectomies performed. They noted that 
preoperative haemoglobin levels were lower and operative blood loss 
was higher in patients who were subsequently transfused. They 
concluded that perioperative blood transfusion may be a significant 
prognostic factor for patients undergoing mastectomy for operable 
breast cancer. 
In early breast cancer treated by mastectomy, Bickel et al showed 
that in 69 patients survival was prolonged in non -transfused 
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patients (n =51) compared with those transfused (n =17). The median 
survival was 63 months in the former and 28 months in the latter. 
This was stated as being statistically significant. A larger group 
(n =112) with more advanced disease was studied. There was no 
significant difference in survival between transfused and 
non -transfused patients. 
Voogt et al, having identified a detrimental effect in colonic 
cancer (vide supra), found no effect of blood transfusion on 
survival in 383 patients who had a modified radical mastectomy for 
breast cancer (Voogt, 1987). A relatively large proportion of these 
patients were transfused (70 %). The ten year survival was 57% for 
transfused and 52% for non -transfused patients. 
Eickhoff et al, compared transfused with non -transfused patients in 
group of 96 women who had mastectomy (Eickhoff et al, 1988). The 
overall survival rates and the recurrence -free survival rates were 
similar in both groups. Similarly, a study of 230 patients with 
breast cancer treated at the Mayo Clinic, Minnesota, concluded that 
transfusions at or before mastectomy were not associated with 
increased recurrence or reduced survival (Kieckbusch et al, 1989). 
Cohen et al, found no evidence of a detrimental effect in mastectomy 
patients (Cohen et al, 1986). 
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4.5.2. Lung 
The first report concerning blood transfusion and lung cancer came 
from Burlington, Vermont (Hyman, 1984). Patients undergoing 
potentially curative resection for stage I and stage II carcinoma of 
the lung were studied (n =105). Both transfused and non -transfused 
groups were matched for sex, age, stage and histological 
characteristics of the tumour. There was a significantly higher 
proportion of right sided lesions in the transfused group. There 
was a trend which suggested that transfused patients had an inferior 
prognosis, but this was not statistically significant. The survival 
rate at five years was 44% in the non- transfused group and 27% in 
the transfused patients. However, after corrections for uneven 
distribution of other prognostic factors using the Cox regression 
method the significance of the association was enhanced (p= 0.03). 
In order to eliminate variation due to technique, Tartter and 
Burrows applied their research to a personal series of 165 
consecutive patients undergoing resection for stage I lung cancer 
(Tartter, 1984). Transfused patients had lower recurrence -free 
rates at five years than non -transfused patients (62% versus 76 %). 
A much larger series from Milan was reported (Pastorino, 1986). 
This analysed 285 cases of stage I lung cancer undergoing 
potentially curative surgery. At eight years the survival was 40% 
for transfused and 41% for non -transfused patients. The 
recurrence -free survival rates were also similar: 36% and 34 %, 
respectively. 
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Pachman et al, found that blood transfusion was associated with a 
lower 3 year survival in 195 patients with lung cancer (Pachman et 
al, 1988). This difference (62.5% in non- transfused versus 40% in 
transfused) was highly significant when stratified for T and N 
stages. 
Keller et al determined the effect of perioperative transfusion on 
recurrence -free survival in 352 patients who underwent pulmonary 
resection for non -small cell lung cancer, but found none (Keller et 
al, 1989). 
Moores et al showed an adverse effect of blood transfusion on 
survival in a group of 330 patients with non -small cell lung cancer 
(Moores et al, 1989). 
4.5.3. Sarcoma 
One hundred and fifty -six patients with high grade soft tissue 
sarcomas of the extremities were analysed to assess the effect of 
blood transfusion on survival and tumour recurrence (Rosenberg, 
1985). These patients had all been entered in prospective trials, 
but the analysis of blood transfusion was retrospective. The five 
year recurrence -free survival rate was 70% in non -transfused 
patients compared with 48% in transfused. This was highly 
significant. Also, a direct relationship was found between the 
number of transfusions and the decrease in disease -free and overall 
survival: the greater the amount of blood transfused the worse the 
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prognosis. A large number of known prognostic variables were 
included in the analysis including age, sex, race of the patient, 
histology, site, resection margins, size of the tumour, operation 
time, adjuvant therapy, anaesthesia and individual surgeon. 
Accounting for these factors a strong association remained between 
blood transfusion and poor prognosis. 
4.5.4. Kidney 
One study has found an association between blood transfusion and 
decreased survival in renal adenocarcinoma (Mikulin, 1986). Exactly 
half of 88 patients who had nephrectomy for this tumour received 
blood transfusion. The five year survival rates were 39% for 
transfused patients and 77% for non -transfused patients. The 
transfused patients were older and had larger tumours than those who 
were not transfused. They also had a higher incidence of venous 
invasion and more distant metastases at the time of surgery. 
Patients with metastases and lymph node involvement were excluded 
and two groups of patients with similar tumour sizes were selected. 
Transfused patients still had a significantly reduced survival. 
A second study of 80 patients with surgically curable renal cell 
carinoma did not show a significant effect of blood transfusion on 
survival (Mayonda, 1986). However, initial analysis had suggested a 
detrimental effect. Subsequent analysis showed this to be due to a 
higher incidence of stage pT2 and pT3 tumours in the transfused 
group. 
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Moffat has reported two series. The first included 67 patients 
undergoing surgery for renal carcinoma and they reported a survival 
advantage in the non -transfused group (Moffat et al, 1985). 
However, the same group studied a larger series of 126 patients of 
63% had been transfused during their stay in hospital (Moffat et al, 
1987). Log rank analysis indicated a significant difference between 
the survival experience of the two groups, but the relationship of 
confounding variables such as age and sex were tested and then 
perioperative blood transfusion no longer appeared to have an 
adverse effect on survival. 
4.5.5. Gastric 
Two retrospective studies have demonstrated a detrimental effect on 
survival associated with blood transfusion. The first included a 
group of 232 patients with gastric cancer undergoing curative 
resections for gastric cancer (Kaneda et al, 1987). The effect was 
strongest in patients with Stage I gastric cancer. The 
administration of adjuvant immunochemotherapy (not specified) was 
seen to decrease the detrimental effect of blood transfusion on 
survival. 
Another study of similar size found that perioperative blood 
transfusion was a significant prognostic factor for recurrence and 
survival after curative surgery for gastric cancer (Demmel et al, 
1988). The Cox regression model was used for the multivariant 
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analysis. Transfusions were given to 82% of the 209 patients 
studied. The other two independent risk factors were tumour stage 
and lymph node involvement. 
A study of 1000 Japanese patients showed that transfused patients 
had poorer 5 -year survival than non -transfused (57% versus 81%), but 
this transfusion was not found to be a significant factor when 
confounding variables had been stratified (Kampschoer et al, 1989). 
4.5.6. Prostate 
Heal et al demonstrated a higher frequency of recurrence of 
prostatic cancer associated with perioperative blood transfusion, 
although survival rates were not significantly different when 
compared with non -transfused patients (Heal et al, 1988). Notably, 
the risk of recurrence was greater in patients who had received 
whole blood. 
McClinton et al, found that transfusion of non -autologous blood had 
a significant detrimental effect on survival after prostatic 
resection (McClinton et al, 1990). The study consisted of 246 
patients of whom 29% had been transfused. As many others have done, 
they used Cox's model of proportional hazards regression analysis 
which allowed them to control for a number of variables which may 
affect survival; of these variables only age and transfusion status 
were found to have significant effects on survival. 
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4.5.7. Head and neck cancer 
Blood transfusion was associated with a poorer prognosis in a group 
of patients undergoing surgery for head and neck cancer, pricipally 
squamous cell carcinoma (Johnson et al, 1987). The disease -free 
survival rate declined progressively in patients given increasing 
numbers of transfusions. Jackson's study of 100 patients with head 
and neck cancer also suggested that blood transfusion also had a 
detrimental effect on survival (Jackson et al, 1989). 
4.5.8. Other tumours 
Blumberg et al augmented their colonic research by studying the 
blood transfusion effect in prostatic and cervical cancer (Blumberg 
1985, 1986). The first study used a proportional hazards model to 
demonstrate a significant risk associated with blood transfusion. 
The latter paper reported that in patients with colonic, rectal, 
cervical and prostatic tumours there was an association between 
transfusion of any amount of whole blood or larger amounts of red 
blood cells at the time of surgery and later recurrence of the 
tumour. This association was confirmed by the use of the Cox 
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proportional hazards technique. More than three units of red cells 
had a significant association with a poorer prognosis. Recipients 
of one unit of whole blood had a significantly higher recurrence 
rate (45 %) than recipients of a single unit of red cells (12 %). 
Recipients of two units of whole blood also had a higher recurrence 
rate (52 %) than those receiving two units of red cells (23 %). The 
authors proposed that a prospective trial using washed red blood 
cells may be the most effective way of addressing the question of 
the blood transfusion effect. 
It has been shown that transfused patients undergoing surgical 
treatment of recurrent carcinoma of the vulva had a poorer prognosis 
than the non -transfused patients (Dalrymple et al, 1986). 
Lastly, there has been one report of a spontaneous regression of a 
melanoma in a patient following a possibly incompatible blood 
transfusion (Cole, 1976). 
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Table 4.2 
Blood transfusion (BT) on survival in cancer (excluding colorectal 
cancer) 
Author Tumour n %BT 
% 5yr survival 
BT No BT p value 
Nowak, 1984 Breast 81 50 70* 62 N.S. 
Tartter, 1984 Breast 169 23 51* 65 <0.05 
Foster, 1984 Breast 226 29 78 79 N.S. 
Block, 1984 Breast 53 36 79 79 N.S. 
Cohen, 1986 Breast ( ?A) lower <0.05 
Bickel, 1985 Breast 195 35 <0.01 
Eickhoff, 1988 Breast 96 29 53 52 N.S. 
Kieckbusch, 1989 Breast 229 49 lower N.S. 
Hyman, 1985 Lung 155 68 27 44 <0.05 
Tartter, 1984 Lung 165 36 51 65 <0.005 
Bickel, 1985 Lung 198 53 <0.05 
Pastorino, 1986 Lung 283 55 41 ** 40 N.S. 
Pachman, 1988 Lung 195 45 lower <0.05 
Keller, 1989 Lung 325 39 lower (8y) N.S. 
Moores, 1989 Lung 169 51 lower (4y) 0.007 
Rosenberg, 1985 Sarcoma 156 32 63 85 <0.0005 
Table 4.2 continued 
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Blood transfusion (BT) on survival in cancer (excluding colorectal 
cancer) 
Author Tumour n %BT 
% 5yr survival 
BT No BT p value 
Moffat, 1985 Renal 67 58 48 58 N.S. 
Mickulin, 1986 Renal 88 50 39 77 <0.001 
Manyonda, 1986 Renal 80 69 36 53 N.S. 
Moffat, 1987 Renal 126 63 47 55 <0.05 
Kaneda, 1987 Gastric 231 52 lower <0.002 
Demmel, 1988 Gastric 209 82 lower <0.002* 
Kampschoer, 1989 Gastric 1000 37 19 39 -47 N.S.* 
Heal, 1988 Prostate 262 14 10 19 N.S. * ** 
McClinton, 1990 Prostate 246 29 18. 35 <0.0025 
Johnston, 1987 Head /neck 179 59 73 (2y) <0.05* 
Jackson, 1989 Head /neck 100 29 69 <0.05 
Blumberg, 1985 Cervix 130 N.S. 
Dalrymple, 1986 Vulva 146 53 75 90 <0.05 
* Recurrence -free survival 
** 8 year survival 
* ** higher frequency of recurrence in transfused group 
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4.6. BLOOD TRANSFUSION AND IMMUNOSUPPRESSION IN OTHER DISEASES 
4.6.1. Inflammatory bowel disease 
Tartter et al (1986) studied 59 patients undergoing intestinal 
surgery because of inflammatory bowel disease, 34 had Crohn's 
disease and 25 had ulcerative colitis. Blood transfusion was given 
to 73% with a mean of 2.95 units of blood. They counted peripheral 
blood lymphocytes. Blood lymphocyte counts were depressed following 
surgery, but returned to normal levels in patients not receiving 
blood. In the transfused patients blood lymphocytes remained 
depressed for six to eighteen months following surgery. Both groups 
of patients had similar severity of disease, similar steroid therapy 
and age etc. However, they did note that preoperative weight loss 
was less in the transfused group and they also gained weight faster 
after surgery. 
Williams and Hughes reported a retrospective study of 60 patients 
who underwent small bowel resection for Crohn's disease (Williams 
and Hughes, 1989a). Of these, 28 had been transfused with 1 -8 units 
of blood and the rest were not transfused. Both groups had similar 
clinical features apart from preoperative haemoglobin, length of 
bowel resected and site of bowel resection. The transfused patients 
had a significantly lower recurrence rate (19% compared with 59 %), 
despite the fact that their clinical features would normally suggest 
a higher risk of recurrence. In subsequent published correspondence 
it was argued that disease location affected the risk of recurrence, 
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and when terminal ileal disease was considered the recurrence rate 
in transfused patients was 21% compared with 30% in non -transfused: 
clearly a less impressive result (Park and Russell, 1988; 1989). 
They also briefly reported a series of 87 patients with inflammatory 
bowel disease and found that blood transfusion did not seem to alter 
disease course. 
Furthermore, Fry et al reported their series of 79 patients treated 
for Crohn's disease by bowel resection (Fry et al, 1989; Peters, 
1989). Recurrence developed in 22% of transfused patients and in 
44% of non -transfused patients with a follow -up period of 3 years. 
These results were independent of disease site. A larger series of 
174 patients was reviewed (Sutherland et al, 1989). In the 72 
patients with small bowel resections, there was no recurrence 
advantage associated with blood transfusion. 
Williams and Hughes replied citing the advantages of their study, 
stating that all patients had small bowel disease, all surgery was 
performed by a single surgeon during a period when resection policy 
did not change, and that the data had been collected prospectively 
with standardised follow -up (Williams and Hughes, 1989b). 
4.6.2. Rheumatoid arthritis 
Many years ago it was thought that blood transfusion may be of value 
in initiating recovery from acute rheumatoid arthritis. Rose (1984) 
describes experience from the early 1950s and noted that blood 
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transfusion was frequently followed by a temporary remission 
associated with a fall in erythrocyte sedimentation rate over a 
period of weeks. This phenomenon was apparently ignored as 
attention was diverted to the therapeutic advances associated with 
gold. 
4.6.3. Abdominal trauma 
Perioperative blood transfusions have been associated with an 
increased incidence of postoperative infectious complications 
following surgery for penetrating abdominal trauma (Nichols, 1984). 
4.6.4. Anaemia 
Fehrmen and Ringden (1982) demonstrated that lymphocytes of 
non -uraemic patients given multiple blood transfusions due to 
chronic anaemia had low mixed lymphocyte culture activity and also 
low mitogenic responses to phytohaemagglutinin. The influence of 
blood transfusion on T lymphocyte subpopulations in anaemic patients 
is reviewed in detail later. 
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4.7. BLOOD TRANSFUSION AND EXPERIMENTAL BURNS 
The effects of transfusion were studied by Waymack and colleagues 
working with Alexander in Cincinnati (Waymack et al, 1986). They 
used a burned rat model to simulate trauma. They assessed cell - 
mediated immunity by measuring ear swelling in response to painting 
skin with dinitrofluorobenzene. Neutrophil function was assessed by 
measuring the ability of macrophages to phagocytose and kill 
bacteria (staphylococcus aureus). The ability of the macrophage to 
migrate into the peritoneal cavity in response to a chemical 
peritonitis was assessed. By injecting a known dose of the same 
bacterium into the dermis and by measuring colony formation from 
samples of the skin excised 24 hours later, they were able to assess 
dermal bacterial resistance. 
Animals transfused with allogeneic blood demonstrated a marked 
suppression of cell- mediated immunity as measured by ear swelling. 
Macrophage migration was also adversely affected by transfusion 
although neutrophil migration was not. Neutrophil function was not 
decreased by transfusion. This series of experiments clearly 
demonstrated that blood transfusion influences some aspects of the 
immune system following injury. 
This group from Cincinnati also studied the influence of transfusion 
on sepsis rates in a rat burn model (Waymack et al, 1987). Rats 
were given a 25% burn and this area of skin was challenged 
bacterially by painting on it a known quantity of Pseudomonas 
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aeruginosa bacteria. Allogeneic transfusion increased mortality 
unless it was given within 24 hours prior to the bacterial challenge 
when it diminished mortality. The authors offered two possible 
explanations for this. Firstly, allogeneic transfusion may cause an 
initial brief immunostimulation prior to the development of a 
longer -lasting immunosuppression. Secondly, it is possible that the 
transfused blood may have contained high levels of anti -pseudomonas 
antibody which were not present in the syngeneic blood used in the 
experiments. 
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4.8. MACROPHAGE PROSTAGLANDINS AND IMMUNOSUPPRESSION 
4.8.1. Introduction 
The macrophage is now known to have a key role in the regulation of 
cell- mediated immunity. Secondly, it has direct antitumour 
activity. Some of these effects are mediated by arachidonic acid 
metabolites secreted by the macrophage. Amongst white blood cells, 
the macrophage is the main source of prostaglandin synthesis and 
this cell may play a central role in the immunosuppressive response 
to blood transfusion. Prostaglandin E and other metabolites of 
arachidonic acid are now known to influence the immune system. 
Prostaglandin E is perhaps the most important and this compound has 
various immunosuppressive effects. 
4.8.2. Regulation of the immune response by macrophages 
The macrophage plays an important role in the regulation of the 
immune response. This has been demonstrated both in vivo and in 
cell culture. The macrophage may have a non -specific ability to 
improve the viability of lymphocytes, or alternatively, the 
macrophage may suppress the proliferation of lymphocytes through 
secretion of a variety of substances. These include thymidine, 
arginase, complement cleavage products, prostaglandin E and 
interferon. The macrophage also produces interleukin 1 which is one 
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of the signals required for T cell proliferation. This latter 
response would appear to be associated with the antigen -presenting 
role of the macrophage. This involves the processing and 
presentation of antigenic molecules to the lymphocyte. This 
function is dependent on the compatibility of products of the genes 
in the major histocompatibilty complex, namely Class Ia antigens. 
This interaction results in production of T cell lymphokines which 
activate the macrophage. The activated macrophage is able to 
phagocytose more easily and it secretes a variety of substances at a 
greater rate. These substances include neutral proteinases, 
interleukin 1, complement, mitogens, arachidonic acid metabolites, 
and hydrogen peroxide. 
The macrophages are important in tumour immunity and they appear to 
have two major roles. Firstly, they act as antigen -presenting cells 
and secondly they are potential effector cells mediating tumour 
lysis. Macrophages require activation to become cytolytic to tumour 
cells. T cells secrete macrophage activating factor (MAF) which is 
a lymphokine following antigen- specific stimulation. It is likely 
that the macrophages depend on T lymphocytes for their role in the 
anti -tumour response. The true identity of MAF has yet to be 
clarified, but several lymphokines have been implicated. However, 
interferon gamma is known to render macrophages tumoricidal. 
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4.8.3. Prostaglandins and immunoregulatirn 
Most of the work on the role of arachidonic acid metabolites in the 
immune response has concentrated on the immunoregulatory role of 
prostaglandin E. In normal individuals the importance of 
prostaglandin E regulation is probably minor. However, in certain 
disease states, including cancer, which are associated with impaired 
cell- mediated immunity, it is likely that the prostaglandin E 
regulatory system is responsible for the immunosuppression. Of 
great importance is our ability to inhibit this immunoregulatory 
system with non -steroidal anti -inflammatory agents of which 
indomethacin is a good example. 
Prostaglandin E2 
This compound is produced in every tissue with the exception of 
mature red blood cells. It has a short half -life which limits its 
action to the site of its production. 
The prostaglandins and the closely associated leukotrienes are 
groups of oxygenated fatty acids which have been detected in almost 
every tissue in man. Prostaglandins (and leukotrienes) are not 
stored in cells, but are formed by specific enzyme activity 
immediately before their release. Fatty acids are released from 
esterified lipid sources held within the cell membrane. The 
mechanism of release of these precursors is still unclear, but it is 
thought that they originate from the phospholipid reserves in the 
cell membranes. Phospolipase A is an important enzyme in this 
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release mechanism, and recent studies with platelets have shown that 
another enzyme, phosphatidylinositol -specific phospholipase C, will 
also release diacylglycerides, from which various lipases can form 
arachidonic acid (Rittenhouse -Simmons, 1979). 
Currently, there are three known substrate fatty acids which are 
prostaglandin /leukotriene precursors. These are 
cis -5,8,11,14 -eicosatetraenoic acid (arachidonic acid), and two 
related compounds, cis -8,11,14 -eicoatrienoic acid, and 
cis -5,8,11,14,17 -eicosapentanoic acid. Of these arachidonic acid is 
thought to be the most important hence the term often used to 
describe the biosynthetic pathway of prostaglandin - arachidonic 
acid cascade. Arachidonic acid is metabolized enzymatically via a 
group of lipoxygenase enzymes or by cyclooxygenase. Non -enzymatic 
oxygenation can also occur by ultraviolet light and by 02- generating 
systems. Enzymatic oxidation via cyclooxygenase results in the 
formation of a series of products, which include the prostaglandins. 
Leukotrienes are formed via the lipoxygenase pathways. 
Non -enzymatic oxidation of arachidonic acid generates chemotactic 
lipids (Ninneman, 1988). 
Prostaglandin synthesis is carried out in steps by two membrane - 
bound enzymes, cyclooxygenase and endoperoxide isomerase, and by the 
soluble enzyme peroxidase (Figure 4.1). After membrane 
phospholipids such as phosphatidylinositol are released from their 
esterified state via phospholipase to form the stable prostaglandin 
precursor arachidonic acid, molecular oxygen is added by the enzyme 
cyclooxygenase to form prostaglangin G2 (PGG2). PGG2 is quickly 
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converted to PGH2 by the enzyme peroxidase. PGG2 and PGH2 are 
unstable , biologically active molecules which are intermediate in 
the transformation of arachidonic acid to prostaglandins. PGG2 and 
PGH2 have a half -life of about 5 minutes. Endoperoxide isomerase 
and peroxidase convert PGH2 to prostaglandin F2alpha, prostaglandin 
E2, prostaglandin I2 (prostacyclin). Prostacyclin is unstable and 
converts to 6- keto -prostaglandin F1 alpha. PGG2 and PGH2 are also 
the precursors of thromboxane A2. Thromboxane A2 is a potent 
cellular regulatory agent with strong platelet activating activity. 
Thromboxane A2 is rapidly hydrolized to thromboxane B2 which is 
inactive. 
The bioactive prostaglandins are formed rapidly from their 
precursors, but are then quickly converted to metabolites with much 
weaker activities and these metabolites often have prostaglandin 
inhibitory activities. In the blood stream, PGE2 has a half -life of 
about 8 minutes (Ramberg et al, 1971) Sequential action of two 
enzymes, prostaglandin -15- hydroxydehydrogenase and 
prostaglandin -13- ketoreductase produce these 15 -keto -13,14 
dihydroxyprostaglandins which are metabolized further to urinary 
























Major metabolites in the arachidonic acid pathways. 
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Antigenic challenge in mice by injection sheep red blood cells led 
to an increase in splenic production of prostaglandin (Webb and 
Osheroff, 1976). This was prevented by prior administration of a 
prostaglandin synthetase inhibitor which also resulted in greater 
production of plaque forming spleen cells. This was the first 
demonstration that antigen challenge caused prostaglandin production 
as a negative feedback mechanism. 
Goodwin studied the effects of various prostaglandins on 
mitogen- stimulated tritiated thymidine uptake in human mononuclear 
cells and purified T cells. They found that PGE1 and PGE2 both 
inhibited thymidine uptake. Their findings suggested that PGE 
inhibited T cell, but not B cell mitogenesis. In in vitro 
experiments, PGE2 has been shown to suppress many T cell functions. 
These include mitogen responsiveness, clonal proliferation, 
antigenic stimulation, lymphokine production, the generation of 
cytotoxic cells in mixed lymphocytic cultures and lymphocyte 
migration. These studies have been reviewed (Goodwin and Ceuppens, 
1983). In blood, the cell responsible for PGE2 production is a 
monocyte. Monocytes exposed to various antigenic stimuli have been 
shown to increase their prodction of PGE2 (Scott et al, 1982; Humes 
et al, 1982). This probably acts as a negative feedback mechanism 
to control the magnitude of the immune response. 
One of the effects of this negative signal through release of 
prostaglandin E2 is the induction of suppressor T lymphocytes which 
inhibit interleukin 2 production in other T cells in the effector 
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arm of the immune response. 
The ability of macrophages to activate suppressor T lymphocytes via 
a prostaglandin- mediated pathway was initially demonstrated by Webb 
and Nowowiejski (1981) in a series of experiments in which splenic 
macrophages were cultured and their ability to induce suppressor 
activity in T lymphocytes was assessed by measuring incorporation of 
tritiated thymidine after stimulation with phytohaemagglutinin. The 
suppression induced by macrophages was reversible by the addition of 
in domethacin. 
Chouaib et al (1984) were able to induce T suppressor cells in 
culture by incubation with prostaglandin E2. They also examined the 
OKT4 (CD4) and OKT8 (CD8) phenotypes of the suppressor cells before 
and after inducton. They found that the precursors were found 
mainly in the CD8 subset, but with some cells in the CD4 subset. 
However, induced suppressor cells were found in the CD8 subset only. 
It was also suggested that the monocytes inhibit the interleukin 2 
producing T cells by direct cell to cell contact. 
Goodwin also cites studies which indicate that lymphocytes from 
healthy individuals over the age of 70 years are much more sensitive 
to inhibition by PGE2 than peripheral blood monocytes from young 
adults (Goodwin, 1983). Goodwin studied the effects of surgery and 
demonstrated a similar increased sensitivty of lymphocytes to PGE2 
(Goodwin et al, 1981). 
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4.8.4. Prostaglandins and natural killer cells 
Natural killer cells are a heterogenous collection of cells some of 
which may be related to the monocyte line, but others have 
characteristics in common with T lymphocytes. Natural killer cells 
are so called because of their capacity to lyse tumour cells without 
being previously sensitised. 
There is evidence to suggest that prostaglandin E can inhibit 
natural killer cell activity in experimental models. Voth et al 
tested the effect of of indomethacin on natural killer cell activity 
in a peritoneal macrophage model (Voth et al, 1986). Indomethacin 
caused a marked activation of natural killer cell activity against 
tumour cells. This activation was reversed by adding prostaglandin 
E2. They also demonstrated a second cell type with killer activity 
after administration of indomethacin and these cells were thought to 
have been macrophages. Prostaglandins have been shown to inhibit 
natural killer cell activity in mice (Brunda, 1980). 
4.8.5. Prostaglandins, prostaglandin synthetase inhibitors and 
immune regulation in cancer 
Prostaglandins have been shown to enhance carcinogenesis in a mouse 
skin tumour model (Lupulescu, 1978). In tumour bearing mice, Pelus 
and Bockman (1979) demonstrated an increased prostaglandin synthesis 
by macrophages. 
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In colon cancer patients, prostaglandin mediated immune suppression 
of peripheral blood T lymphocyte mitogenesis is increased and this 
abnormality can be partially reversed by indomethacin added to the 
cell cultures (Balch et al, 1984). This study found that the 
depression of the immune response was greater in elderly patients 
and in patients with metastatic disease. Production of various 
arachidonic acid metabolites by peripheral blood monocytes was 
measured in this study. It was found that only PGE2 production was 
raised. 
Similar studies have also demonstrated that indomethacin enhances 
the mitogen response of T lymphocytes in patients with melanoma 
(Tilden et al, 1981), head and neck cancer (Balch et al, 1982), 
Hodgkin's disease (Goodwin et al, 1977), and lung cancer (Han and 
Takita, 1980). 
4.8.6. Prostaglandins and immune regulation in burns 
Patients with severe burns are known to be immunosuppressed due to 
the direct effects of the burn or because of the general 
immunosuppressive effects of major trauma. They are also a group of 
patients which is likely to receive multiple blood transfusions. 
The major manifestation of this immunosuppression is sepsis. 
Therefore cell- mediated immunity in burns victims has been well 
investigated. 
It is known that burns patients have a decreased ability to produce 
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the T lymphocyte growth factor interleukin 2 and this finding was 
associated with suppression in the number of T- helper (CD4) 
lymphocytes which persisted for a long time during the recovery 
period (Wood et al, 1984). 
This group also described similar findings in patients with non -burn 
injuries. They followed this research by establishing an 
experimental model of thermal injury. Mice were given a 25% scald 
and the splenocyte production of interleukin 2 was measured. 
Normally it is suppressed in these mice, but after administration of 
indomethacin to the culture medium, interleukin 2 production was 
enhanced (Wood et al, 1987). 
In a separate series of experiments, the effects of exogenous 
prostaglandin E2 on lymphocyte blastogenesis and interleukin 2 were 
studied. It was found that thermal injury was associated with an 
increased susceptibility to the inhibitory effects of prostaglandin 
E2. This work clearly suggests a prostaglandin E2 action is 
involved with this reduction of interleukin 2 production. 
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4.9. PROSTAGLANDINS AND BLOOD TRANSFUSION 
4.9.1. Dialysis patients 
It is known that patients on chronic haemodialysis who receive 
multiple transfusions have comparatively high levels of 
prostaglandin E in their blood (Lenhard et al, 1985; Jackson et al, 
1985; Roy et al 1985). 
4.9.2. Transplant models 
Administration of prostaglandin has been shown to prolong the 
survival of murine skin allografts while prostaglandin synthetase 
inhibitors decrease graft survival (Anderson et al, 1977). 
It has been shown that indomethacin blocks the blood transfusion 
induced immunosuppression associated with a prolonged graft survival 
in a rat heart transplant model (Shelby et al, 1987). They also 
demonstrated that anti -PGE antibody blocked allogeneic blood induced 
suppression by neutralising endogenous PGE in the experimental 
animals. 
4.9.3. Blood transfusion models 
Waymack (et al, 1987) investigated the effect of transfusions on the 
production of arachidonic acid metabolites by cultured macrophages. 
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Using a rat model they demonstrated that allogeneic blood 
transfusions decreased macrophage migration in response to 
inflammatory stimuli. This response was elicited by injecting 
brain -heart infusate into the peritoneal cavity. Allogeneic blood 
transfusion was also associated with increased macrophage production 
of prostaglandin E2. Control groups given infusions of Ringer's 
lactate solution or syngeneic blood yielded more macrophages after 
peritoneal lavage and these harvested macrophages produced less 
prostaglandin E2 in culture. 
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4.10. INDOMETHACIN AND CANCER 
Pollard et al (1977) demonstrated that treatment of tumour bearing 
rats with indomethacin retarded the rate and extent of metastases of 
prostatic adenocarcinoma cells. There is also evidence that 
prostaglandin inhibitors such as indomethacin and aspirin inhibit 
the growth of various transplanted tumours (Levine et al, 1972; 
Sykes and Maddox, 1972; Lynch et al, 1978; Lynch and Salomon, 1979). 
Indomethacin has been shown to influence the course of colonic 
carcinogenesis. Pollard and Luckert (1980) induced colonic tumours 
in Sprague Dawley rats by administering five weekly doses of 
dimethylhydrazine by gavage. Treatment with indomethacin reduced 
the incidence of colonic tumours significantly. Also in the rats 
treated with indomethacin which did develop tumours, the tumours 
were smaller in number and size compared with the controls. 
Indomethacin was administered by dissolving it in drinking water at 
a concentration of 20mg /L. Normal rats given a similar dose of 
indomethacin survived for 6 months with no evidence of clinical 
illness. However, autopsy on these rats showed that they had 
developed small knobs on the small intestine. Histologically they 
contained connective tissue, capillaries and polymorphonuclear 
leucocytes. Normal rats treated with a higher dose of indomethacin 
in the drinking water (40 mg /L) were found to be unwell after nine 
days and all had died by seven weeks. They had developed purulent 
peritonitis. 
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The same group also studied the effect of indomethacin on the 
development of colonic tumours in rats given a single injection of 
the acetate derivative of dimethylnitrosamine (Pollard and Luckert, 
1981a, 1981b). It is known that this carcinogen is inactivated 
within 48 hours of injection into rats. In this experiment 
indomethacin therapy was commenced 14 days after the single 
injection of carcinogen. It is unlikely, therefore, that the 
mechanism involves the initial carcinogenic action of the chemical. 
A further series of experiments demonstrated a prolonged antitumour 
effect of indomethacin on chemically induced colonic tumours 
(Pollard and Luckert, 1983). In these experiments indomethacin was 
introduced to the rats as late as 66 and 77 days after the 
carcinogen had been administered, and the antitumour effect was 
demonstrable for at least 40 weeks. 
Caignard et al (1984) reported results which conflicted with those 
of Pollard. They used Sprague Dawley rats and induced colonic 
tumours by giving five doses of dimethylhydrazine. There was no 
significant difference between the controls and rats treated with 
indomethacin (4/13 and 5/14 rats developed colonic tumours 
respectively). They also studied the effect of indomethacin on the 
development of transplanted colonic tumour cells and found that 
there was none. The same group also found that indomethacin 
treatment did not modify the growth of tumour produced in rats by 
injection with syngeneic colon cancer cells (Olsson et al, 1984). 
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The induction of colonic tumours by dimethyihydrazine was abrogated 
by synchronous treatment with indomethacin in a study of Sprague 
Dawley rats (Rubio et al, 1989). 
Summary 
Macrophages activated by antigenic stimulation can induce T 
lymphocytes which have suppressor activity. This appears in part to 
be mediated by an increase in macrophage synthesis of prostaglandin 
E2. This can be reversed by prostaglandin synthetase inhibitors 
such as indomethacin. 
There is also evidence that the immunosuppressive effects of blood 
transfusion are associated with increased synthesis of 
prostaglandins by macrophages. Similarly, indomethacin may red ce 
prostaglandin synthesis by macrophages following allogeneic blood 
transfusion and so reverse the immunosuppressive effect of blood 
transfusion, assuming that the effect is due to PGE2 and not another 
cytokine. 
There is experimental evidence which demonstrates that indomethacin 
itself can influence tumour behaviour and cause inhibition of tumour 
growth. However, colonic cancer models have yielded conflicti 
results in this respect. 
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5.1. CLINICAL RETROSPECTIVE STUDY 
5.1.1. Patients 
Case records were retrieved for all patients (314) who underwent 
laparotomy for colorectal cancer during the four year period 1977 to 
1980 in Derbyshire Royal Infirmary and Derby City Hospital. 
Identification of cases was performed in three ways: 
a) The theatre operation records were complete for this period 
and all operations performed at both hospitals were recorded 
in the operation books. The initial data base consisted of 
names, hospital numbers and dates of all operations of the 
following categories: bowel resection of any type, undefined 
laporotomy, specific colorectal cancer operations. 
b) Patient details were retrieved from the Department of 
Pathology records on all specimens categorised as colonic or 
rectal cancer. 
c) During the period of the study, the majority of patients had 
been entered in the Large Bowel Cancer Project. A complete 
listing of these patients was obtained from the Large Bowel 
Cancer Project database. 
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Case records were then obtained from the hospital Medical Records 
Department. It had been intended to extend the study back to 
include the years 1974 and 1975, but the cases notes of patients who 
had died during this period had recently been destroyed without 
microfilm recording (due to economic constraints). 
The cases notes were then searched to obtain the relevant clinical 
details. Blood transfusion status was ascertained from the case 
notes. All patients cross -matched by the blood bank in hospital had 
a form inserted into their case notes. This form recorded details 
of blood group, amount of blood cross -matched and the number of 
units used, together with the relevant dates. Transfusion 
procedures at ward level required a thorough checking process to 
ensure patients received the correct cross -matched units. This 
system was the current safeguard against mis- matched transfusions 
and was adhered to rigidly by medical and nursing staff. The person 
checking the blood pack had to write the pack number and time on the 
transfusion form in the case notes. Therefore, the presence of a 
transfusion form yielded an accurate record of the amount of blood 
transfused and the date of transfusion. The absence of a 
transfusion form implied that the form had been lost or that the 
patient had never been cross -matched. 
The hospital Blood Bank held records of blood issue and blood 
returns, but these records could not confirm that a particular 
patient had received the unit(s) not returned to the Blood Bank. 
Transfusion forms were found in the case notes of 304 patients, 
therefore complete transfusion data were not obtainable in 10 
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patients. It would have been possible for a patient to have had a 
transfusion form which indicated that no units were used during the 
perioperative period, but who subsequently was cross -matched again 
and transfused with the second transfusion form being lost. It is 
felt that the chances of this happening were small. To exclude this 
possibility, the Blood Bank records should have been checked against 
each patient in the colorectal cancer database. However, the lack 
of computerization of the Blood Bank records made this task 
impractible, as the Blood Bank served a wide area of specialities, 
including two large District General Hospitals, a Children's 
hospital and several other smaller units. Pathological information 
was also obtainable from duplicate records kept in the Pathology 
Department. 
Complete data sets (including clinical details) were obtained for 
302 patients. Of these patients, 25 died within 30 days of surgery. 
These perioperative deaths were due mainly to cardiovascular and 
respiratory complications. A further 41 patients had palliative 
procedures for unresectable tumour or were found to have metastatic 
disease. Thus, 236 patients had curative surgery. 
In order to limit the analysis to patients who had an abdominal 
operation only, the 77 patients who had abdomino -perineal resections 
were excluded from the second survivorship study which, therefore, 
comprised 159 cases. 
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5.1.2. Definitions 
Curative resection was defined as the removal of the primary tumour 
which was histologically complete, with no evidence of distant 
metastases at the time of surgery. Perioperative blood transfusion 
means transfusion of whole blood or packed cells received during the 
period from initial presentation until 30 days following tumour 
resection. Some patients were found to have had transfusions after 
this point for a variety of reasons (e.g. prostatic surgery), but 
these were disregarded because of the unreliability of this 
information for all patients in the study who may have been treated 
at other centres. 
5.1.3. Follow -up data collection 
Follow -up data were derived from the case records, but supplemented 
where necessary from the Derby Cancer Registry and the collaborative 
study of colorectal carcinoma called the Large Bowel Cancer Project 
(Phillips et al, 1984). Given the resources available at the time 
it was not possible to trace patients who were lost to follow -up and 
not confirmed to have died, by contacting the appropriate general 
practitioner. 
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5.1.4. Computers and statistical programs 
The data for the retrospective study were entered into a statistical 
system called Minitab (Ryan et al, 1985). The life table analysis 
data were processed using a BBC "B" microcomputer. Initially, a 
statistical program called BSTAT was used (Feltham, 1985). 
5.1.5. Statistics 
The group of patients who received perioperative blood transfusion 
was compared with the group of patients who had not been transfused 
with blood. Clinical details, known prognostic factors and survival 
data were assessed and compared using a variety of statistical 
methods: 
a) Student's t test 
The unpaired t test was calculated using the following 
formula: 
t = D / sqr (SV (N1 * N2)/(N1 * N2)) 
where t = value of t 
D = mean difference between groups 
SV = pooled variance 
N1 = number of subjects in group 1 
N2 = number of subjects in group 2 
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b) Chi square test 
the chi square statistic is 
chit - sum (observed - expected)2 / expected 
c) Life table analysis 
The method used to construct the life tables in the clinical 
studies was that described by Armitage (1971). 
d) Mantel -Haenszel method 
In the clinical study, this method was used to compare the 
survival and recurrence -free survival curves of the group of 
transfused patients with those of the group of non- transfused 
patients. This method was described by Mantel and Haenszel 
(1959) and the application of the method is further described 
by Schwartz et al (1980). 
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e) Logrank test 
The logrank test is an approximate form of the 
Mantel -Haenszel method (Peto et al, 1977). It uses a chi 
square test for comparing the observed and expected numbers 
of deaths (or recurrence) in two groups. The relative 
simplicity of this test has led to its frequent use in 
clinical studies. It is known that the value of chi squared 
will always be less than the square of the normal deviate 
given by the Mantel -Haenszel method (Schwartz et al, 1980). 
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5.2 COLON CARCINOGENESIS MODEL 
5.2.1 Introduction 
A number of chemical carcinogens have been discovered which induce 
colonic tumours in animals. When administered to rats and mice 
these compounds produce colonic tumours which are similar in many 
respects to human tumours. The ideal carcinogenic agent should be 
organ specific and not be toxic to other organs. In fact, most 
colonic carcinogens produce tumours in other organs. 
The first experimental induction of intestinal tumours involved mice 
fed with dibenzathrene or methylcholanthrene (Lorenz and Stewart, 
1941), but these tumours were found in the small intestine only and 
not the large bowel. It was then found the feeding some inbred 
strains of hamsters 3- methylcholanthrene caused males, but not 
females, to develop colonic tumours (Homburger, 1972). In the 
1950's it was known that there was a high incidence of bladder 
carcinoma in the dye industry workers. One of the byproducts of the 
manufacture of dyes is the biphenyl group of compounds. Some of 
these compounds were found to produce small and large bowel tumours 
in rats (Walpole, 1952). A familial syndrome resembling motor 
neurone disease (amyotrophic lateral sclerosis) had a high incidence 
in Chamorro tribe in the island of Guam. It was thought that a 
dietary factor may be involved in the aetiology of this disease. 
The nuts of the tropical plant Cycas circinalis were ground to make 
cycad meal which was eaten by the tribe. Rats were used to study 
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the disease. However, rats fed with cycad meal did not develop the 
neurological pathology, but some of the animals were found to have 
adenocarcinomas of the colon (Laqueur et al, 1963). This group 
subsequently proved that the carcinogenic agent in cycad meal was 
cycasin, a glucoside of methylazoxymethanol. Cycasin did not prove 
to be a useful experimental carcinogenic agent because it was an 
unstable compound and cycad nuts were apparently hard to come by. 
In fact, cycasin was not carcinogenic when administered parenterally 
to rats. The carcinogenicity is due to splitting of the cycasin by 
bacterial glucosidase in the rat intestine. This derivative is 
methylazoxymethanol. 
Working in Freiburg, Druckey studied a series of compounds related 
to methylazoxymethanol (Druckrey, 1970). The main chemicals used 
were azoxymethane and its precursors, azomethane and 
1,2- dimethylhydrazine. These chemicals are now known to be the most 
effective carcinogens for selective induction of intestinal tumours 
in rats, and also in mice. Azoxymethane is thought by some to be the 
most effective carcinogenic agent, but this chemical may increase 
the yield of small bowel neoplasms in rats (Nigro et al, 1973). 
5.2.2. Dimethylhydrazine 
Roe reviewed the experience of nine manufacturers of hydrazine who 
had analysed the health of their workers (Roe, 1978). Five of these 
companies had manufactured hydrazine since years which ranged from 
1940 to 1956. A total of 423 workers were involved and there was no 
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evidence to suggest an increased risk of death related to exposure 
to hydrazine or by- products. 
The chemical dimethylhydrazine is unstable at room temperature and 
is rapidly dehydrogenated in the prescence of trace metals. 
Therefore, the chelating agent ethylene -diaminotetracetate (EDTA) is 
added to the solution to prevent this (Haase, 1973). 
5.2.3. Dimethylhydrazine and the animal model 
Metabolism of dimethyl hydrazine 
Dimethylhydrazine is metabolised and conjugated in the liver and is 
then secreted in bile (LaMont and O'Gorman, 1978). The hepatic 
metabolism probably involves the cytochrome P -450 pathway (Hathway, 
1984). The active carcinogen is methyldiazonium which is an 
alkylating agent. This metabolic activation does not require the 
presence of bacterial gut flora. The active agent reaches colonic 
mucosal cells by direct intestinal transit and also through the 
blood stream. The basic carcinogenic effect is known to be the 
methylation of DNA within the colonic mucosal cells. This 
methylation of DNA also occurs in the liver and kidney, but these 
organs are not the prime target of the carcinogenic process. 
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Course of carcinogenesis 
With carcinogenic treatment there is a generalised increase in 
cellular proliferation and mitotic figures can be seen in the upper 
third of the crypts and on the surface epithelium. Then there is a 
decrease in the number of goblet cells, hyperplasia of the glands 
and areas of focal atypia. These changes have been shown to occur 
after two or three months of treatment. 
The first appearance of microscopic adenomas and adenomatous polyps 
is between four and six months after starting treatment. These 
polyps then grow and may undergo malignant change. They commonly 
cause rectal bleeding and may cause intestinal obstruction either by 
stenosis or intussusception. The disease process progresses with 
peritoneal metastases rather than involvement of other organs. 
However, hepatic metastases are not uncommon. Pulmonary metastases 
are uncommon. In Druckrey's work, the mean induction time for 
colonic tumours was 184 days using a weekly dose of 21 mg /kg of 
dimethylhydrazine. If a reduced dose was used (7 mg /kg) the tumour 
induction time increased to an average of 333 days. He also found 
that a lower dosage of 3 mg /kg given orally in the drinking water 
did not produce colonic tumours, but they did develop malignant 
haemangiomas of the liver. 
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Rat colon anatomy 
The normal anatomy of the rat colon and the histopathology of 
chemimically induced colonic tumours were studied by Lindstrom 
(1978). The colon in the rat varies in length (21 to 27 cm) and 
five main segments are recognised: the caecum, proximal colon, major 
flexure, distal colon and rectum. The caecum and proximal colon are 
fairly mobile and are attached to a mesentery which is shared with 
the small bowel. The proximal colon when opened has a 
characteristic herring bone pattern on the mucosal aspect. The next 
segment, the major flexure, is short and the mucosal pattern 
consists of longitudinal folds. These folds continue into the 
distal colon and rectum. Plaques of lymphoid tissue are to be found 
throughout the length of the bowel. These lymphoid patches may be 
important in the pathogenesis of chemically induced carcinogenesis. 
A strong association has been found between this gut associated 
lymphoid tissue and adenocarcinoma of the colon (Deasy et al, 1982). 
It was reported that a definite lymphoid patch existed at each of 
the colonic sites where dimethylhydrazine -induced tumours occur, but 
not at sites where tumours were not found. 
Rat colon histology 
Histologically, the rat colon and rectum consist of a lamina 
propria, muscularis mucosa, and an external layer of smooth muscle. 
This layer consists of an inner circular and an outer longitudinal 
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layer. There is also a subserosal layer under the serosa. The 
mucosa varies depending on the part of the colon. In the caecum the 
tubular glands are lined with columnar epithelium and goblet cells 
which tend to be evenly distributed among the various parts of the 
tubules. In the proximal colon the tubules are branched. The 
mucous membrane of the major flexure is thicker with longer tubular 
glands. The mucosa is thinner again in the distal colon and is 
similar in the rectum. Lymphoid plaques consist of collections of 
lymph follicles in the boundary between the mucosa and the submucosa 
and occasionally it is seen to break through into the muscularis 
mucosa. He also described a special type of goblet cell in the 
basal parts of the tubular crypts in the proximal colon of the rat. 
The staining properties of these cells demonstrated a faint or 
negative PAS reaction and a strong reaction with alcian blue, but 
negative for sulphomucins. It was proposed that this cell 
represented a third type of mucosal cell apart from the normal 
columnar epithelial cell and the normal goblet cell. This third 
cell type has no counterpart in human colonic mucosa. 
Histopathology of dimethylhydrazine carcinogenesis 
The histopatholological features of dimethylhydrazine induced 
colonic tumours have also been studied by Ward (1974). Mucinous 
adenocarcinomas occur primarily as sessile or plaque -like lesions in 
the proximal half of the colon. Many occur adjacent to lymphoid 
follicles. These tumours consist mainly of mucus -laden signet ring 
cells. The serosa may be invaded and the tumours metastasise to the 
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peritoneum and the regional lymph nodes. Polypoid adenomas and 
nonmucinous adenocarcinomas occur more frequently in the distal half 
of the colon. Polypoid lesions can be classified as either polypoid 
adenocarcinomas or polypoid adenomas containing areas of extreme 
atypia or carcinoma -in -situ, but without invasion of the stalk. 
Rats also develop well- differentiated adenocarcinomas of the 
duodenal mucosa and also, less frequently, of the jejunal mucosa. 
Most of these tumours are arise close to the orifice of the bile 
duct and it has been suggested that an activated carcinogen is 
secreted in the bile. 
5.2.4. Dimethylhydrazine Carcinogenesis Procedure 
Preparation of reagents 
The carcinogen was obtained from Aldrich Chemicals in the form of 
1,2- dimethlyhydrazine 2HC1. The chemical was processed in batches 
which consisted of 10 g of the anhydrous powder. 
The dimethylhydrazine was prepared in a fume cupboard under aseptic 
conditions. During these procedures disposable rubber gloves and a 
plastic gown were worn. A two litre flask was placed on a magnetic 
stirrer and one litre of 0.9% saline was poured into the flask. To 
this was added 15 g of ethylene -diaminotetracetate (EDTA) (Sigma: 
Poole, UK). This was done to prevent dehydrogenation which occurs 
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rapidly in the presence of trace metals (Druckrey, 1970). The pH of 
the solution was brought to pH 7.0 using molar NaH2CO3 (Sigma, 
Poole, UK). The pH was measured using a pH meter. Then 10 g of 
dimethylhydrazine was added gradually. Again the pH was corrected - 
in fact the dimethylhydrazine would not dissolve if the acidity was 
high. The volume of the batch was 1.08 1. After the compounds had 
been seen to have dissolved completely, the solution was sterilized 
by filtration through a 0.22um filter unit (Flow Laboratories: 
Irvive, UK) divided into 20 ml aliquots which were placed in sterile 
universal containers (Sterilin: Teddington, UK). These were 
labelled and frozen at -70 °C. The aliquots were removed and allowed 
to return to room temperature prior to injection. 
The initial dose used was 16 mg /kg. Therefore, a rat weighing 200 g 
received 0.35 ml, a rat weighing 500 g received 0.86 ml, and a rat 
weighing 750 g received 1.29 ml of the carcinogenic solution. 
Control solution 
A control solution was used in the initial experiments. This was 
prepared in a similar manner, but the dimethylhydrazine was omitted. 
This represented a 1.5% solution in saline of ethylene - 
diaminotetracetate (EDTA) (Sigma: Poole, UK) with pH corrected to pH 
7.0 by addition of NaH2CO3 (Sigma: Poole, UK) in molar 
concentration. This was also divided into 20 ml aliquots and frozen 
as described above. 
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Animals and method of administration 
Male Sprague Dawley rats were bought in (A Tuck and Son Ltd, 
Raleigh, UK) and were admitted to the animal facilities weighing 
150 -200 g. The animals were fed on a standard pellet diet 
(Pilsbury's Modified) and tap water ad libitum. The rats were 
individually numbered using system of ear punching. After one to two 
weeks acclimatisation the rats were examined and any ill animals 
destroyed. The animals were given weekly injections of 16 mg /kg 
dimehtylhydrazine, using sterile disposable hypodermic needles 
(Becton Dickinson: Wembley, UK) and sterile polypropylene syringes 
(Becton Dickinson: Wembley, UK). The animals were restrained 
manually without anaesthesia and were weighed prior to injection. 
The exact dose was calculated and the carcinogen was given by the 
subcutaneous route. Disposable gloves and plastic aprons were worn 
while handling the solution and during the injections. The total 
number of injections given to each rat was 16 initially, but was 
reduced to 14 in the last series of experiments. 
Assessment of carcinogenesis 
The rats were killed at the appropriate time by ether anaesthesia. 
The animals were weighed and inspected for external signs of 
pathology. The most obvious signs were related to the development 
of tumours of the external auditory canal. 
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A midline incision was made in the abdominal wall. The presence of 
ascitic fluid was noted. The incision was extended into the thorax 
to allow removal of the lungs. The lungs were palpated and sliced 
at intervals with a scalpel in order to look for pulmonary 
metastatic deposits. The large and small intestines were brought 
out through the abdominal wound. The midline incision was extended 
downwards through the scrotum towards the anus. The muscle layers 
beneath this were incised to expose the pubic bones. The 
circumference of the anus was incised and the anus then lifted using 
toothed forceps. The anal canal and lower rectum could then be 
dissected to the floor of the pelvis. The testicular tissues were 
brushed aside. Next the bladder and seminal vesicles were held up 
in toothed forceps. These were removed by cutting across the base 
of the bladder with scissors. The anterior part of the pelvic ring 
could now be clearly seen. A blade of a pair of blunt -ended strong 
dissecting scissors was passed caudally beneath the pubic symphisis. 
This structure was then cut and the two ends of the pelvic ring 
separated by spreading the scissors. The pelvic rectum could now be 
seen encircled by the sphincters which were divided anteriorly. The 
anus was picked up in toothed forceps. This traction enabled the 
colon to be dissected from the posterior abdominal wall. As the mid 
portion of the colon was reached the small bowel and caecum were 
rotated to their embryonic position. The caecum and large bowel 
were then removed intact and placed in 0.9% saline (Sigma: Poole, 
UK). 
A careful search was made of the visceral and parietal peritoneum 
for metastatic deposits. The greater omentum was spread and closely 
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examined as this was the commonest site of peritoneal tumour 
deposits. The small bowel was removed whole and placed in 0.9% 
saline. The liver was removed and weighed and sliced in sections to 
look for hepatic metastases. The spleen was inspected. Both 
kidneys were removed and examined for the presence of renal cysts. 
The large bowel was opened longitudinally with scissors. The caecum 
was removed at this point to facilitate examination. Faecal 
material was washed off with fresh saline. The length of large 
bowel, which measured about 30 cm, was placed on a metal rule. The 
length was noted. The position and diameters of each macroscopic 
tumour were noted. Many tumours were related to the lymphoid patch 
found in the wall of the rectum and diagrams were made of these 
tumours. The diameters were measured using calipers. Magnification 
was obtained using a 1.5 binocular loupe. The large bowel was then 
wrapped like a swiss roll on a wooden rod and placed in 10% formalin 
(phosphate buffered) solution. The caecum was opened and the 
position and size of any tumours were noted. The small bowel was 
opened longitudinally and any tumours were noted. In the initial 
series of experiments the cranium was also opened and the brain 
removed. This was serial sectioned with a scalpel and a search made 
for possible tumour deposits. This was not a rewarding procedure 
and was later abandoned. 
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Histopathology 
Sections were taken from individual tumours arising in the rat bowel 
wall which had been fixed in formalin. These were processed 
automatically and embedded in wax. This procedure was performed by 
technical staff in the Department of Pathology, (Western General 
Hospital, Edinburgh) under the direction of Dr I Nawroz who was the 
Pathologist collaborating in this project. Sections were cut and 
mounted on glass slides and stained with haemotoxylin and eosin. 
The sections were then examined by the Pathologist who was unaware 
of the distribution of experimental groups. Details of the 
histopathological features were recorded. "Tumours" were classified 
as normal mucosa, adenoma or carcinoma according to established 
definitions (Morson and Sobin, 1976). Adenocarcinoma consists of 
coloumnar or cuboidal epithelium with varying degrees of loss of the 
normal differentiation pattern. The histological classification was 
based on the WHO definitions of grade: G1 is the most differentiated 
with well - formed tubules and the least nuclear polymorphism and 
fewest mitoses, G3 is the least differentiated, having only 
occasional glandular structures, pleomorphic cells and a high 
incidence of mitoses, while G2 is intermediate between G1 and G3 
Hermanek, 1982; Qizilbash, 1982). Invasion is described as T1 if the 
submucosa, but not the muscularis mucosae is invaded; T2 if the 
muscularis propria, but not the subserosa is invaded; T3 is invasion 
of the non -peritonealized pericolic or perirectal tissues The 
primary tumour is denoted by the prefix "p "). Mucin production was 
noted as was the presence of a lymphocyte infiltrate and the 
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presence of signet cells in which intracellular mucin pushes the 
nucleus to one side. It was not possible to identify the regional 
lymph nodes in the specimens and no data have been included on lymph 
node metastases. 
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5.3. T LYMPHOCYTE SUBSET ANALYSIS 
5.3.1. Development of the techiques 
The monoclonal antibody revolution has given rise to many diverse 
applications. Milstein and Kohler (1975) devised methods for 
producing clones of cells which make a single antibody. This can be 
achieved by inoculating and immunising mice with cells or cell 
fragments from another species e.g. rat or human. The mouse spleen 
cells, normal antibody- forming cells, are fused with an appropriate 
B -cell myeloma tumour line. Eventually, single clones of hybrid 
cells can be grown in tissue culture. Relatively large amounts of 
antibodies can be made. These antibodies are, of course, identical 
in structure and affinity for antigen. As a research tool, 
monoclonal antibodies possess a remarkable asset. Assuming that the 
cell lines from which they are derived are immortal, then the 
antibodies derived from this process over a period of time should be 
identical. 
These techniques have been used to produce monoclonal antibodies 
which react with markers expressed on the surface of lymphocytes. 
The initial experimental work involved mice. Cantor and Boyse 
(1975) described the Ly series of lymphocyte differentiation 
antigens which were used to demonstrate the existence of T -cell 
subpopulations or subsets bearing distinct surface phenotypes. 
Subsequently, spleen cells from mice were immunised with rat 
thymocyte membranes with the production of several monoclonal 
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antibodies (Williams, 1977). Two relevant antibodies were studied, 
these were called W3/13 and W3/25. Labelled lymphocytes were 
analysed using a fluorescence activated cell sorter. It was found 
that monoclonal W3/13 labelled all thoracic duct T- lymphocytes, but 
not B- lymphocytes. Monoclonal antiboby W3/25 labelled a large 
proportion, but not all, of T- lymphocytes. It was anticipated that 
using the fluorescence activated cell sorter it would be possible to 
separate these subpopulations of lymphocytes and study their 
function. Milstein's group reported work on the W3/25 antibody 
labelled cells (White, 1978). They found that W3/25 labelled 80% of 
rat thymocytes, but only 52 -58% of thoracic duct lymphocytes. When 
B -cells were excluded only 71 -75% of the remainder were labelled. 
The fluorescence activated cell sorter allowed separation of these 
two cell fractions (W3/25 positive and W3/25 negative). 
They described two immune functions which were associated with the 
W3/25 positive subsets. Firstly, helper cell activity for an 
anti -hapten plaque forming cell response was confined to the 
labelled population and secondly graft- versus -host activity was 
likewise confined to the labelled subset. The unlabelled subset 
mediated an allogeneic suppressive effect. The MRC 0X8 monoclonal 
antibody was found to label a significant subpopulation of rat 
thymocytes and all W3/25 -ve peripheral T lymphocytes (Brideau, 
1980). Barclay (1981) used MRC OX 8 and W3/25 monoclonal antibodies 
on cryostat sections of rat spleen and lymph nodes. He found that 
both these populations were present throughout the T- dependent 
areas. In the B areas there were only scattered T cells which were 
largely W3/25 positive cells. When rat spleen lymphocytes and 
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BCG- activated cells were labelled and tested for natural killer (NK) 
activity it was found that rat natural killer cells were 
heterogeneous in their surface antigen expression (Cantrell, 1981). 
The test used was 51Cr release assay. Subpopulations of rat NK 
cells express the 0X8 and W3/13 defined antigens, but not the W3/25 
defined antigen. 
It was known that T cell- deprived animals failed to reject 
allografts, but the mechanism of this effect was unknown. Dallman 
(1982) reported a series of experiments which examined the roles of 
lymphocyte subsets in rats bearing skin allografts. Monoclonal 
antibodies W3/25 and OX 8 were used to deplete thoracic duct 
lymphocytes of one or other of these subsets. The residual cells 
were then injected into syngeneic T cell- deprived rats which had 
been given allogeneic skin grafts. OX 8 labelled cells had no 
effect on graft rejection, but removal of the W3/25 labelled cells 
prolonged graft survival. They examined the thoracic duct 
lymphocytes of adult thymectomised, lethally irradiated, bone marrow 
restored rats. A small proportion of these cells were labelled with 
0X8 antibody. These cells had non -specific cytotoxic activity. 
These cells, although labelled with 0X8, were considerably larger 
than normal lymphocytes. This was determined by their scatter 
profile on the fluorescence activated cell sorter. 
The authors also cited a personal communication from Cantrell that 
natural killer cells are larger than normal lymphocytes. It was 
suggested therefore that the nonspecific cytotoxicity obtained from 
adult thymectomised, lethally irradiated, bone marrow restored rat 
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thoracic duct lymphocytes was derived from OX 8 positive natural 
killer cells. 
5.3.2. Lymphocyte subset functions in rodents 
The functions of W3/25 and 0X8 T lymphocytes are summarised in the 
following table: 
Function Monoclonal antibody Reference 
W3/25 0X8 
Helper activity for B cells + - $ 
Helper activity for T cells + 
Proliferation in MLR + + + * 
Graft -vs -host reactivity + + $ 
Graft -vs -host disease + + + & 
Suppression of antibody + $ 
Suppression of antibody 
formation in allogeneic 
interactions 
+ $ 
Cytotoxic T (cell) precursor + £ 
Cytotoxic (effector) T (cells) + £ 
Key to references: $ = White (1978), Brideau (1980), Mason (1980); 
* = Mason (1981); & = Mason (1981b); £ = Dallman (1982). 
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5.3.3. T lymphocyte subset enumeration procedures 
Blood sampling 
All rats were anaesthetised using the open ether method using 
diethyl ether (May & Baker Pharmaceuticals Ltd, UK). Blood samples 
were obtained form the tail vein or from the jugular vein after 
surgical exposure of this vessel in the root of the neck. Terminal 
samples were obtained by direct cardiac puncture. About two 
millilitres of blood were placed in sample tubes (Becton Dickinson: 
Oxford, UK) containing sodium heparin. The tubes were then gently 
agitated. 
Lymphocyte separation 
Using a polypropylene syringe (Becton Dickinson: Oxford, UK) and 
hypodermic needle (Becton Dickinson: Oxford, UK) 2m1 of 
Ficoll -Hypaque density gradient (Pharmacia: Milton Keynes, UK) was 
placed into a 10m1 polystyrene centrifuge tube (Sterilin Ltd: 
Teddington, UK). The rat whole blood was layered carefully onto the 
surface of the Ficoll -Hypaque. The tubes were then centrifuged at 
450g for 30 minutes at 20 °C. The plasma was removed carefully using 
a sterile glass Pasteur pipette (Alpha Laboratories Ltd, Gillingham, 
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UK). The plasma was discarded. The milky interface between the 
Ficoll Hypaque and plasma contains monocytes and lymphocytes. This 
interface was removed using a pipette and placed in separate test 
tubes. To these tubes was added 10m1 of fresh RPMI culture medium 
(Flow Laboratories: Irvine, UK). They were then centrifuged at 250g 
for 10 minutes at 4 °C. The supernatant was removed and a known 
quantity of fresh RPMI was added to the pellet of cells lying in the 
bottom of the tube. This volume varied according to the volume of 
whole blood in the original sample. This facilitated dilution of 
the lymphocytes. 20 ul was removed from the suspension to count the 
cells present. The suspension was centrifuged at 250g for 10 
minutes at 4 °C. 
A portion of the isolated cells was used to prepare a microscope 
slide for differential analysis, using a cytocentrifuge (Shandon 
Cytospin 2 - Shandon Southern Products Ltd: Runcorn, UK) to assess 
the purity of the lymphocyte preparation. The proportion of 
contaminating polymorphonuclear cells was less than 5 %. The cells 
were counted using a Coulter Counter (Coulter Electronics Ltd, 
Luton, UK). The number of cells in the pellet could then be 
calculated. The cells were then resuspended at a specific 
cellularity for the T cell counts. This was 4x106/ml. Four 
samples were then prepared. In one of these polypropylene 
centrifuge tubes (Sarstedt: Leicester, UK) was placed 2ml of 
phosphate buffered saline (PBS) /10% fetal calf serum (Flow 
Laboratories: Irvine, UK) to which 400u1 of the cell suspension were 
added. The tube was centrifuged at 300g for 10 minutes at 4 °C. The 
supernatant was discarded and 400u1 of PBS /10% FCS was added to the 
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cell pellet. The cells were resuspended and 100u1 of this 
suspension were transferred into each of the three remaining test 
tubes which contained the monoclonal antibodies. 
The monoclonal antibodies used were (vide infra): 
W3/13 for total T lymphocytes (Sera -Lab Ltd: Crawley Down, UK) 
W3/25 for helper T lymphocytes (Sera -Lab Ltd) 
0X8 for suppressor /cytotoxic lymphocytes (Sera Lab Ltd). 
The three sample tubes aforementioned contained 10u1 of monoclonal 
antibody soloution, 90u1 of PBS /10 %FCS and 100u1 of cells suspended 
at a concentration of 4 x 106/ml. This left 100u1 of cell 
suspension in the control tube. The four tubes were placed in an 
ice bath for one hour. They were shaken at 15 minute intervals. 
Then 2m1 of PBS /10 %FCS were added to each tube. They were 
centrifuged for 10 minutes at 300g at 4°C. 
This was repeated. Two separate tubes had been prepared. The first 
contained 45u1 of anti -mouse IgG labelled with flouroscein (Miles 
Scientific: Slough, UK) and 405 ul of PBS /10 %FCS. This was mixed 
thoroughly before use using a rotamix. The second tube contained 
40u1 rat serum and 460u1 PBS /10 %FCS. After the prepared lymphocytes 
had been washed twice and the supernatant removed, to each of the 
four tubes were added 50u1 of anti -mouse IgG and 50u1 of the rat 
serum in medium. All four tubes were placed in an ice bath for for 
30 minutes and were shaken every 10 minutes. 
The tubes were removed from the ice bath and 2m1 of PBS /10 %FCS were 
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added and they were centrifuged for 10 minutes at 300g at 4 °C. The 
supernatant was removed and this process was repeated. 
Storage of labelled lymphocytes 
After the previous step, 100uL of 4% paraformaldehyde (pH >8) (Taab 
Laboratories Ltd: Reading, UK) was added to each sample tube. The 
samples were stored wrapped in foil in the fridge at 4oC until 
counting which was done in batches within a maximum time of two 
weeks. It has been shown fixation in paraformaldehyde solution does 
not affect flow cytometric analysis of cells previously stained with 
fluorescein conjugated antibodies (Lanier and Warner, 1981). The 
maximum tested storage time of fixed cells labelled in this way was 
2 months without significant alterations in light scatter or 
fluorescence properties. Glutaraldehyde fixation was associated 
with high immunofluorescence backgrounds. This method was used 
routinely in our laboratory using rat lymphocytes and, therefore, 
validation was not performed. 
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Monoclonal antibodies 
W3/13 - monoclonal antibody against rat T lymphocytes 
This is a mouse IgG antibody which is specific for 
polymorphonuclear cells, all thymocytes and T lymphocytes, 
haemopoietic stem cells and plasma cells but not B 
lymphocytes. 
W3/25 - monoclonal antibody against rat T helper cells 
This is a mouse IgG antibody which is specific for most 
thymocytes, helper T lymphocyte subset and macrophages. No 
other cell are known to be recognised. 
OX 8 - monoclonal antibody against rat T cells (non -helper 
subset). 
This is a mouse IgG antibody which labels most thymocytes and 
the peripheral T cell sub -set which includes cytotoxic and 
suppressor T cells. The helper T cell sub -set is not 
labelled. Some NK (natural killer) cells are also labelled. 
F.I.T.C. conjugated anti mouse IgG. 
This conjugate is prepared in the rabbit and is specific for 
mouse IgG. The product used is derived from highly purified 
IgG fraction and high purity fluorescein isothiocyanate. 
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In the preliminary experiments we found that there seemed to be a 
degree of non -specific binding of the various monoclonal antibodies 
which had been purchased as ascitic fluid preparations. This was 
avoided when the more expensive supernatant preparations were used 
instead. 
Analysis of T lymphocyte subsets 
Initially the samples were counted using a light microscope. The 
number of cells with full immunofluorescence were counted in 
ultraviolet light in one view of the eyepiece. Then the total 
number of lymphocytes were counted in one view with normal light. 
Several views were counted until a total of at least 200 lymphocytes 
had been counted. 
Subsequently for the experiments described in this thesis, flow 
cytometric analysis was used to analyse the T lymphocyte subsets. 
The Becton Dickinson FACS 440 was used. This equipment was 
maintained and operated by staff of the Department of Haematology, 
University of Wales College of Medicine. For each sample of 
labelled cells the machine counted approximately 5000 lymphocytes. 
It counted the number of these cells which fluoresced, therefore the 
proportion of labelled cells could be calculated. This process was 
repeated for the four samples (three labelled and one unlabelled 
control) prepared from each rat. 
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Comparison of groups of lymphocyte subsets 
The results of the experiments involving enumeration of T lymphocyte 
subsets are expressed as means of the proportions of all T 
lymphocytes which have been labelled with a particular monoclonal 
antibody. The correct statistical method for comparing means of 
proportions involves a process called partitioning of chi square 
(Dr. T Peters, personal communication). However, because the cell 
sorter counts a constant number of cells per batch (5,000) it can be 
shown that the calculation involves a formula which is equivalent to 
the standard Student's t test. The following worked example 
demonstrates the method and compares T- helper cell populations of 
rats with advanced cancer with those of age- matched normal rats. 










mean 24.95 36.84 unpaired t -test: 
SD 7.73 6.49 t = -3.332 for 14 degrees of freedom, 
SE 2.73 2.30 p (two- tailed) = 0.005 
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Chi squared method. 
Normal rats. 
animal 1 2 3 4 5 6 7 8 total 
% Th 28.5 34.3 36.7 21.2 14.0 18.7 23.1 23.1 199.6 
% non -Th 71.5 65.8 63.3 78.8 86.0 81.3 76.9 76.9 600.4 
total 100 100 100 100 100 100 100 100 800 
Cancer rats. 
animal 9 10 11 12 13 14 15 16 total 
% Th 46.0 37.7 36.7 42.6 40.6 35.9 30.0 25.8 295.3 
% non -Th 54.0 62.3 63.3 57.4 59.4 64.1 70.0 74.2 504.7 
total 100 100 100 100 100 100 100 100 800 
The difference between the two groups (normal and cancer) is 
represented by a Chi squared, 1 degree of freedom (2 x 2) table: 
199.6 295.3 
600.4 505.7 
However, ALL differences between rats could be represented by a chi 
squared on 15 degrees of freedom directly from a 2 x 16 table: 
Chi squared, 15 degrees of freedom - 
28.52 + 34.32 + 36.72 + ... 30.02 + 25.82 - 4952 /(0.3093)(0.6907) 
100 100 100 100 100 1600 
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The differences between rats within the groups are represented by: 
Chi squared with 14 degrees of freedom 
Chi2 14df = Chi2 15df minus Chi2 1df 
F 
= 60.196 - 26.429 
33.767 
(Chi2 1/1) / (Chi2 14/14) 
F 1,14 = 10.95 (0.005 point = 11.06) 
p < 0.01 
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5.4. BLOOD TRANSFUSION 
5.4.1 Donor rats 
Male rats of the highly inbred line Dark Agouti DA (RT -Ia) were used 
as blood donors throughout the series of experiments. The rats were 
originally obtained from Harlan Olac (Bicester, UK), and had been 
specifically bred for this and other work in the Cardiff Royal 
Infirmary Animal Unit. These rats were maintained under 
conventional husbandry conditons and fed on a standard pellet diet 
supplemented with fresh tap water ad libitum. The donor rats were 
normal and had not been used in previous experiments and had not 
previously been used as blood donors. 
The donor animals were anaesthetised with ether and the thorax 
swabbed with alcohol. Blood was withdrawn by cardiac puncture using 
a sterile polypropylene 10mL syringe (Becton Dickinson: Oxford, 
UK)and a 21 guage sterile hypodermic needle (Becton Dickinson: 
Oxford, UK). The donor animals weighed about 350 g and it was 
usually possible to obtain 8 -10m1 of blood from each rat. Prior to 
cardiac puncture a small amount of heparin sodium (Leo Laboratories 
Ltd: Aylebury, UK) was placed in the syringe to prevent the blood 
clotting. The concentration of heparin used was about 30 units /ml 
(the variation was dependent on the amount of blood aspirated). 
This blood was transfused to the recipients within one hour. 
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5.4.2. Transfusion procedure 
The recipient rats were anaesthetised lightly with ether (May and 
Baker: UK). They were placed on the operating bench and the tail 
was swabbed with chlorhexidine solution (ICI Pharmaceuticals: 
Macclesfield, UK). A sterile 23 guage butterfly needle (Becton 
Dickinson: Oxford, UK) was inserted into one of the lateral tail 
vein about two centimetres distal to the base of the tail. Blood or 
saline (Travenol Laboratories Ltd: Thetford, UK) was then injected 
slowly, the needle withdrawn and pressure applied to the site of 
venepuncture. For the tumour model, the volume injected was 1.5 ml 
in all cases. Three attempts were made to enter the tail vein and 
if venepuncture was unsuccessful a cut -down was performed on the 
jugular vein. A small incision was made above the left clavicle 
initially to expose the jugular vein. After gentle blunt dissection 
of the subcutaneous fat and incision of the deep fascia this vein is 
easily identified as it passes proximally beneath the pectoral 
muscle. Pressure on the pectoral muscle itself dilates the vein and 
the vessel can easily be entered using a 25 guage hypodermic needle. 
Injecting saline is the easier manoeuvre as a "backflash" of blood 
is seen on entering the vein. When blood is injected this does not 
happen so the vessel must be well visualised before the first 
attempt is made. On withdrawing the needle in this position it was 
important to apply pressure to achieve haemostasis. The wound was 
closed with a continuous 4/0 chromic catgut suture (Ethicon: 
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Edinburgh, UK). The rats were inspected later to look for haematoma 
formation (only two rats developed haematomas which necessitated 
withdrawal from the experiment). 
5.5 INDOMETHACIN 
Indomethacin was donated by Merck Sharp & Dohme Research 
Laboratories. 
Over one week the amount of drinking water consumed by experimental 
rats was measured. The indomethacin was dissolved in 2mL of ethanol 
and subsequently in 10 litres of tap water to give an approximate 
of indomethacin of 2mg /kg /day. The drinking bottles containing the 
indomethacin solutions were changed three times a week. 
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5.6. PERITONEAL MACROPHAGE MODEL 
5.6.1. Animals 
Inbred male Lewis (RT11) weighing 200 -250g (Bantin and Kingman, UK) 
were used as transfusion recipients and also syngeneic donors. 
Inbred adult male DA (RT1a) rats (Bantin and Kingman, UK) were used 
as allogeneic blood donors. The animals were housed in standard 
laboratory cages in groups of four or five with a 12h: 12h 
light -dark cycle. The rats were fed water and pelleted rat food ad 
libitum. 
5.6.2. Blood transfusion procedure 
Donor rats were premedicated using acepromazine (C -Vet, Bury St 
Edmunds) 0.125 mg /kg body weight by intramuscular injection into the 
hind limb. Using this drug for premedication the amount of 
barbiturate necessary to induce anaesthesia is reduced by 
approximately one third. Anaesthesia was induced using Hypnorm 
(Janssen Pharmaceutical Ltd, Oxford) 0.33 mL per kg body weight by 
intramuscular injection into the other hind leg. One mL of Hypnorm 
contains 0.315mg fentanyl citrate and 10mg fluanisone. Fentanyl is 
an analgesic of the morphine type and fluanisone is a neuroleptic of 
the butyrophenone group. 
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The thorax of the animal was swabbed with alcohol and a direct 
cardiac puncture performed using a sterile polypropylene 10 mL 
syringe (Becton Dickinson: Wembley, UK) with a sterile disposable 
21g needle (Becton Dickinson: Wembley, UK). 
Citrate -phosphate- dextrose (CPD) solution was used as anticoagulant 
and was prepared by dissolving 26.03g trisodium citrate (dihydrate) 
(Sigma: Poole, UK), and 3.27g citric acid (monohydrate) (Sigma: 
Poole, UK), and 2.22g sodium dihydrogen phosphate (monohydrate) 
(Sigma: Poole, UK), and 25.5g dextrose (Sigma: Poole, UK) to one 
litre of distilled water. The solution was sterilised by filtration 
through a 0.22um filter (Millipore: London, UK). The blood was 
stored in sterile polypropylene tubes (Costar: Cambridge, UK) 
containing 20% CPD. The whole blood was either transfused within 
the next 90min or stored for 24hr at 4 °C. Serum was prepared by 
adding 3 -5mL blood to sterile polystyrene tubes (Sterilin: 
Teddington, UK). The blood was allowed to clot at room temperature 
for 2 hours and then stored at 4 °C for a further 20 hours when the 
serum was removed using a sterile plastic Pasteur pipette (Alpha: 
UK) and transferred to a 10mL polystyrene centrifuge tube (Sterilin: 
Teddington, UK) and centrifuged at 1500g for 30 minutes at room 
temperature. The serum was transferred to sterile polypropylene 
tubes. Two control solutions were used to transfuse the rats, one 
consisting of 250uL CDP and 1mL NaC1 0.9% (Antigen Ltd, Eire), and 
the second being NaCl 0.9% only. 
Recipient rats were anaesthetised using the same regime used for the 
donor rats. Transfusions consisted of 1mL of either fresh blood, 
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stored blood, serum, CPD /NaCÌ, or NaCl. After skin disinfection 
with ethanol, transfusions injected into a peripheral vein using a 
sterile 2mL polypropylene syringe (Becton Dickinson: Wembley, UK) 
and a sterile 23 guage hyodermic needle (Becton Dickinson: Wembley, 
UK). If a lateral tail vein could not be entered then the dorsal 
penile vein or the long saphenous vein on a hind limb was used. The 
animals were allowed to recover and returned to the cages to be 
reviewed later to check their recovery. 
5.6.3 Elicitation of peritoneal macrophages 
Three days after transfusion the rats were given an intraperitoneal 
injection of sterile 4mL bovine brain heart infusion broth (Gibco: 
Paisley, UK). The broth was prepared by dissolving 38g of broth 
powder in 1L of distilled water and subsequent sterilisation by 
autoclave. The broth was stored in sterile polystyrene containers 
(Sterilin: Teddington, UK). 
5.6.4. Macrophage harvesting 
Seven days after transfusion the rats were anaesthetised as before 
and killed by cardiac air embolus. The abdominal wall was swabbed 
with ethanol and a midline skin incision made with a sterile scalpel 
(Swann- Morton: Sheffield, UK). A small incision was made in the 
muscle wall to expose the peritoneum. Without opening the 
peritoneal cavity, 10mL of sterile, cooled phosphate buffered 
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saline(PBS): pH 7.3 containing 5mM ethylene -diaminotetracetate 
(EDTA) (Sigma: Poole, UK) was injected into the peritoneal cavity. 
After one minutes mixing, the peritoneal cavity was incised and the 
lavage fluid aspirated using a sterile plastic Pastuer pipette. The 
fluid was transferred to a sterile polystyrene 10mL centrifuge tube 
(Sterilin: Teddington, UK) which was placed in an ice bath. 
5.6.5. Preparation of the macrophages for culture 
The peritoneal fluid was centrifuged at 300g (4 °C) for 10 minutes. 
The following cell preparation was performed in a flow cabinet 
(Envair: Rossendale, UK). The supernatant was discarded and 10mL 
PBS pH 7.3 added to the resuspended cell pellet and the suspension 
centrifuged at 300g (4 °C) for 10 minutes. This step was repeated 
once and the supernatant discarded. Contaminating red blood cells 
were lysed hypotonically by adding 5 mL 0.2% NaC1 to the resuspended 
cell pellet followed after one minute by 5 mL 1.6% NaC1 and the 
suspension centrifuged at 300g (4 °C) for 10 minutes and the 
supernatant was then discarded. The cells were resuspended in 5mL 
PBS and 400uL removed for counting and staining. 
5.6.6. Counting cells and assessing viability 
A counting chamber with improved Neubauer ruling was used (Johnstone 
and Thorpe, 1987). A 200uL sample of cell suspension was added to a 
polypropylene test tube (Sarstedt: Leicester, UK) and to this was 
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added 200uL of 0.4% trypan blue stain (Sigma: Poole, UK) added, 
vortexed and incubated for 5 minutes in an ice bath. A 20uL sample 
was added to the counting chamber under the cover slip and the cells 
allowed to settle for one minute. The cells contained in 25 large 
squares were counted, representing a volume of 100uL, using a 
laboratory tally counter. Viable cells exclude trypan blue whereas 
non -viable cells take up the stain. The total of cells contained in 
the original 5mL is calculated. 
The remaining 4.6mL of cell suspension was centrifuged at 300g (4°C) 
for 10 minutes and the supernatant discarded. The cells were 
resupended in Medium 199 (Flow Laboratories: Irvine, UK) with 
Earle's balanced salt solution and supplemented with 
penicillin /streptomycin, L- glutamine and 7.5% fetal calf serum (all 
Flow Laboratories: Irvine, UK) to achieve a final concentration of 
106 cells per mL. 
5.6.7. Non -specific esterase stain 
The morphologic identification of mononuclear phagocytes in a mixed 
cell population is not always reliable. The purity of the monocyte 
preparation may be guaged by a number of procedures. A simple and 
reliable technique is the the histochemical stain for non -specific 
esterase (Hayhoe and Quigley, 1980). The cytoplasm of monocytes and 
macrophages will stain diffusely with this stain, but neutrophils 
fail to stain (Figure 5.1). Some lymphocytes do stain, but in a 
small granular (2 -3 granules per cell) distribution rather than 
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diffusely. 
Cells were incubated with alpha -naphthyl butyrate in the presence of 
the stable diazonium salt, pararosaniline hydrochloride. Enzymatic 
hydrolysis of ester linkages by the alpha -naphthyl butyrate 
esterase, liberated free naphthyl compounds (at pH 5.8 -6.2), which 
complex with the diazonium salt to form highly coloured red /brown 
deposits at the sites of enzyme activity. 
Procedure 
a) Preparation of slides 
Initially microscopic slides were prepared by placing a drop 
of cell suspension on a glass slide and forming a smear by 
drawing the drop across the slide with a second slide. This 
method proved to be unsatisfactory for two reasons. Firstly, 
there was an uneven distribution the various cell types: all 
cells were concentrated near the edges of the smear and 
non -specific esterase positive cells were found in greater 
numbers at the beginning and at the end of the cell smear. 
This made counting the proportions of cell types inaccurate. 
Secondly, the smear method resulted in disruption of many 
cells: the macrophages seemed to be particularly fragile. 
This method was abandoned if favour of the cytocentrifuge 
method (Table 5.6.1). 
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TABLE 5.6.1 
Comparison of rat peritoneal macrophage enumeration techniques using 
the non -specific esterase stain. 
Technique 
smear + 
lab prepared reagents 
cytocentrifuge + 
lab prepared reagents 
cytocentrifuge + 
stain kit 





31 13.1 (6.53) 33.8 (15.9) 47% 
27 14.9 (6.6) 41.0 (11.3) 28% 
22 10.5 (2.42) 31.0 (6.85) 22% 
*CV - coefficient of variation for the macrophage counts. 
The first set of data was derived from a pilot study which preceded 
the main experiment. 
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Figure 5.1 
Non -specific esterase staining of a peritoneal cellular 
suspension. Monocytes take on a characteristic red brown 
stain in the cytoplasm. Lymphocytes may stain in a small 
'dot' area in the cytoplasm. Magnification x 400. 
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Figure 5.2 
Non -specific esterase staining of a peritoneal cellular 
suspension. Monocytes take on a characteristic red brown 
stain in the cytoplasm. Lymphocytes may stain in a small 
'dot' area in the cytoplasm. Magnification x 1000. 
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Microscope slides were prepared for use using a cytocentrifuge 
(Shandon Cytospin II: Shandon Southern Products Ltd, Runcorn, 
UK). The optimal number of cells for the slide preparation 
was found to be 5x105 in 100uL PBS. Therefore, 200uL from the 
5mL suspensions of the harvested rat peritoneal cells was 
diluted with with PBS (1:5, v:v) and placed in polypropylene 
test tubes (Sarstedt: Leicester, UK). The cytocentrifuge was 
loaded with labelled empty glass microscope slides (Chance 
Propper Ltd: Worley, UK) which had been washed previously. 
The cytocentrifuge was set to run for 4 minutes at a speed of 
1000rpm with low acceleration. The cell suspension was 
vortexed to ensure mixing and 100uL added to the 
cytocentrifuge carriers and centrifuged onto the slides. The 
slides were removed and air -dried for at least 15 minutes 
prior to fixation. 
b) Fixation 
The preparations were fixed using a glutaraldehyde fixative 
solution. Glutaraldehyde fixative solution was prepared by 
adding 9mL 25%(w/v) glutaraldehyde solution (Sigma: Poole, UK) 
to 21mL deionized water and 45mL reagent grade acetone 
(Rathbone Chemicals: Walkerburn, UK). The solution was mixed 
well and stored in an airtight amber glass bottle in the 
freezer, at below -10 °C. The fixative solution was placed in 
a pre -cooled Coplin jar and kept capped in the freezer at 
below -10 °C. The fixative solution was mixed vigorously 
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before use and returned to the storage container immediately 
after use. The air dried slides were fixed for exactly 5 
minutes in the freezer, at below -10 °C. The slides were 
removed from the fixative and rinsed in gently running 
deionized water for 30 seconds. The slides were allowed to 
air dry for at least 15 minutes prior to proceeding with the 
stain. 
c) Staining reaction 
Evaluation of staining was carried out using reagents 
purchased separately (Sigma: Poole, UK) and using an 
alpha -naphthyl butyrate non -specific esterase stain kit 
(Sigma: Poole, UK). Using the former method, the staining 
patterns were unreliable with marked variation in intensity of 
the staining patterns. Using the kit, greater consistency was 
achieved, but this still did not reach total consistency and 
all slides were prepared and stained in duplicate. 
The reagents were bought as a kit: alpha naphthyl butyrate 
esterase kit (Sigma: Poole, UK). The phosphate buffer 
solution consisted sodium and potassium phosphates (not 
specified) and had a concentration of 0.067 mol /L, pH 7.7 at 
25 °C. Microbial growth was retarded by filtration through 
0.22 micron filter unit (Flow Laboratories: Irvine, UK). 
Before use 40mL buffer was warmed to 37 °C. To 1.5mL 
pararosaniline solution (40g /L in 2mol /L hydrochloric acid) 
was added 1.5mL 4% sodium nitrite solution. This was vortexed 
vigoroulsy, and stood for 5 minutes before it was added to the 
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buffer. Then 5mL of alpha -naphthyl butyrate solution (2.4g /L, 
solubilizers and methanol warmed to 37 °C prior to use) was 
added. The final solution was mixed well and poured into two 
Coplin jars. The slides were added and incubated for one hour 
at 37 °C. After one hour the slides were removed and the used 
solution discarded. The slides were rinsed for 3 minutes in 
deionized water and allowed to air dry for at least fifteen 
minutes before counterstaining. The slides were 
counter- stained for 5 minutes in methylene blue. This 
solution was prepared immediately before use by adding 5mL 
methylene blue (1.4 %(w /v) in 95% ethanol) to 45mL deionized 
water. Counter -staining was done using Giesma's stain 
originally, but the methylene blue supplied with the kit 
proved to have superior visual qualities. 
d) Evaluation of slides 
Slides were evaluated using 400x /1000x magnification. Two 
staining patterns were recognised. One was a focal (dot) type 
characterized by 1 -2 centrally located areas of activity or a 
diffuse cytoplasmic red -brown reaction. The latter pattern 
represents monocytes and macrophages. Neutrophils do not 
stain and lymphocytes may stain with the focal type of 
pattern. On each slide 200 cells were counted and the 
proportion of non- specific esterase positive cell calculated. 
Page 137 
5.6.8. Macrophage culture 
The methodology which had been established previously by the author 
was extended using microtitre culture techniques (Beavis et al, 1989 
Appendix 2). After counting and resuspension of the harvested in 
culture medium cells to a concentration of 106 cells /mL, 300uL 
aliquots were placed in triplicate in 96 well polystyrene tissue 
culture plates (Flow Laboratories: Irvine, UK). These were 
incubated at 37 °C in 5% carbon dioxide, /95% air for one hour. The 
culture medium was then removed from each well by aspiration 
through a sterile 21 guage hypodermic needle. Fresh M -199 culture 
medium was added to the wells and the plates incubated for a further 
20 hours. A 250uL sample of each well supernatant was removed and 
stored in 96 well polystyrene trays and sealed with a self- adhesive 
plate sealer (Flow Laboratories: Irvine, UK). The samples were 
stored overnight at -20 °C to be assayed the next day or, otherwise, 
stored at -70 °C. 
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Comparison of adherent and non -adherent cell populations (non- 
specific esterase stain). 
Peritoneal cell suspensions were obtained from six untreated control 
rats and prepared according to the preceding protocols and 
resuspended in culture medium at a concentration of 106 cells /mL. 
Replicate samples of each were placed in a 96 well polystyrene 
tissue culture plate. After one hour, the supernatants were removed 
and placed in polypropylene test -tubes. Adherent cells were removed 
from the wells by adding PBS containing 5mM EDTA, a polypropylene 
pipette tip was used to dislodge the cells and the sealed plates 
were shaken mechanically. Microscopic examination of the tissue 
culture plate monolayers before and after supernatant removal 
indicated that about one quarter of the adherent cells had not been 
removed. Cyto- centrifuge preparations of the thoroughly vortexed 
samples were made immediately and stained using the non -specific 
esterase technique (Table 5.6.2). In all samples at least 200 cells 
were counted. 
Table 5.6.2 
Comparison of adherent and non- adherent cells 
non- specific esterase stain +ve 
mean SD 
adherent cells (n =6) 





The levels of prostaglandin E2 of the supernatant samples were 
determined using a high affinity rabbit polyclonal anti -PGE2 
radioimmunoassay and iodinated PGE2 tracer purchased as a kit from 
Du Pont UK Ltd (Stevenage, UK) using modifications to the suggested 
protocol. 
5.7.1. Introduction 
Prostaglandin E2 (PGE2) has been detected in plasma and urine and in 
a variety of human tissues ( Samuelsson et al, 1975). However, the 
level of PGE2 is often very low ( <10nM) and requires sensitive 
procedures for accurate measurement. The early methods of bioassay 
and gas chromatography /mass spectometry were either too insensitive, 
non -specific, or cumbersome for routine use (Samuelsson et al, 1970; 
Ferreira et al, 1967; Green et al, 1973). The development of 
specific antisera resulted in radioimmunoassays which approached the 
sensitivity required (Levine, 1973; Jaffe et al, 1974). However, 
the relatively low specific activity of the tritiated PGE2 used in 
these assays limited the sensitivity that could be obtained. High 
specific activity, iodinated, prostaglandin tracers were developed 
and used to increase the sensitivity of these radioimmunoassay 
systems (Maclouf et al, 1976). 
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5.7.2. Principle of the method 
The prostaglandin assay used in the current experiments is based on 
the use of an iodinated prostaglandin E2 as tracer and rabbit 
anti- prostaglandin E2 as the antiserum (specific antibody). 
The basic principle of the radioimmunoassay involves competitive 
binding, where a radioactive antigen competes with a non -radioactive 
antigen for a fixed number of antibody binding sites. When 
unlabelled antigen from standards or samples and a fixed amount of 
tracer (labelled antigen) are allowed to react with a constant and 
limiting amount of antibody as the amount of unlabelled antigen is 
increased (Figure 5.3). The binding activity of the antibody is 
quantitated using results obtained for the standards which are used 
to construct a standard (dose- response) curve from which the 
concentration of the unknowns are determined by interpolation. A 
typical binding curve is indicated (Figure 5.4) 
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FIGURE 5.3 Radioimmunoassay priciple 
Labelled antigen + Specific antibody : Labelled antigen 
Ag* Ab antibody complex 
Ag*Ab 
Unlabelled antigen 
Ag (in standard solutions 
or unknown samples) 
ar 




pg PGE2 added 
Figure 5.4 
100 
Typical standard curve for the prostglandin E2 
radioimmunoassay. 
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The methodology of the assay then deviates from the Du Pont kit 
method in that separation of the antibody -antigen complexes from 
free antigen is achieved by an incubation with normal rabbit serum 
and donkey antirabbit serum. The kit method achieves this 
separation with polyethylene glycol. One mL of the cold 
precipitating fluid is added to the tubes containing sample, tracer 
and antibody - and then incubated in an ice bath for 30 minutes. 
This is a precipitation method which is based on molecular size i.e. 
the difference in size of the smaller free antigen and the larger 
bound complex. Using this method, the antigen- antibody reaction is 
reversible and dissociation may be a problem. In order to avoid the 
variability associated with dispensing the viscous precipitating 
fluid and the temperature and duration of the incubation, the 
double- antibody method was used. This method allows a large lattice 
to build up and this with the labelled antigen whichis bound to the 
first antibody can be precipitated (Hunter, 198 ). In general, the 
disadvantages of the double antibody method relate to the increased 
cost and to the need to use the second antibody in relatively large 
concentrations. 
After centrifugation, the supernatant containing the unbound antigen 
is decanted, and the pellet containing the antibody -antigen complex 
is counted in a gamma counter. Results obtained for the standards 
are used to construct a standard (dose- response) curve from which 
the unknowns are read by computerized interpolation. 
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5.7.3. Reagent description and preparation 
a) PGE2 [ 
1251 
] Tracer (Du Pont UK Ltd; Stevenage, UK) 
The tracer concentrate contained < 2uCi of PGE2, [125I], in 
0.75mL of acetonitrile. Stored at -20oC, the tracer was 
stable for at least one month after receipt in the 
laboratory. The half -life of this isotope is 80 days. 
For use in the assay, an appropriate aliquot of tracer 
concentrate was diluted 1:20 (v:v) in assay buffer in a 
polypropylene tube. The tracer was transferred using a 
positive displacement pipettor (Oxford, Eire) and 
disposable polypropylene pipette tips (Oxford, Eire). 
b) PGE2 Antibody (Du Pont UK Ltd; Stevenage, UK) 
The lypholized rabbit anti -PGE2 was stored at 2 -8 °C and was 
stable for two months after receipt. It was reconstituted 
with 13mL of assay buffer for use. This solution was 
stored at 2 -8 °C and was stable for two months. 
c) PGE2 Standard Concentrate (Du Pont UK Ltd; Stevenage, UK) 
This solution contained 100 ng /mL of prostaglandin E2 in 
acetonitrile. Immediately before use in the assay, an 
aliquot of the stock solution was diluted to prepare 
standards (vide infra). Stored at -20oC, the tracer was 
stable for at least two months after receipt in the 
laboratory. Care was taken to avoid evaporation of the 
solvent and resultant concentration of the standard. 
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Unnecessary exposure to air and ambient temperature was 
avoided and after use the vials were capped and immediately 
returned to the freezer. 
d) Assay Buffer (Du Pont UK Ltd; Stevenage, UK) 
This solution consisted of 0.9% NaC1, 0.01M EDTA, 0.3% 
bovine gamma globulin, 0.005% Triton -X -100, 0.05% sodium 
azide, 0.0255M NaH2PO4.H20, 0.0245M Na2HPO4.7H20, pH 6.8. 
Stored at at 2 -8 °C and was stable for two months. 
Additional buffer solution was made as necessary to the 
same composition (all materials - Sigma: Poole, UK). The 
assay buffer contained additives (Triton -X -100 and gamma 
globulin) which minimize the non -specific adsorption of 
prostaglandin E2 to the wall of the test tubes used in the 
assay. 
e) Donkey Anti -Rabbit Serum (Scottish Antibodies Production 
Unit, Carluke, UK) 
This antibody forms complexes with the the anti -PGE2 
antibody in the assay. The donkey anti- rabbit serum (DARS) 
was stored at -20 °C, and the same batch was used throughout 
the experiments. The DARS was diluted 1:8 (v:v) to obtain 
a working stock. 
Optimization of the DARS concentration in this assay had 
been performed previously. Different dilutions of DABS 
were tested to find the concentration that gave 
approximately 50% binding in the zero standard. For the 
batch used in this assay a 1:8 (v:v) dilution was used. 
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f) Normal rabbit Serum (Scottish Antibodies Production Unit, 
Carluke, UK) 
This antibody aids formation of large complexes. The 
normal rabbit serum (NRS) was stored at -20 °C, and the same 
batch used throughout the experiments. The NRS was diluted 
1:140 (v:v) to obtain a working stock. 
5.7.4. Sample handling 
Sample handling was performed using the Oxford Sampler System range 
of positive displacement pipettes (Oxford, Eire). The pipette tips 
were disposable and made of polypropylene (Oxford, Eire). The 
peformance characteristics of these pipettes were assessed by 
weighing consecutive dispensed aliquots on a microbalance. The 
50 -200uL pipette was the principal pipette used in this assay and 
the performace characteristics are tabulated in Table 5.7.1. 
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TABLE 5.7.1 
Sample handling - performance characteristics of 50 -200uL pipette 
Volume set number of Mean weight Standard coefficient 
uL measurements ug deviation of variation 
50 20 47.680 0.7010 2.6% 
100 20 96.340 1.3830 1.4% 
150 20 145.995 1.0267 0.7% 
This pipette was also tested by dispensing 100uL aliquots of [14C] 
phosphatidylcholine into test tubes and counting the scintillation 
in a beta counter. By this method a coefficient of variation of 
3.717% was observed. 
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5.7.5. Procedure 
a) Preparation of Prostaglandin E2 Working Standards 
An aliquot of the PGE2 standard concentrate (tube "a" in 
the dilution scheme - Table 5.7.3) was diluted with assay 
buffer in order to prepare a series of working prstaglandin 
E2 standards (tubes b -h in the dilution scheme). The 
dilution to cover a standard curve range of 0.25pg to 25pg 
added (per 0.1mL) is shown in Table 5.3. Working 
standards were freshly prepared immediately before use and 
were placedin 3.5mL polypropylene test tubes (Sarstedt: 
Leicester, UK). 
TABLE 5.7.3 












0.1mL (100uL) standard + 1.9mL assay buffer 500 
0.1mL of dilution a + 1.9mL assay buffer 25 
0.4mL of dilution b + 0.6mL assay buffer 10 
0.4mL of dilution c + 0.4mL assay buffer 5 
0.4mL of dilution d + 0.4mL assay buffer 2.5 
0.4mL of dilution e + 0.6mL assay buffer 1.0 
0.4mL of dilution f + 0.4mL assay buffer 0.5 
0.4mL of dilution g + 0.4mL assay buffer 0.25 
*This concentration represents actual mass added to the assay tube. 
Dilutions b to h were used for the standard curve. 
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b) Radioimmunoassay procedure 
All reagents were prepared as previously described, mixed 
and allowed to equilibrate to room temperature. 
Polypropylene 3.5mL centrifuge tubes (Sarstedt, Leicester, 
UK) were labelled in duplicate for total counts, blank each 
standard and each sample. 100uL of each diluted standard 
(b -h) were put into tubes in duplicate and 100uL of each 
diluted sample were pipetted in duplicate into the 
appropriate tubes. 100u1 of tracer solution was added to 
each tube and the solutions vortexed at 2200 cycles per 
minute for 5 seconds (Sarstedt CM -9: Leicester, UK). 100uL 
of antiserum were pipetted into all tubes containing 
standards and samples and vortexed for 5 seconds. 
The samples were incubated for two hours at room 
temperature. Then, 100uL of normal rabbit serum were added 
to the the blank, standard and sample tubes and mixed. 
Next, 100uL of donkey anti -rabbit serum were added and 
vortexed. The tubes were capped and placed in the fridge 
to incubate at 4 °C for 18 hours. The tubes were then 
centrifuged in a refrigerated centifuge at 1,550 x g for 30 
minutes at 4 °C. With the exception of the total counts 
tubes, the supernatants were decanted and blotted on 
absorbant paper. All tubes were then counted in a gamma 
counter. 
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c) Radioimmunoassay controls 
The assay system included the following controls: 
TOTAL COUNTS - containing 100uL tracer only 
BLANK- containing 200uL buffer, 100uL tracer 
0 STANDARD - containing 100uL buffer, 100uL tracer, 100uL 
anti -PGE antibody 
STANDARD SAMPLES - seven concentrations in duplicate 
(Table 5.7.3) 
INTRA -ASSAY CONTROLS - containing standard samples 
appropriate to the mid -point of the linear portion of the 
radio -ligand binding curve (5pg PGE2). At least six 
control tubes were included distributed throughout the 
assay, but upto twelve tubes were included in the larger 
assays ( >50 samples). 
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5.7.6. Gamma counter 
Bound radiolabelled PGE2 was analysed using the LKB Wallac 
Multigamma 1260 gamma counter was used (LKB: Stockholm, Sweden). 
This was a microcomputer controlled gamma counter which 
simultaneously counts 12 samples of a gamma emitting isotope. 
5.7.7. Calculation of unknowns 
The microcomputer used a spline function program to calculate the 
concentration of the unknowns. The spline function method provides 
a means of describing the standard curve in radioimmunoassay which 
allows calculation of the concentration of unknown samples with a 
high degree of precision. The mathematical procedures relating to 
spline function have been described in detail in the literature 
(Grenville, 1967; Reinsch, 1967; Reinsch, 1971; Hayes, 1974). 
All counts were corrected to counts per minute (CPM). The counts 
were averaged for each set of duplicates. The net counts for all 
standards and samples were calculated by subtracting from each the 
average blank counts. 
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The normalized percent bound ( %B /B0) for each standard and sample 
was calculated according to the formula: 
%B /B0 = net CPM of standard or sample x 100 
net CPM of "0" standard 
The computer plotted %B /B0 for each standard using a semilogarithmic 
graph versus the corresponding amounts of of PGE2 added in 
picograms. The PGE2 in each sample was determined (by the computer) 
by interpolation from the standard curve. The sample values were 
then corrected for dilution to determine the original concentration 
in the supernatant sample. 
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5.7.8 Cross -reactivity of the assay 
The manufacturer's manual gives data concerning cross -reactivity 
(Table 5.7.4). 
TABLE 5.7.4 
Cross -reactivity of PGE2 antibody used in assay. 







Thromboxane B2 0.02 
PGF2 <0.01 
Compound % cross- 
reactivity 





Linoleic acid <0.001 
PGD2 <0.001 
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5.7.9. Reproducibility of the assay 
Intra -assay reproducibility was evaluated by running multiple 
replicates of samples with of known concentration of PGE2 standard 
concentrate dilutions (TABLE 5.7.5). 
TABLE 5.7.5 
Intra -assay variation (5pg PGE2 added to tube) 






1 8 2793 214 13% 
2 8 3463 306 9% 
3 6 1860 106 6% 
4 6 2766 186 7% 
5 8 2767 98 3.5% 
6 6 2764 187 7% 
7 12 1976 137 7% 
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5.7.10. Inter -assay variation 
Inter -assay reproducibility was evaluated on the one occassion when 
two separate batches of tracer were available, but using the same 
batches of antibody and standard PGE2 concentrate (Table 5.7.6). 
TABLE 5.7.6 
Inter -assay reproducibility 
Tracer 
A 
Replicates PGE2 added RIA concen- SD 
tration, mean 
6 5pg 4.22pg 1.08 
B 7 5pg 4.80pg 
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0.84 
5.7.11 Effects of storage conditions on sample PGE2 
concentration 
PGE2 standard concentrate was diluted in assay buffer. Aliquots of 
PGE2 solution containing 5pg /100uL were added to polystyrene 96 well 
culture plates and also to sterile polypropylene 2mL storage vials. 
The samples were stored at -20 °C for 24 hours. They were then 
thawed and assayed for PGE2 (Table 5.7.7). There was no significant 
difference between the two methods of storage. 
TABLE 5.7.7 
Effects of storage conditions on sample PGE2 assay 
Container Replicates PGE2 added Corrected SD 
(n) counts /min 
Polystyrene 6 5pg 2767 104 
Polypropylene 8 5pg 2763 205 
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5.7.12. Matrix correction 
The samples from the cell culture supernatants include diluted fetal 
calf serum. To investigate the possibility of fetal calf serum 
affecting the binding curve, standard curves were performed with two 
concentrations of fetal calf serum and compared with a standard 
curve derived from samples in normal buffer. 
Fetal calf serum was added to buffer to obtain concentrations 
equivalent to a 1:50 (v:v) and 1:100 (v:v) dilutions of supernatant 
samples. These dilutions were required in concurrent experiments 
not described here. The final concentration of fetal calf serum in 
the assay buffer were therefore 0.15% and 0.075% respectively. The 
resultant binding curves are shown in Figure 5.5. It will be seen 
that there is a clear shift to the left with a fetal calf serum 
concentration of 0.15 %. The effect of 0.075% FCS is less clear, but 
a similar shift was found when the experiment was repeated (data not 
shown). In all subsequent assays, the standards were diluted with 
buffer containing a constant concentration of FCS (0.75 %). 
Supernatant samples were diluted 1:9 (v:v) with normal buffer and 
further dilutions made with buffer containing 0.75% FCS. 
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Page 159 
5.7.13. Macrophage PGE2 production - time course 
The time course of this rat peritoneal macrophage PGE2 production 
had been established previously (Beavis et al, 1989: Appendix 2). 
PGE2 was generated by resting cultured peritoneal macrophages in a 
time dependent manner reaching a maximum after 19 hours of 
incubation (Figure 5.6). In order to check the level of the plateau 
of PGE2 produced by resting cells, replicate macrophage preparations 
from an individual rat were cultured for 18 and 24 hours 
respectively. The results indicated a level of 2000- 2500pg per 106 
macrophages (Table 5.7.8). The higher level of PGE2 production 
found in the Edinburgh laboratory compared with that found in the 
Cardiff laboratory is probably due to the different method of 
counting macrophages in the peritoneal cell suspension: the previous 
method depended on morphological features to identify macrophages 
and this probably over -estimated the number present. 
TABLE 5.7.8 
Macrophage PGE2 production after 18 and 24 hours culture 
n PGE2 production /106 macrophages 
18 hour culture 9 
24 hour culture 9 
2272pg (SD =1637) 
2536pg (SD =2184) 
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Macrophage PGE2 production time course 
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Pilot study: macrophage prostaglandin E2 production by normal 
control rats and by rats transfused with allogeneic blood - 
time course studies (see Appendix 2). 
Page 161 
5.7.14. PGE2 production by adherent and non -adherent cells 
Replicate samples of five control rat peritoneal cell suspensions in 
culture medium were plated out and cultured for one hour. 
Supernatants were removed from each well and put in separate empty 
wells on the same plate. Fresh culture medium was added to the 
original wells containing the adherent cells. The cells were 
cultured for a further 20 hours. The supernatants from the adherent 
cell wells were removed and stored in polypropylene vials and 
assayed for PGE2 the next day. The cell suspensions from the wells 
containing non -adherent cells were removed and placed in 
polypropylene centrifuge tubes and centrifuged at 300g for 10 
minutes. Samples of the resultant supernatants were stored in 
polypropylene vials and assayed with the first set of samples (Table 
5.7.9). It should be noted that the non -adherent cell sample 
includes PGE2 produced by the total cells during the first culture 
period of one hour (to allow macrophage adherence to take place). 
TABLE 5.7.9 
PGE2 production by adherent and non -adherent cells 
(n) mean SD 
adherent cells, PGE2 pg/106 macrophages 5 1213 45 
non -adherent cells, PGE2 pg /mL 5 160 35 
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5.7.15. Statistical analysis 
Statistical analysis has been performed using a non -parametric 
method for paired data (Wilcoxon rank sum test). The reasons for 
using a paired analysis are twofold, the first was planned and the 
second became obvious as the experiment progressed. The use of 
paired analysis was endorsed by the statistical adviser to this part 
of the project (Dr G Raab). Firstly, within each cycle, each of the 
two or three subgroups was transfused with fresh blood, stored blood 
or serum derived from one syngeneic or allogeneic rat. A paired 
analysis was performed between fresh and stored blood transfusions 
because both blood units were obtained from the same rat. Secondly, 
there was an obvious variation in results with the separate 
experimental groups through the course of the experiment (Table 
5.7.10). The experiment was carried out in five cycles: the first 
two cycles each hade two groups of eight rats, while the last three 
cycles had three groups of eight rats. The PGE2 /106 macrophages of 
the first two groups were much lower on average than those levels 
found in the last three groups and this was independent of the 
macrophage counts. A paired analysis could also be made between the 
transfused and control rats within subgroups because the cells 
retrieved were subjected to the same experimental conditions. A 
sizable inter -assay variation relating to the radio -immunoassay was 
demonstrated and this may have contributed. There may have been 
unknown differences in the animals, such as infection causing 
pre -stimulation of the monocytes. 
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TABLE 5.7.10 
Inter cycle variation in PGE2 production. 
Cycle - 
(date started) 






1 (4.12.89) 12 15.0 (7.2) 40.6 (15.1) 2358 (1890) 
2 (8.1.90) 15 14.8 (6.2) 42.1 (7.1) 2501 (2089) 
3 (22.1.90) 22 10.5 (2.4) 31.0 (6.9) 7410 (4478) 
4 (12.2.90) 22 11.6 (2.7) 41.7 (7.1) 4580 (1893) 
5 (27.2.90) 22 11.2 (2.9) 39.2 (6.2) 7134 (3917) 
Cycle: this consisted of 2 or 3 groups which each contained 8 
individual rats each of which seven received a different transfusion 
and one was untreated. The dates of RIA were - 1: 14.12.89; 
2: 17.1.90; 3: 21.2.90; 4: 21.2.90; 5: 7.3.90. 
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6.1. CLINICAL RETROSPECTIVE STUDY 
6.1.1. Patients and exclusions 
During the period 1977 -1980, 314 patients underwent bowel resection 
for colorectal cancer. After exclusion of patients who had 
palliative surgery, patients who died during the perioperative 
period, and patients whose records were incomplete, there were 236 
patients left to study (Table 6.1.1). 
TABLE 6.1.1 
Exclusions 
incomplete records 12 
perioperative deaths 25 
palliative surgery only 41 
curative resection 236 
total 314 
The mean length of follow -up for the whole group (n = 236) was 34.1 
months. The length of follow -up in months: mean (SD), was similar 
in transfused and non -transfused patients: 32.6 (22.7) months versus 
37.5 (23.6) months respectively. 
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6.1.2. Clinical features 
The distribution of tumour site in the 256 patients who had curative 
resections, including abdomino -perineal resections, is shown in 
Table 6.1.2. 
TABLE 6.1.2 







high /mid rectum 
low rectum 
total 
n (% total) % transfused 
22 9% 59% 
25 11% 68% 
13 5% 46% 
16 7% 56% 
45 19% 51% 
38 15% 71% 
77 30% 91% 
256 100% 70% 
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Blood transfusions were given to 165 patients (70 %). This group was 
compared with the group of 71 patients who did not receive blood 
transfusions (Table 6.1.3). 
TABLE 6.1.3 
Comparability of patients who received blood and those who did not 
- clinical features. 
Blood transfusions 
Variable 
sex: n, % 
Yes (n =165) No (n =71) P 
male 88, 53% 37, 53% 
female 77, 47% 34, 47% N.S. 
age: years - mean (SD) 68.4 (11.2) 66.7 (11.2) N.S. 
presentation for surgery: n, % 
emergency 11, 7% 12, 17% 
elective 154, 93% 59, 83% 0.028 
Student's t test or Chi square test 
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TABLE 6.1.4 
Comparability of patients who received blood and those who did not - 
pathological features. 
Variable 
site of tumour: n, % 
Blood transfusions 
Yes (n =165) No (n =71) p* 
right colon 
left colon and rectum 
adherent tumour: n, % 
annular tumour: n, % 
























- mean (SD) 
clinical stage: n, °,6 
Dukes B 111, 67% 49, 69% N.S. 
Dukes C 






















* Student's t test or Chi square test 
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TABLE 6.1.5 
Distribution of surgeons performing the curative resection. 











Yes (n =165) No (n =71) 
44, 27% 17, 24% 
9, 5% 4, 6% 
15, 9% 4, 6% 
9, 5% 4, 6% 
22, 13% 10, 14% 
23, 14% 10, 14% 
43, 26% 22, 31% 
99, 60% 39, 55% 
66, 40% 32, 45% 
TABLE 6.1.6 
Patients undergoing staged procedures 





Yes (n =165) No (n =71) p* 










However, significantly more of the transfused patients had a staged 
resection rather than a single operation compared with 
non- transfused patients (39/165 versus 8/71; p = 0.045). 
The pathologists reported the number of lymph nodes seen in the 
resected specimen and counted the number of lymph nodes in which 
tumour was seen (Table 6.1.7). Lymph node involvement was seen in 
54/165 in the transfused group and in 22/71 in the non -transfused 
group. 
TABLE 6.1.7 
Lymph node involvement in patients with Dukes C lesions 
Blood transfusions 
Variable Yes (n =54) No (n =22) p* 
lymph nodes seen: mean (SD) 7.13 (6.15) 5.59 (3.28) N.S. 
lymph nodes involved: mean (SD) 2.72 (2.07) 2.18 (1.82) N.S. 
* Student's t test. 
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6.1.3. Survivorship data 
TABLE 6.1.8a 
Life table calculations for transfused patients: all deaths during 
60 month period following curative resection of colorectal cancer. 
time at est. probability percentage 
(months) died lost alive risk death survival survivors 
0 -6 15 1 165 164.5 0.09 0.91 100 % 
7 -12 13 4 149 147 0.09 0.91 90.88 
13 -18 12 7 132 128.5 0.09 0.91 82.84 
19 -24 16 2 113 112 0.14 0.86 75.11 
25 -30 14 3 95 93.5 0.15 0.85 64.38 
31 -36 10 1 78 77.5 0.13 0.87 54.74 
37 -42 7 4 67 65 0.11 0.89 47.68 
43 -48 8 3 56 54.5 0.15 0.85 42.54 
49 -54 5 4 45 43 0.12 0.88 36.30 
55 -60 1 9 36 31.5 0.03 0.97 32.08 
>60 26 31.06 
See Figure 6.1 
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TABLE 6.1.8b 
Life table calculations for non -transfused patients: all deaths 
during 60 month period following curative resection of colorectal 
cancer. 
time at est. probability percentage 
(months) died lost alive risk death survival survivors 
0 -6 5 1 71 70.5 0.07 0.93 100% 
7 -12 7 1 65 64.5 0.11 0.89 92.91 
13 -18 4 1 57 56.5 0.07 0.93 82.82 
19 -24 3 1 52 51.5 0.06 0.94 76.96 
25 -30 6 2 48 47 0.13 0.87 72.48 
31 -36 3 1 40 39.5 0.08 0.92 63.23 
37 -42 0 4 36 34 0.00 1.00 58.42 
43 -48 2 3 32 30.5 0.07 0.93 58.42 
49 -54 3 3 27 25.5 0.12 0.88 54.59 
55 -60 1 4 21 19 0.05 0.95 48.17 
>60 16 45.63 






0 20 40 60 
months 
on 
Life table analysis 5 year survival curves for patients 
undergoing curative resection for colorectal cancer. 
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TABLE 6.1.8c 
Life table calculations for transfused patients: recurrence -free 












0 -6 20 1 165 164.5 0.12 0.88 100% 
7 -12 18 3 144 142.5 0.13 0.87 87.84 
13 -18 14 6 123 120 0.12 0.88 76.75 
19 -24 18 2 103 102 0.18 0.82 67.79 
25 -30 10 3 83 81.5 0.12 0.88 55.83 
31 -36 7 1 70 69.5 0.10 0.90 48.98 
37 -42 8 4 62 60 0.13 0.87 44.05 
43 -48 9 3 50 48.5 0.19 0.81 38.17 
49 -54 3 4 38 36 0.08 0.92 31.09 
55 -60 1 9 31 26.5 0.04 0.96 28.50 
>60 21 25.36 
See Figure 6.2 
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TABLE 6.1.8d 
Life table calculations for non -transfused patients: recurrence -free 












0 -6 7 1 71 70.5 0.10 0.90 100% 
7 -12 12 1 63 62.5 0.19 0.81 90.07 
13 -18 3 1 50 49.5 0.06 0.94 72.78 
19 -24 3 1 46 45.5 0.07 0.93 68.37 
25 -30 4 1 42 41.5 0.10 0.90 63.86 
31 -36 3 1 37 36.5 0.08 0.92 57.70 
37 -42 2 3 33 31.5 0.06 0.94 52.96 
43 -48 2 2 28 27 0.07 0.93 49.6 
49 -54 1 3 24 22.5 0.04 0.96 45.92 
55 -60 2 4 20 18 0.11 0.81 43.88 
>60 14 39.01 






20 40 60 
months 
80 
Life table analysis 5 year recurrence -free survival curves for 
patients undergoing curative resection for colorectal cancer. 
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TABLE 6.1.8e 
Comparison between survival rates of transfused and non -transfused 
patients following curative resection of colorectal cancer with 




SE 95% con limits 
non -transfused 
%survival SE 95% con limits 
0 -6 100 0.00 100.00 100.00 100 0.00 100.00 100.00 
6 -12 90.88 2.24 86.48 95.28 92.91 3.06 86.92 98.90 
12 -18 82.84 2.13 78.67 87.02 82.82 3.60 75.77 89.88 
18 -24 75.11 2.13 70.94 79.28 76.96 2.83 71.42 82.50 
24 -30 64.38 2.48 59.51 69.25 72.48 2.51 67.55 77.40 
30 -36 54.74 2.38 50.08 59.39 63.23 3.53 56.31 70.14 
36 -42 47.68 2.08 43.59 51.76 58.42 2.67 53.20 63.65 
42 -48 42.54 1.83 38.95 46.13 58.42 0.00 58.42 58.42 
48 -54 36.30 2.04 32.30 40.29 54.59 2.62 49.46 59.72 
54 -60 32.08 1.77 28.60 35.55 48.17 3.48 41.34 55.00 
>60 31.06 1.00 29.09 33.02 45.63 2.47 40.80 50.47 
The logrank test gives a chi -squared value of 3.25; p > 0.05. 
The Mantel -Haenszel method gives a standardised normal deviate of 
1.902; p < 0.03. 
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TABLE 6.1.8f 
Comparison between recurrence -free survival rates of transfused and 
non -transfused patients after curative resection of colorectal 




SE 95% con limits 
non- transfused 
%survival SE 95% con limits 
0-6 100 0.00 100.00 100.00 100 0.00 100.00 100.00 
6-12 87.84 2.55 82.85 92.84 90.07 3.56 83.09 97.05 
12-18 76.75 2.44 71.95 81.54 72.78 4.49 63.98 81.57 
18-24 67.79 2.25 63.38 72.20 68.73 2.47 63.53 73.20 
24-30 55.83 2.56 50.81 60.84 63.86 2.52 58.93 68.79 
30-36 48.98 2.03 45.00 52.96 57.70 2.93 51.97 63.44 
36-42 44.05 1.77 40.58 47.51 52.96 2.62 47.82 58.10 
42-48 38.17 1.93 34.38 41.96 49.60 2.30 45.09 54.11 
48-54 31.09 2.13 26.91 35.27 45.92 2.50 41.02 50.82 
54-60 28.50 1.43 25.69 31.31 43.88 2.00 39.97 47.79 
>60 27.42 1.05 25.36 29.49 39.01 3.25 32.64 45.38 
The logrank test gives a chi -squared value of 2.016; p > 0.05. 
The Mantel- Haenszel method gives a standardised normal deviate of 
1.514; p > 0.06. 
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In order to restrict analysis to patients undergoing an abdominal 
resection only, the patients who had low rectal lesions treated by 
abdomino- perineal resection were excluded. 
Of the 159 patients in the study group, excluding abdomino -perineal 
resections, 95 (60 %) received one or more transfusions of whole 
blood or packed red cells. The number of units of blood transfused 
varied between 1 and 13 with a mean of 3.1 units. The patients who 
received blood were similar to those who did not when the clinical 
factors were compared, with the exception of preoperative 
haemoglobin concentration (Table 6.1.9). The patients who were 
transfused had a lower preoperative haemoglobin than those who were 
not. When the pathological features of the two groups were 
compared, some significant differences were found (Table 6.1.10). 
The seniority of the surgeon did not influence the transfusion rate. 
When a consultant performed the resection 58% of patients (n =80) 
were transfused. When the resection was performed by a junior 
surgeon 61% of patients (n =79) were transfused. A higher proportion 
of patients who had staged procedures (n =40) were transfused 
compared with those who had a primary resection (n =119); (83% versus 
52 %, p <0.002). 
Page 181 
TABLE 6.1.9 
Comparability of patients who received blood and 




Yes (n =95) No (n =64) p* 
male 46 48 
female 54 52 N.S. 
Age, years - mean (SD) 68.9 (10.1) 66.3 (11.4) N.S. 
Preoperative haemoglobin 
males, g /dl - mean (SD) 12.5 (2.37) 14.1 (2.25) <0.01 
females, g /dl - mean (SD) 12.0 (1.94) 13.6 (1.84) <0.01 
Presentation for surgery, % 
emergency 12 19 
elective 88 81 N.S. 
* 
Student's t test or Chi square test 
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TABLE 6.1 .10 
Comparability of patients who received blood and 
those who did not - pathological features. 
Blood transfusions 
Variable Yes (n =95) No (n =64) p* 
Site of tumour, % 
right colon 38 38 
left colon and rectum 62 62 N.S. 
Tumour adherent to 31 14 <0.05 
other structures, % 
Annular tumour, % 34 17 <0.05 
Tumour diameter, cms 4.0 (1.52) 4.2 (1.62) N.S. 
- mean (SD) 
Clinical stage, % 
Dukes B 72 70 
Dukes C 28 30 N.S. 
Histological grade 
well differentiated 36 34 
moderately differentiated 58 61 
poorly differentiated 6 5 N.S. 
* Student's t test or Chi square test 
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TABLE 6.1.11a 
Life table calculations for transfused patients: all deaths during 
60 month period following curative resection of colorectal cancer 
(excluding AP resections). 
time 







0 -6 8 0 95 95.0 0.08 0.92 100% 
7 -12 7 3 87 85.5 0.08 0.92 91.58 
13 -18 4 4 77 75.0 0.05 0.95 84.08 
19 -24 10 2 69 68 0.15 0.85 79.60 
25 -30 8 3 57 55.5 0.14 0.86 67.89 
31 -36 7 0 46 46 0.15 0.85 58.11 
37 -42 5 3 39 37.5 0.13 0.87 49.26 
43 -48 5 1 31 30.5 0.16 0.84 42.69 
49 -54 1 6 25 22 0.05 0.95 35.70 
55 -60 0 3 18 16.5 0.00 1.00 34.07 
>60 15 34.07 
See Figure 6.3 
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TABLE 6.1.11b 
Life table calculations for non -transfused patients: all deaths 
during 60 month period following curative resection of colorectal 
cancer (excluding AP resections) 
time 







0 -6 5 1 64 63.5 0.08 0.92 100% 
7 -12 6 0 58 58 0.10 0.90 92.13 
13 -18 3 1 52 51.5 0.06 0.94 82.60 
19 -24 3 1 48 47.5 0.06 0.94 77.78 
25 -30 4 2 44 43 0.09 0.91 72.87 
31 -36 2 1 38 37.5 0.05 0.95 66.09 
37 -42 2 3 35 33.5 0.06 0.94 62.57 
43 -48 1 3 30 28.5 0.04 0.96 58.83 
49 -54 3 3 26 24.5 0.12 0.88 56.77 
55 -60 1 4 20 18 0.06 0.94 49.82 
>60 15 47.05 




Life table analysis 5 year survival curves for patients 
undergoing curative resection for colorectal cancer (excluding 
patients who had abdomino- perineal resections. 
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TABLE 6.1.11c 
Life table calculations for transfused patients: recurrence -free 
survival during 60 month period following curative resection of 











0-6 10 0 95 95 0.11 0.89 100% 
7-12 10 2 85 84 0.12 0.88 89.47 
13-18 5 4 73 71 0.07 0.93 78.82 
19-24 13 2 64 63 0.21 0.79 73.27 
25-30 6 3 49 47.5 0.13 0.87 58.15 
31-36 3 1 40 39.5 0.08 0.92 50.81 
37-42 6 3 36 34.5 0.17 0.83 46.95 
43-48 4 1 27 26.5 0.15 0.85 38.78 
49-54 2 4 22 20 0.10 0.90 32.93 
55-60 0 4 16 14 0.00 1.00 29.64 
>60 12 29.64 
See Figure 6.4 
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TABLE 6.1.11d 
Life table calculations for non -transfused patients: recurrence -free 
survival during 60 month period following curative resection of 











0 -6 7 1 64 63.5 0.11 0.89 100% 
7 -12 9 0 56 56 0.16 0.84 88.98 
13 -18 2 1 47 46.5 0.04 0.96 74.68 
19 -24 3 1 44 43.5 0.07 0.93 71.46 
25 -30 3 2 40 39 0.08 0.92 66.54 
31 -36 2 1 35 34.5 0.06 0.94 61.42 
37 -42 2 3 32 30.5 0.07 0.93 57.86 
43 -48 2 2 27 26 0.08 0.92 54.06 
49 -54 1 3 23 21.5 0.05 0.95 49.9 
55 -60 2 4 19 17 0.12 0.88 47.58 
>60 13 41.99 
See Figure 6.4 
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Figure 6.4 
Life table analysis 5 year recurrence -free survival curves for 
patients undergoing curative resection for colorectal cancer 
(excluding patients who had abdomino -perineal resections. 
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TABLE 6.1.11e 
Comparison between survival rates of transfused and non -transfused 
patients following curative resection (excluding AP resections) with 




SE 95% con limits 
non- transfused 
%survival SE 95% con limits 
0 -6 100 0.00 100.00 100.00 100 0.00 100.00 100.00 
6 -12 91.58 2.85 85.99 97.16 92.13 3.38 85.50 98.75 
12 -18 84.08 2.72 78.76 89.08 82.60 3.68 75.38 89.82 
18 -24 79.60 2.18 75.32 83.87 77.78 2.70 72.50 83.07 
24 -30 67.89 3.42 61.19 74.59 72.87 2.75 67.49 78.25 
30 -36 58.11 3.20 51.83 64.38 66.09 3.23 59.77 72.42 
36 -42 49.26 3.08 43.23 55.29 62.57 2.43 57.81 67.32 
42 -48 42.69 2.73 37.33 48.05 58.83 2.56 53.81 63.85 
48 -54 35.70 2.86 30.09 41.31 56.77 2.03 52.79 60.74 
54 -60 34.07 1.59 30.97 37.18 49.82 3.76 42.45 57.19 
>60 34.07 0.00 34.07 34.07 47.05 2.69 41.78 52.32 
The logrank test gives a chi -squared value of 2.196; p > 0.05. 
The Mantel -Haenszel method gives a standardised normal deviate of 
1.5547; p = 0.06. 
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TABLE 6.1.11f 
Comparison between recurrence -free survival rates of transfused and 
non- transfused patients after curative resection (excluding AP 




SE 95% con limits 
non- transfused 
%survival SE 95% con limits 
0 -6 100 0.00 100.00 100.00 100 0.00 100.00 100.00 
6 -12 89.47 3.15 83.30 95.65 88.98 3.93 81.27 96.68 
12 -18 78.82 3.16 72.63 85.02 74.68 4.37 66.12 83.24 
18 -24 73.27 2.39 68.58 77.96 71.46 2.22 67.11 75.82 
24 -30 58.15 3.74 50.83 65.47 66.54 2.75 61.15 71.92 
30 -36 50.81 2.80 45.31 56.30 61.42 2.84 55.85 66.98 
36 -42 46.95 2.14 42.75 51.15 57.86 2.44 53.07 62.65 
42 -48 38.78 3.03 32.84 44.72 54.06 2.59 48.98 59.15 
48 -54 32.93 2.70 27.64 38.22 49.90 2.83 44.37 55.44 
54 -60 29.64 2.21 25.31 33.97 47.58 2.27 43.14 52.03 
>60 29.64 0.00 29.64 29.64 41.99 3.72 34.70 49.27 
The logrank test gives a chi -squared value of 0.84; p > 0.25. 
The Mantel -Haenszel method gives a standardised normal deviate of 
1.271; p > 0.11. 
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6.2 DIMETHYLHYDRAZINE (DMH) CARCINOGENESIS MODEL 
6.2.1. The carcinogenic effects of dimethylhydrazine in the 
Sprague Dawley rat (Experiment A) 
Experimental plan 
The aim of this experiment was to evaluate the dimethylhydrazine 
colonic cancer model in male Sprague Dawley rats. In particular, 
the time course of the carcinogenesis was analysed to enable future 
experiments to be planned. 
Eighty -nine 8 -week old male Sprague Dawley rats were divided into 
three groups. Group 1 consisted of 36 rats which received 16 weekly 
injections of dimethylhydrazine at a dose of 16 mg /kg body weight. 
The solution used included 1.5% EDTA as described in the Methods 
Section. Group 2 consisted of 36 rats which received 16 weekly 
injections containing only 1.5% EDTA. The volume of the dose was 
equal to the volume of dimethylhydrazine injections given to rats in 
Group 1. Group 3 consisted of normal rats. All rats were kept in 
plastic cages and fed with the normal diet and given water ad 
libitum. Each rat had been numbered and was weighed at weekly 
intervals prior to each injection and at intervals thereafter. 
Surviving rats were killed at 36 weeks after the first carcinogenic 
injection. A postmortem examination was performed on these rats and 
also on rats which had died during the course of the experiments. 
Rats which were obviously in poor condition were killed. Some 
representative pathological specimens were examined histologically. 
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The growth of rats treated with dimethylhydrazine is compared with 
those in the control group (Table 6.2.1 and Figure 6.5). 
TABLE 6.2.1 
Growth rate - mean body weight (n; standard deviation) gm. 
Group 1 = dimethylhydrazine and EDTA. Group 2 = EDTA alone. 
group 1 group 2 p value* 
week number 
0 201 (36; 47.9) 209 (35; 25.8) 0.37 
2 329 (36; 54.2) 317 (35; 31.5) 0.30 
4 417 (36; 51.0) 446 (34; 39.4) 0.01 
6 483 (36; 52.7) 493 (34; 41.8) 0.39 
8 534 (36; 52.2) 565 (34; 47.1) 0.01 
10 572 (36; 57.4) 607 (34; 50.3) 0.01 
12 598 (36; 60.2) 641 (34; 58.5) 0.0035 
14 630 (36; 60.1) 682 (34; 65.8) 0.001 
16 648 (36; 61.9) 698 (34; 62.9) 0.0013 
24 709 (36; 58.6) 760 (32; 91.2) 0.007 
30 690 (23; 74.3) 815 (24; 93.9) 0.0001 
36 705 (10; 89.4) 799 ( 7; 97.9) 0.06 
* t test, comparing Group 1 with Group 2. 
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Figure 6.5 
Growth curves for male Sprague Dawley rats treated with 
dimethylhydrazine (DMH) or EDTA (control). 
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Carcinogenesis. 
There were no spontaneous tumours to be found in the rats injected 
with EDTA or in the group of normal rats. All the rats developed 
colonic tumours, some with metastatic disease. A few rats developed 
tumours of the small bowel. Some developed macroscopic tumours 
involving the external auditory canal. These tumours appeared as 
papilliform lesions appearing in the canal or as cystic lumps in the 
preauricular area of the face. Eventually the cysts burst, 
discharging a white caseous material, and then they became infected 
ulcers. When this type of lesion was noticed the affected rat was 
killed as the Home Office Inspector had directed. Other causes for 
withdrawing rats from the experiment are listed in Table 6.2.2. 
A small number of rats in each of the three groups developed signs 
of ataxia indicative of labyrinthitis probably due to a virus. This 
presented with the presence of "snuffles" on the nose and an 
abnormal posture. Affected rats could not maintain balance in what 
appeared to be a similar manner to humans suffering vertigo. These 
rats were also killed if these signs persisted. 
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TABLE 6.2.2 
Indications for killing rats during the experiment. 
group 1 group 2 group 3 
ataxia 3/13 1/1 1/1 
ear tumour 8/13 0/1 0/1 
poor condition (cancer) 2/13 0/1 0/1 
total number killed 13 1 1 
In group 1, fourteen rats died spontaneously during the course of 
the experiment and the probable causes of death found at post mortem 
examination are listed in Table 6.2.3. Two rats in group 2 died, 
one had signs of ataxia and had consolidated lungs at postmortem and 
the other rats had no obvious cause of death. One rat in group 3 
died and this was probably due to pneumonia. 
TABLE 6.2.3 
Cause of death in rats which died spontaneously (group 1 only). 
respiratory infection 1 
metastatic disease 4 
? colonic infarction 1 
unknown, but with bowel tumours 8 
total spontaneous deaths 14 
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The number of rats which were alive 36 weeks after starting 
dimethylhydrazine injections (group 1) was nine out of the original 
thirty -six (Table 6.2.4) 
TABLE 6.2.4 
Survival rates for rats treated with dimethylhydrazine (group 1). 
week number alive % survival 
0 36 100 
12 36 100 
24 32 89 
30 18 50 
36 9 25 
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The distribution of primary tumours found in all rats in group 1 is 
described in Table 6.2.5. Ten of these rats had metastatic 
deposits. Six rats had hepatic metastases and three of these rats 
also had omental or peritoneal deposits of tumour. Four rats had 
omental secondaries alone and one rat had lung metastases in 
addition to liver metastases. 
TABLE 6.2.5 







rats affected mean (SD, range) per rat 
35 4.78 (3.11, 0 -12) 
28 1.89 (1.76, 0 -7) 





6.3. T CELL SUBSETS IN NORMAL AND AGED SPRAGUE DAWLEY RATS 
(Experiment B) 
Experimental plan. 
The 16- week -old normal male Sprague Dawley rats used in this 
experiment were also used in Experiment D. Rats aged about 40 weeks 
were used and these had been some of the normal control animals in 
Experiment A. The aim of this experiment was to determine normal 
values for T lymphocyte subpopulations and to examine changes in the 
various subsets which might occur with age. Both groups of animals 
had been fed on a normal diet and had not been subject to previous 
investigation. In the course of this experiment some blood samples 
were taken which could not be analysed because the blood had clotted 
during venepuncture. Three samples were from the group of 16 week 
old rats and one from the older group. These rats were excluded 
from the study. The two groups are compared in Table 6.3.1. 
TABLE 6.3.1 
mean % cells labelled (SD) 
monoclonal antibody W3/13 W3/25 0X8 
16 wk old rats, n =16 65.0 (8.9) 27.2 (8.0) 36.6 (11.5) 
40 wk old rats, n =16 65.5 (7.1) 25.5 (6.0) 40.6 (8.1) 
p value (t test) 0.86 0.48 0.26 
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6.4 T LYMPHOCYTE SUBSETS AND THE DIMETHYLHYDRAZINE COLONIC 
CANCER MODEL. 
6.4.1. Do rats with advanced cancer have altered T cell 
subsets? (Experiment C). 
Experimental plan 
Peripheral blood lymphocyte subpopulations were enumerated in rats 
with advanced carcinogenesis. These rats were described in 
Experiment A and only nine of these were available for testing. One 
of these samples clotted. Sixteen rats were tested in group treated 
with EDTA injections (three rats excluded due to samples clotting). 
Sixteen of the age -matched controls were tested (one sample 
excluded) as part of Experiment B. These three groups are compared. 
The eight rats with cancer were compared with the first eight in the 
consecutive series of EDTA and normal age- matched rats respectively. 
TABLE 6.4.1 
Comparison of rats with advanced dimethylhydrazine -induced cancer 
with age- matched controls 
mean % cells labelled (SD) 
monoclonal antibody W3/13 W3/25 0X8 
rats with cancer, n =8 70.1 (7.7) 36.8 (6.5) 45.4 (9.6) 
controls, n =8 68.1 (7.5) 25.0 (7.7) 43.7 (7.4) 
p value (t test) 0.60 0.005 0.70 
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TABLE 6.4.2 
Comparison of rats with advanced dimethylhydrazine -induced cancer 
with age- matched rats treated with EDTA 
mean % cells labelled (SD) 
monoclonal antibody W3/13 W3/25 0X8 
rats with cancer, n =8 70.1 (7.7) 36.8 (6.5) 45.4 (9.6) 
EDTA- treated rats, n =8 74.4 (7.1) 30.1 (6.5) 58.4 (8.8) 
p value (t test) 0.26 0.057 0.014 
TABLE 6.4.3 
Comparison of rats treated with EDTA with age- matched controls 
mean % cells labelled (SD) 
monoclonal antibody W3/13 W3/25 0X8 
EDTA- treated rats, 
controls, n =16 












p value (t test) 0.50 0.56 0.05 
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Using the pre- transfusion samples from the rats in Experiments D1, 
D2, and E, the influence of eight previous weekly injections of 
dimethylhydrazine on lymphocyte subsets was examined (Table 6.4.4). 
TABLE 6.4.4 
Comparison of rats after 8 weekly injections of dimethylhydrazine 
(DMH) with normal age- matched controls 
mean % cells labelled (SD) 
monoclonal antibody W3/13 W3/25 0X8 
DMH rats, n =46 65.3 (11.1) 28.0 (10.0) 34.0 (8.4) 
normal rats, n =39 72.5 (10.0) 32.8 (9.3) 37.1 (9.07) 
p value (t test) 0.0026 0.022 0.103 
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6.5. ALLOGENEIC BLOOD TRANSFUSION AND T CELL SUBSETS 
6.5.1. T lymphocyte subets in normal rats treated with blood 
transfusion (Experiment D1) 
Experimental plan. 
Male Sprague Dawley rats, aged sixteen weeks received three 
intravenous transfusions of allogeneic blood from donor DA rats. 
The volume of each infusion was 1.5 ml and the interval between each 
was seven days. The blood was transfused within an hour of removal 
from the donor. Heparin was used for anticoagulation. T lymphocyte 
subsets in the peripheral blood were assessed before and two weeks 
after transfusion (Table 6.5.1) 
TABLE 6.5.1 
Effect of allogeneic blood transfusion on T lymphocyte subsets in 
normal 16 week old rats - paired data 
mean % cells labelled (SD) 
monoclonal antibody W3/13 W3/25 0X8 
pre -transfusion, n =14 76.7 (8.9) 37.6 (8.4) 36.3 (7.6) 
post -transfusion 67.7 (7.1) 32.9 (7.1) 36.5 (11.5) 
p value: t test 0.006 0.13 0.97 
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6.5.2. Effect of normal saline transfusion on T lymphocyte 
subsets in normal rats (Experiment D2) 
Experimental plan. 
This experiment was run concurrently with Experiment Dl. Male 
Sprague Dawley rats, aged sixteen weeks received three intravenous 
transfusions of heparinised 0.9% saline. The volume of each 
infusion was 1.5 ml and the interval between each was seven days. 
T lymphocyte subsets in the peripheral blood were assessed before 
and two weeks after transfusion (Table 6.5.21. 
TABLE 6.5.2 
Effect of 0.9% saline transfusion on T lymphocyte subsets in normal 
16 week old rats - paired data 
mean % cells labelled (SD) 
monoclonal antibody W3/13 W3/25 0X$ 
pre -transfusion, n =16 71.6 (8.4) 30.4 (9.8) 40.2 (9.2) 
post -transfusion 65.9 (7.2) 28.7 (10.7] 42.9 (13.2) 
p value: t test 0.045 0.64 0.55 
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6.5.3. T lymphocyte subsets in aged rats treated with blood 
transfusion (Experiment D3) 
Experimental plan. 
Male Sprague Dawley rats, aged 36 weeks received three intravenous 
transfusions of allogeneic blood from donor DA rats. The volume of 
each infusion was 1.5 ml and the interval between each was seven 
days. The blood was transfused within an hour of removal from the 
donor. Heparin was used for anticoagulation. T lymphocyte subsets 
in the peripheral blood were assessed before and two weeks after 
transfusion (Table 6.5.3). 
TABLE 6.5.3 
Effect of allogeneic blood transfusion on T lymphocyte subsets in 
normal 36 week old rats - paired data 
mean % cells labelled (SD) 
monoclonal antibody W3/13 W3/25 0X8 
pre -transfusion, n =6 63.3 (7.8) 23.1 (7.1) 37.5 (7.7) 
post- transfusion 69.3 (7.2) 23.8 (5.8) 47.2 (6.4) 
p value: t test 0.26 0.84 0.039 
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6.5.4. Effect of 0.9% saline transfusions on T lymphocyte 
subsets in aged rats (Experiment D4) 
Experimental plan. 
This experiment was run concurrently with Experiment D3. Male 
Sprague Dawley rats, aged 36 weeks received three intravenous 
transfusions of heparinised 0.9% saline. The volume of each 
infusion was 1.5 ml and the interval between each was seven days. T 
lymphocyte subsets in the peripheral blood were assessed before and 
two weeks after transfusion (Table 6.5.4). 
TABLE 6.5.4 
Effect of 0.9% saline transfusion on T lymphocyte subsets in normal 
36 week old rats - paired data 
mean % cells labelled (SD) 
monoclonal antibody W3/13 W3/25 0X8 
pre- transfusion, n =6 65.2 (9.2) 24.0 (2.4) 39.5 (8.4) 
post- transfusion 69.1 (12.7) 29.2 (4.4) 43.3 (6.9) 
p value: t test 0.56 0.029 0.42 
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6.6. TRANSFUSION AND T CELL SUBSETS IN RATS TREATED WITH DMH 
6.6.1. T lymphocyte subsets in rats treated with 
dimethylhydrazine effects of transfusion with blood 
(Experiment E1) 
Experimental plan. 
Male Sprague Dawley rats, aged sixteen weeks which had already 
received eight weekly subcutaneous injections of dimethylhydrazine, 
received three intravenous transfusions of allogeneic blood from 
donor DA rats. The volume of each infusion was 1.5 ml and the 
interval between each was seven days. Dimethylhydrazine injections 
continued during the course of transfusions. T lymphocyte subsets 
in the peripheral blood were assessed before and two weeks after 
transfusion (Table 6.5.1) 
TABLE 6.6.1 
Effect of allogeneic blood transfusion on T lymphocyte subsets in 
16- week -old rats which have been treated with dimethylhydrazine - 
paired data 
mean % cells labelled (SD) 
monoclonal antibody W3/13 W3/25 0X8 
pre -transfusion, n =17 65.8 (10.6) 27.2 (8.0) 35.2 (7.61) 
post- transfusion 68.0 (9.1) 24.2 (8.7) 33.9 (9.7) 
p value: t test 0.51 0.30 0.67 
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6.6.2. T lymphocyte subsets in rats treated with 
dimethylhydrazine effects of transfusion with 0.9% saline 
(Experiment E2) 
Experimental plan. 
Male Sprague Dawley rats, aged sixteen weeks which had already 
received eight weekly subcutaneous injections of dimethylhydrazine, 
received three intravenous transfusions of heparinised 0.9% saline. 
The volume of each infusion was 1.5 ml and the interval between each 
was seven days. Dimethylhydrazine injections continued during the 
course of transfusions. T lymphocyte subsets in the peripheral 
blood were assessed before and two weeks after transfusion (Table 
6.6.2). 
TABLE 6.6.2 
Effect of 0.9% saline transfusion on T lymphocyte subsets in 
16- week -old rats which have been treated with dimethylhydrazine - 
paired data 
mean % cells labelled (SD) 
monoclonal antibody W3/13 W3/25 0X8 
pre -transfusion, n =14 69.0 (10.6) 29.9 (12.4) 34.4 (9.3) 
post -transfusion 63.3 (10.6) 21.5 (8.7) 35.9 (12.9) 
p value: t test 0.12 0.024 0.69 
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6.7. RELATIONSHIP OF T CELL SUBSETS TO CARCINOGENESIS 
(Experiment F) 
An experiment had been performed (published elsewhere) to assess the 
effect of allogeneic blood transfusion on colonic carcinogenesis 
(Ross et al, 1989 Appendix 1). In this experiment there was no 
significant difference in the number of histologically proven 
colonic tumours found in rats transfused with allogeneic blood 
compared with those transfused with saline. During the course of 
carcinogenesis venous blood had been sampled to enumerate the T 
lymphocyte populations. The helper /suppressor ratios for rats in 
both transfsuion groups were calculated and pooled and the median 
helper /suppressor ratio determined. The new group of rats was 
divided into two groups about this median. The T cell ratio data 
were then tabulated with the histopathological data (Table 6.7.1). 
The aim was to determine whether rats with low helper /suppressor 
ratios developed more tumours. Low helper /suppressor ratios may 
indicate immunosuppression and this state may enhance the process of 
carcinogenesis. The helper /suppressor ratios were also plotted 
against the tumour yield of each rat (Figure 6.6). 
Page 209 
TABLE 6.7.1. 
T lymphocyte (W3/35)/(0X8) helper /suppressor ratio (h /s ratio) and 
DMH colonic carcinogenesis in Sprague Dawley rats. 
n mean tumours per rat (SD) ** 
h/s ratio <0.65* 10 3.70 (1.57) 
h/s ratio >0.65 11 3.45 (2.73) 
* For the whole group of 21 rats the median h/s ratio was 0.65 







y = 0.92821 - 5.3632e-2x R^2 = 0.096 
O 




0 2 4 6 8 10 
Colonic tumors per rat 
12 
Relationship of peripheral blood helper /suppressor (H /S) 
T lymphocyte ratios to development of dimethylhydrazine 
colonic carcinogenesis. Correlation of H/S ratio and tumour 
yield. 
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6.8. DOES INDOMETHACIN REVERSE BLOOD TRANSFUSION INDUCED 
ENHANCEMENT OF COLONIC CARCINOGENESIS IN RATS? 
(Experiment G) 
Experimental design 
Male Sprague Dawley rats were given 14 weekly injections of 
dimethyl- hydrazine (16mg /kg). During week 8 they were randomly 
divided into four groups. Group A (n =19) received no treatment 
(i.e. they were not transfused and did not receive indomethacin). 
Group B (n =20) were given three weekly 1.5ml transfusions of 
heparinised allogeneic blood from DA rats under ether anaesthesia. 
Group C (n =18) were not transfused, but were given indomethacin (3 
mg /kg body weight per day). Group D (n =20) were given heparinised 
allogeneic blood from DA rats and treated with indomethacin for five 
weeks. 
Seven rats died during the course of the experiment. In Group A, 
two rats were put down because of respiratory infections; in Group 
B, one rat died under anaesthesia prior to blood transfusion; in 
Group C one rat was killed because of a respiratory infection and 
one was found dead during the 25th week (the cause of death was 
unclear); in Group D one rat died under anaesthesia prior to 
transfusion and a second was found dead during week 15 (this rats 
had pneumonia at post mortem examination). 
All surviving rats were killed at 28 weeks. The rats were weighed 
(Table 6.8.1) and examined for histological evidence of tumours 
(Tables 6.8.2 -3; Figure 6.7). The histologic) features of every 
tumour were assessed (Table 6.8.4). The amount of indomethacin 
given to the rats is given in Table 6.8.5. 
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TABLE 6.8.1 
Dimethylhydrazine carcinogenesis in Sprague Dawley rats treated with 
allogeneic blood with or without indomethacin: 'comparison of body 
weight. 
treatment group blood indomethacin blood and 
none alone alone indomethacin 
(A) (B) (C) (D) 
number of rats 17 19 16 18 
weight, g; 
mean (SD) 
1 week 0 270 (67) 297 (89) 281 (80) 291 (86) 
2 week 28 659 (161) 670 (183) 669 (176) 656 (179) 
There were no significant differences between the groups using 
student' t test. 
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TABLE 6.8.2 
Dimethylhydrazine carcinogenesis in Sprague Dawley rats treated with 














number of rats 17 19 16 18 
rats with tumours 
colonic 17 19 16 18 
small bowel 0 1 0 1 
ear 2 0 1 1 
metastatic 3 3 2 3 




Dimethylhydrazine carcinogenesis in Sprague Dawley rats treated with 
allogeneic blood with or without indomethacin: comparison of 
colonic tumour development (histologically proven adenoma and 
carcinoma). 
treatment group blood indomethacin blood and 
none alone alone indomethacin 
(A) (B) (C) (D) 
number of rats 17 19 16 18 
colonic tumours 3.29 6.68 4.69 4.67 
animal, mean (SD) (1.76) (3.97) (3.46) (2.57) 
A versus B: p < 0.02, Mann -Whitney test 
See Figure 6.7 
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14- 














C BT Ind 
Treatment group 
BT+Ind 
Effect of blood transfusion (BT), indomethacin alone (Ind) and 
blood transfusion combined with indomethacin compared with 
untreated controls on colonic tumour development in 
dimethylhydrazine carcinogenesis. 
Controls versus BT: P<0.02 Mann Whitney U test. 
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TABLE 6.8.4. 
Dimethylhydrazine carcinogenesis in Sprague Dawley rats treated with 
allogeneic blood with or without indomethacin. 
treatment group blood indomethacin blood and 
none alone alone indomethacin 
(A) (B) (C) (D) 
number of rats 
adenoma; n, % 



















G2 71% 75% 68% 75% 
G3 23% 21% 18% 18% 
mucin production 57% 56% 56% 64% 
lymphocyte infiltration 49% 54% 44°% 44% 
presence of signet cells 13% 6% 11% 6% 
invasion pT1 60% 67% 64% 68% 
pT2 40% 33% 36% 32% 
There were no significant differences between the four groups, using 
chi square analysis. 
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TABLE 6.8.5 
Total dose of indomethacin given to experimental subjects. 
water drunk per day 
ml /day; mean (SD) 
body weight 
kg; mean (SD) 
indomethacin dose 
mg /kg /day; mean (SD) 






49.6 (6.64) 45.7 (7.13) N.S. 
0.560 (0.03) 0.527 (0.01) N.S. 
1.84 (0.23) 1.75 (0.194) N.S. 
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6.9. BLOOD TRANSFUSION AND MACROPHAGE PROSTAGLANDIN E2 
PRODUCTION (Experiment H) 
Experimental plan 
The aim of this experiment was to determine the effects of various 
blood transfusions on prostaglandin E2 by rat peritoneal 
macrophages. Lewis male inbred rats (n =104) were divided into eight 
experimental groups each with 13 rats. On day 0, seven groups were 
transfused under general anaesthesia, while the eigth group was an 
untreated control. One of the transfused groups was transfused with 
anticoagulant solution to control for the effects of anaesthesia and 
operative procedure. Two groups were transfused with fresh blood, 
either syngeneic or allogeneic. Two groups were transfused with 
stored blood, either syngeneic or allogeneic. Two groups were 
transfused with serum, either syngeneic or allogeneic. On day 4, 
sterile bovine brain heart infusate was injected into the peritoneal 
cavity of all rats. On day seven, peritoneal lavage was performed 
under terminal general anaesthesia. After processing and counting 
the cell suspensions were cultured in plastic trays. After one hour 
non -adherent cells were removed and fresh culture media added. 
After a 20 hour incubation the supernatants were removed and 
subsequently a radioimmunoassay performed to measure prostaglandin 
E2 produced by the cells during the 20 hour culture period. A 
non -specific esterase stain was used to indentify and count the 
macrophages. 
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During the experiments seven rats died soon after transfusion, two 
peritoneal lavage samples were excluded due to contamination with 
peripheral blood, one of the stored blood units and the relevant 
spare sample clotted, and in one case the non -specific esterase 
stain failed in both of the replicate cytocentrifuge preparations. 
The group distribution of these events can be seen in Table 6.9.1 as 
there were thirteen rats in each experimental group at the start of 
the experiment. 
Statistical analysis has been performed using a non -parametric 
method for paired data (Wilcoxon rank sum test). Analysis of the 
peritoneal cells and the macrophage counts are shown (Table 6.9.1 
and Figures 6.8 and 6.9). 
Macrophage prostaglandin E2 production during the 20 hour period Of 
culture is shown in Table 6.9.2 and in Figure 6.10. 
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Table 6.9.1 
Effect of transfusion on peritoneal cell counts 
Treatment group n Total cells Macrophages 
mean (SD) mean (SD) 
untreated 13 13.5 (7.1) 5.7 (3.25) 
anticoagulant 12 13.6 (3.3) 5.6 (2.4) 
allogeneic - fresh 12 11.6 (2.1) 4.0 (1.3) 
syngeneic - fresh 11 11.9 (3.2) 4.9 (2.2) 
allogeneic - stored 10 9.9 (2.3) 3.8 (1.3) 
syngeneic - stored 11 10.9 (2.7) 4.2 (1.2) 
allogeneic - serum 12 13.4 (6.5) 4.9 (2.7) 
syngeneic - serum 12 13.2 (5.6) 4.9 (1.7) 
There were no significant differences between the groups: 
Wilcoxon rank sum test. 
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TABLE 6.9.2. 
Effects of transfusions on macrophage PGE2 production 
Treatment group n PGE2 production /20 hours 







allogeneic - fresh 12 4637 (2803) 
syngeneic - fresh 11 4528 (3261) 
allogeneic - stored 10 5874 (3726)* 
syngeneic - stored 11 6852 (3526)* 
allogeneic - serum 12 7956 (6580)* 
syngeneic - serum 12 5000 (3557) 




















cntrl CPD al-fr sy-fr al-st sy-st al-se sy-se 
Transfusion groups 
Effect of various transfusions on peritoneal cellular response 
to injection with brain heart infusate. Labels: cntrl = 
untreated control; CPD = citrate -phosphate- dextrose infusion; 
al -fr = allogeneic fresh blood; sy -fr = syngeneic fresh blood; 
al -st = allogeneic stored blood; sy -st = syngeneic stored 


















cntrl CPD al -fr sy -fr al -st sy -st al- sesy -se 
Transfusion groups 
Effect of various transfusions on peritoneal macrophage 
response to injection with brain heart infusate. Labels: 
cntrl = untreated control; CPD = citrate -phosphate- dextrose 
infusion; al -fr = allogeneic fresh blood; sy -fr = syngeneic 
fresh blood; al -st = allogeneic stored blood; sy -st = 






















cntrl CPD al -fr sy -fr al -st sy- stal- sesy -se 
Transfusion group 
Effect of various transfusions on peritoneal macrophage 
prostaglandin E2 (PGE2) production expressed as PGE2 in 
picograms produced by one million macrophages during the 20 
hour period of culture. Labels: cntrl = untreated control; 
CPD = citrate -phosphate- dextrose infusion; al -fr = allogeneic 
fresh blood; sy -fr = syngeneic fresh blood; al -st = allogeneic 
stored blood *; sy -st = syngeneic stored blood *; al -se = 
allogeneic serum *; sy -se = syngeneic serum. 
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7.1. CLINICAL STUDY 
7.1.1. Aim of the study 
The purpose of this retrospective study was to test the theory that 
blood transfusion could have a detrimental effect on survival after 
potentially curative surgery for colorectal cancer. 
7.1.2. Limitations relating to the methodology 
Retrospective studies are known to have many inherent deficiencies 
which may make it difficult to interpret the perceived differences 
in survival rates between two treatment groups. These problems are 
discussed firstly in relation to the current study and secondly in 
relation to interpretation of the increasing number of reports from 
other centres. 
a) Uncontrolled variables 
There are many variables which could be controlled for in a 
randomized prospective trial, but are clearly impossible to control 
for in a retrospective study: 
Previous blood transfusion and pregnancy may be important 
historical factors which have the potential to affect 
subsequent immune response to alloantigens. This information 
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is not obtainable from the cases notes, but in a prospective 
study the patients could be questioned directly. 
Other medical treatment during the follow -up periods may 
affect the course of the disease in ways as yet unknown. 
Medications such as aspirin or other non -steroidal 
anti -inflammatory agents could be prescribed by general 
practitioners for the relief of symptoms due to metastatic 
disease or for indications unrelated to colorectal cancer. 
The patients may use other medications from the field of 
alternative medicine - evening primrose oil is an example of a 
compound which may affect the immune response to cancer. 
b) Incomplete data is an important factor. In the Methods Section 
the method of determining blood transfusion status was described 
and reliance was placed on documentation in the case notes. In this 
study this documentation was probably reliable because it was an 
important part of the mechanism of identification used to ensure 
that mismatched blood was not transfused. However, this methodology 
does not account for the patient who was cross -matched, but not 
transfused and who was cross -matched on a second occasion 
postoperatively and transfused. If by chance the second cross -match 
form was lost, this patient would have been included, erroneously, 
in the non -transfused group. There is no reliable information 
concerning the use of blood products such as platelets, fresh frozen 
plasma, and plasma protein fractions. These are important because 
all of these components could influence the immune response and they 
are more likely to be administered to patients who have had four or 
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more transfusions of blood. 
c) Incomplete follow -up data represents another problem, it is 
generally thought that if greater than 10% of cases are lost, then 
the survivorship analysis will be unreliable. However, the log rank 
methods of survivorship analysis allows for the analysis of studies 
in which some of the patients have not reached the final (relating 
to the study) census point. In this study the final census point 
was five years, but not all patients reached this as the data 
retrieval was performed at the end of 1984. The patients underwent 
surgery during the period from January, 1977 to Decmber, 1980. 
Therefore, a patient who underwent surgery at the end of 1980 could 
only have been reviewed for 4 years and would be included as lost to 
follow -up at the 54 month and 60 month census point. Furthermore, 
after 2 years patients changed from six month reviews to yearly 
reviews, which means that our December, 1980 patient may not have 
data for the 42 month and 48 month census points if he or she had 
had a slightly delayed clinic appointment. The methodology used in 
this study allows for this eventuality by assuming that this 
patient's disease behaves in a similar way to the remainder of the 
study population who continue to be reviewed. To put it another 
way, it is assumed that the reason for non- review is not related to 
the patient's state of health or disease progress. Clearly a 
patient who moves from the district would meet these criteria. 
In the present study there was a tendency to an early discharge from 
follow -up for patients with early tumours. In fact, it has 
transpired that this was a deliberate (and justifiable) review 
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policy of one of the consultant surgeons. Furthermore, this surgeon 
was recognised as having a particular interest in colorectal cancer 
and he personally performed the definitive resections in 26% of 
cases reported in this study. Overall, he was responsible for a 
third of cases (some of these operations were performed by junior 
surgeons). These patients, who were discharged from follow -up, were 
usually Dukes stage B with well differentiated tumours and were 
discharged from the clinic after 18 to 24 months. In constructing 
the life table analysis these patients would be counted as lost to 
follow -up and treated accordingly (ie assumed to behave like the 
rest of the patients remaining in the study). This group of "lost" 
patients will be weighted because of an excess of patients with a 
superior prognosis. This will result in apparently poorer survival 
figures for the whole group at five years. It is recognised that 
the majority of colorectal cancer recurrence occurs within 
following surgery, but patients will survive beyond this point. 
This problem of "lost" patients illustrates an important unreliable 
feature of this retrospective study. 
d) The observed effect may be simply co- incidence of phenomena. 
This is certainly a possibility with this study: the majority ( >80 %) 
of the patients had also been included in the prospective 
multicentre Large Bowel Cancer Project (Cheslyn- Curtis, 1990). This 
much larger study did not demonstrate a significant blood 
transfusion effect on survival. Statistically, if 20 centres 
undertook a similar study, one of them by chance alone could reveal 
a significant effect of blood transfusion at the P =0.05 level. 
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e) The effect may be real, but due to other factors which may be 
associated with the receipt of transfused blood. Many factors will 
influence the perceived need for blood during the perioperative 
period. These factors include age, general state of health, 
cardiovascular ability to withstand blood loss, preoperative 
anaemia, technical problems in resection, anaesthetic techniques, 
the skill and experience of the surgeon, and the various doctors' 
preferred transfusion regime (or lack of regime). Many of these 
factors will influence cancer prognosis, and many of these factors 
are difficult to evaluate in retrospective studies. 
7.1.3. Interpretation of the results 
For the group of patients as a whole (including abdomino -perineal 
resections), it has been demonstrated that patients who received 
perioperative blood transfusion had a poorer five year survival rate 
when compared with non -transfused patients (31% versus 46%). 
Statistically, this result was of borderline significance using the 
log rank test. However, using the more sensitive Mantel -Haenszel 
method this difference is significant (p < 0.03). In this group of 
patients there was a similar trend which suggested that 
recurrence -free survival rates were inferior in the transfused 
patients, but this failed to reach statistical significance. This 
group of 256 patients included 77 (30%) who had abdomino -perineal 
resections for low rectal cancer. It is well known that cancer at 
this site has a poorer prognosis and behaves in a different manner 
than more proximal colorectal tumours. This fact alone could 
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account for the association between blood transfusion and poor 
prognosis. 
In the present study there was also a higher incidence of annular 
tumours and staged procedures in the transfused group. It has been 
shown that survival is poorer after a staged procedure compared with 
survival after a primary resection for large bowel obstruction 
caused by cancer (Fielding and Wells, 1974). This increased 
mortality could be associated with the cumulative cardiovascular 
risks of anaesthesia in elderly patients. Alternatively, it could 
be postulated that multiple anaethesia and surgical trauma cause 
immunosuppressìon with a resultant increased risk of sepsis and 
tumour recurrence. Large bowel obstruction, presumably the sequel 
of an annular type of tumour, is also known to be associated with a 
poor prognosis (although an annular tumour, per se, may not have 
this association. Furthermore, there was a much higher incidence of 
emergency operations in the transfused group and the commonest 
indications for emergency surgery are large bowel obstruction and 
perforation, both of which are associated with a poorer prognosis. 
When the patients who had had abdomino -perineal resections were 
excluded, the association of blood transfusion with poor prognosis 
was no longer statistically significant. In addition, the higher 
frequency of tumours adherent to another structure (cg small bowel, 
uterus, abdominal wall) in the transfused group now reached 
statistcal significance, as did the incidence of pre- operative 
anaemia. It would appear, therefore, that in this group of patients 
the survival disadvantage associated with blood transfusion is 
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likely to be due to differences in the severity of the cancer 
disease: patients with several variables known to be associated with 
a poorer prognosis were more likley to be transfused. The receipt 
of blood transfusion must surely be a marker of disease severity. 
Several studies have attempted to account for the influence of known 
prognostic variables by using sophisticated statistical methods such 
as the Cox proportional hazards model (Burrows and Tarrter, 1987; 
Blumberg et al, 1985; Parrott et al, 1986; Creasy et al, 1987). 
This multivariate analysis demonstrated a significant independent 
effect of transfusion on cancer recurrence or death. Despite these, 
it is difficult to counter the argument that perioperative blood 
transfusion is an indicator of the severity of the cancer disease. 
Francis and Judson (1987) found a significantly higher incidence of 
recurrence in patients who received blood during surgery compared 
with those who were given blood either before or after surgery. 
They suggest that factors influencing the need for transfusion 
during surgery had a greater influence on prognosis than the receipt 
of blood itself. 
This study (like the other retrospective studies) has compared two 
groups of patients with colorectal cancer. Most studies, including 
the present, have shown that transfused patients have a poorer 
prognosis, and some have have demonstrated that the difference 
reaches statistical significance. Before drawing conclusions 
regarding the possible reasons for this observation, it should be 
clear that two different groups of patients are being compared. 
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Although both groups (transfused and non -transfused) may be similar 
in terms of age, sex, clinical stage, histological grade, and site 
of the tumour, they must differ in some way to account for the fact 
that one group was transfused and the other was not. In other words, 
blood transfusion selects patients who have a poorer prognosis. 
When these results are compared with the other retrospective studies 
of colorectal cancer patients, a further observation may be made. 
Overall, the survival rates in the present study are markedly 
inferior to those elsewhere. One explanation for this phenomenon is 
that patients in this study were drawn from an relatively large 
geographic area which included rural areas. It is possible that 
patients with colorectal cancer may have presented at a later stage 
to the district general hospitals involved in the project. However, 
there is some pathological evidence to support this. The distance 
from the patient's home to the hospital was found to be 
statistically associated with decreased survival in patients with 
breast cancer (Kieckbusch et al, 1989). However, the hospital 
concerned was a tertiary referral centre. 
7.1.4. The variable findings of published studies 
The literature review tabulated the findings of the many studies of 
colorectal cancer patients. About a third of these concluded that 
there was a statistically significant relationship between blood 
transfusion and decreased survival. Another third have indicated a 
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exert influence such as: anaesthetic techniques and agents, deep 
venous thrombosis prophylaxis, undescribed differences in the 
patient populations, intraoperative blood loss, duration of 
operation, exact time of transfsuion in relation to surgery, methods 
used in exclusion of metastasis may vary (liver ultrasound, CT 
scan), accuracy of perioperative clinico- pathological staging, 
nutritional status. Virtually no information is available to enable 
possible differences in blood banking factors to be considered. 
Firstly, there may differnces in the blood donor populations; if a 
virus is responsible for the effects then it is conceivable that 
these population variations may be transient. The methods of blood 
processing and storage may vary. During the last fifteen years 
which cover the time period of the retrospective studies, there has 
been a trend away from the use of whole blood towards plasma 
extraction and use of packed cells. The amount of plasma in 
transfused blood may therefore vary from centre to centre. It will 
be clear as this discussion proceeds that plasma may be one of the 
important constituents of blood with regard to immuosuppression. 
There may be a threshold level at which a transfusion effect becomes 
evident. This may not be reached in some transfused patients, 
perhaps because of variable transfusion policies between centres. 
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7.2 DIMETHYLHYDRAZINE MODEL 
7.2.1 Dimethylhydrazine carcinogenesis (Experiment A) 
Rats which received 16 weekly DMH injection had all developed 
malignancies 36 weeks after the first injection. Of the original 36 
rats in this group 18 had died by 30 weeks and at 36 weeks only 9 
remained alive. Three of the DMH- treated rats were killed because 
they had respiratory infections in the early part of the study. 
None of the 36 rats treated with EDTA injections developed cancer, 
but one did develop signs of ataxia and upper respiratory tract 
infection. The untreated control group consisted of 16 rats and 
none of these developed cancer, but one was killed because of a 
respiratory infection. 
It was surprising to find that at thirty weeks only 50% of the 
subjects were alive. Beyond this point the surviving rats continued 
to deteriorate and most of then had developed infected, ulcerating 
ear tumours. Those animals examined after death at about 30 weeks 
generally had evidence of metastatic disease and all had obvious 
multiple bowel tumours. Overall, the mean number of colonic tumours 
per rat at 36 weeks was 4.78 (SD =3.1) 
On reviewing the literature these results can be compared with 
others. However, this comparison is difficult because of variations 
in dose, route of administration, total dose of dimethylhydrazine 
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given, frequency of doses, and strains of experimental rats used 
(Table 7.2.1). 
TABLE 7.2.1. DMH rat models of colonic carcinogenesis 
Author, year Strain Sex Dose Total Route End Tumours /rat 
DMH,mg dose,mg point mean 
Ward, 1974 Fischer M 26.6 532 sc 30 3.9 
38 4.7 
Garmaise, 1974 SD M 30 300 o 22 1.7 
Reddy, 1974 Fischer M 10 200 sc 20 0.8 
Rogers, 1975 SD M 30 150 o 30 20% dead 
40 50% dead 
45 90% dead 
Maskens, 1976 BDIX M 20 460 sc 36 8.0 
Barkla, 1977 SD M 21 420 sc 30 6.0 
Filipe, 1975 Wistar M 20 580 sc 26 4.0 
Reddy, 1976 Fischer M 10 200 sc 30 0.25 
This study SD M 16 256 sc 36 4.8 
SD M 16 224 sc 28 3.3 
Data from Experiment A and from Experiment G (untreated controls) 
refers to rats surviving at the end point. 
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What are the possible explanations as to why the present protocol 
resulted in apparently high mortality? 
It is possible that the present experimental rats developed more 
extensive metastatic disease which accounted for their early demise. 
This is difficult to assess. Of the 13 rats killed deliberately 
during the experiment, only two had macrosopic evidence of metsatic 
disease. Of the 14 rats which died spontaneously, only 4 had 
evidence of metastatic disease. Five of the nine rats reaching 36 
weeks had various distant metastases. It would seem unlikely that 
metastaic disease caused the high mortality rate. 
On review of the experimental records it was noted that four 
additional rats in the DMH group had had signs of respiratory 
infection, but not severe enough to warrant killing them. From 
reviewing the data from other papers it would seem that the degree 
of carcinogenesis in this study was average. However, the mortality 
rate in this study is undoubtably high in comparison. It is likely 
that the high incidence of respiratory infections may have accounted 
for this high mortality. Respiratory infection was not a problem in 
the other carcinogenic experiments (Experiment G and Appendix 2). 
Neither of these experiments was associated with a high mortality 
rate, although the experiments were terminated at 28 and 30 weeks 
respectively. 
Page 240 
It will be seen that 56% of the group of DMH- treated rats developed 
ear tumours. These were squamous cell carcinomas of the external 
auditory canal. The observed incidence is higher than those 
previously reported (Druckrey, 1970; Bansal et al, 1978; Martin et 
al, 1973). However, in a small series reported by Cruse et al 
(1978) 4/9 female Wistar rats treated with dimethylhydrazine and 
Corynebacterium parvum developed ear tumours. An incidence of of 
36% of rats with ear tumours was found by Ward (Ward et al, 1974). 
Reddy et al found that in rats treated with 20% corn oil, 59% 
developed ear tumours compared with 15% in rats fed a standard diet. 
Several other reports of experimental carcinogenesis do not mention 
ear tumours - this suggests that it was not a problem. The high 
incidence of ear tumours is important because of the natural course 
of the disease. Eight of the 13 rats killed prematurely because of 
the presence of ulcerating and infected ear tumours. 
During the course of the experiment three rats injected with DMH 
developed skin necrosis at the injection site. In subsequent 
experiments injections were given in alternate flanks. This area of 
dermal necrosis measured about 1cm in diameter. It is feasible to 
suggest that this dermal necrosis may have caused a dgree of 
immunosuppression in a manner similar to a burn wound (Wood et al, 
1987). This would render the animals more susceptible to infection 
or the carcinogenic process. However, the small number of rats 
involved would make this an insignificant factor. 
It is known that a diet with a high fat content may enhance 
carcinogenesis 
( Bansal et al, 1978; Sakaguchi et al, 1984; Reddy, 
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1976). The standard rat diet used in the present study has an 
average fat content (3.5%) and this level has not been reported to 
increase carcinogenesis. 
Various other factors are known to enhance carcinogenesis such as 
drugs which may alter the bowel flora (A- Kareem et al, 1984; Nigro 
et al, 1973), protamine (Phillips et al, 1984), anaesthesia and 
surgery Neese et al, 1986), pregnancy (Sjogren, 1980). However, 
none of these factors seem to be relevant in this experiment. 
It is possible that the experimental rats were immunosuppressed due 
to a cause unknown and this caused the high incidence of respiratory 
infections and ear tumours, and ultimately the high mortality. The 
relationship of this theory to the observed T lymphocyte subset 
analysis is discussed later. It is also possible that any 
immunosuppression was a direct consequence of the unidentified 
pathogen which caused the respiratory infection or a direct 
consequence of the malignant ear and bowel disease. 
In summary, it is suggested that the unexpected high mortality 
observed in this experiment was due, firstly, to premature culling 
of rats with respiratory infection. Other rats in the 
carcinogenesis group were also noted to have had signs of 
respiratory infection which may have contributed to the number of 
spontaneous deaths. Secondly, the high incidence of ear tumours 
resulted in additional rats being culled prematurely because of 
infective complications. 
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7.2.2 T cell subsets and the cancer model 
T cell subsets in normal rats 
Throughout the early experiments when T lymphocyte subsets were 
enumerated, the results showed consistently low helper /suppressor 
ratios in the various groups of normal rats which were untreated 
controls (Table 7.2.1). 
TABLE 7.2.1. Helper /suppressor ratios in normal rats 
Experiment age of rat (weeks) helper /suppressor ratio* 
B 16 16 0.74 
40 16 0.63 
40 8 0.57 
C 12 39 0.88 
D 14 14 1.04 
16 16 0.75 
36 6 0.62 
36 6 0.61 
* helper /suppressor ratio = %W3/35 +ve cells / %0X8 +ve cells 
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What is the normal helper /suppressor ratio for Sprague Dawley rats? 
A literature search revealed little information or data concerning 
helper /suppressor ratios in normal rats. However, although there 
appears to be marked strain variation a helper /suppressor ratio of 
less than one must be considered to be abnormal. Naturally 
lymphopenic BB rats (non- diabetic) were found to have a mean 
helper /suppressor ratio of 0.86, while normal Wistar Furth rats had 
a ratio of 1.31 (Elder et al, 1983). Another report stated that 
normal Wistar Furth rats had a helper /suppressor ratio of 1.3, but 
this became less as the rats aged more than one year (Ross et al, 
1984b). 
Young WAG rats had a mean ratio of 1.76 in another series of 
experiments (Lennard et al, 1986). Normal Brown Norway rats have a 
ratio of 3.0 (Fernandez -Cruz et al, 1982) 
Causes of low helper /suppressor ratios 
The effect is unlikely to be spurious because similar results were 
observed in several groups of normal rats (Table 7.2.1). 
The methodology used may have been deficient in some way. There is 
a predominance of cells labelled with the 0X8 monoclonal antibody. 
At first it was suggested that the W3/35 and 0X8 monoclonal 
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antibodies had been confused during aliquoting of batches. However, 
this was excluded by cross -checking labelling with the original 
batches with new batches (data not shown). 
Non -specific binding was thought to be a problem in pilot 
experiments which used a monoclonal antibody preparation derived 
from ascitic fluid. When a supernatant preparation was introduced 
this reduced the amount of non- specific binding as seen on the FACS 
machine, but did not obviously affect cell counts. 
The observed helper /suppressor ratios may have been real. 
Functional studies show that 0X8 labels cells which have suppressor 
activity (Mason et al, 1981b) and also cytotoxic T cell precursors 
and effector cells (Dallman et al, 1982). 0X8 positive cells 
probably include natural killer cells. Predominance of 0X8 positive 
cells is usually correlated with immunosuppression, but clearly 
there are other cytotoxic cells present. The frequency of rats with 
respiratory infections during the period of these early experiments 
has been described already. It is possible that a virus infection 
may have affected many of the rats and caused immunosuppression 
which in turn caused the high mortality. Such an immunosuppressive 
agent may well have cause alterations in the lymphocyte 
sub -populations. 
However, if the rats with low helper /suppressor ratios are 
immunosuppressed, then one might expect dimethylhydrazine 
carcinogenesis to be enhaced in this group. There was no 
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correlation between helper /suppressor ratios and the number of 
colonic tumours developed in rats treated with DMH (Figure 6.6). 
Turning to T lymphocyte subsets in humans, there appears to be a 
marked variation as seen between various strains of rat. In humans 
T cell CD4 and CD8 subset ratio changes have been shown to correlate 
with progression of human immunodeficiency virus -related disease 
(Macy et al, 1988). A large cohort of healthy people was studied to 
establish a normal range of CD4 /CD8 ratios. The ratios of 1.00 to 
3.15 were established as the 5th and 95th percentile. This also 
meant that 5% of normal healthy people had "abnormally low" CD4 /CD8 
ratios. Clearly, to establish the relevance of the low 
helper /suppressor ratios seen in the current experimental rats, 
further studies should be undertaken to compare peripheral blood 
lymphocyte subsets in a range of rat strains. 
Experiment B 
The purpose of Experiment B was to determine the distribution of 
peripheral T lymphocyte subsets in normal Sprague Dawley rats of 
varying ages. There were no differences in the proportions of 
labelled cells making up the subsets when 16 week old rats were 
compared with 40 week old rats. It is admitted that these ages 
probably correspond to pubertal and young adult developmental stages 
in the rat rather then adult and geriatric. There are no reports 
concerning peripheral T lymphocyte subset changes associated with 
age in rats. However, one paper reports that in Brown Norway rats 
the percentage of lymphocytes (isolated from the spleen and lymph 
nodes) labelled with Thy -1 monoclonal antibody was smaller in old 
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rats compared with young rats (Gilman et al, 1981). The authors 
found no differences regarding cells labelled with W3/35 antibodies. 
They suggested that homeostatic functions controlling the immune 
system may not be functioning in aged rats. 
Experiment C 
The purpose of Experiment C was to determine the distribution of T 
lymphocyte subsets in the various groups of Sprague Dawley rats in 
the carcinogenesis model. Of the original 36 rats in this group 18 
had died by 30 weeks and at 36 weeks only 9 remained for analysis of 
lymphocyte subsets. 
The rats with advanced cancer had a larger proportion of W3/25 
labelled T lymphocytes (helper) compared with age matched normal 
rats. The rats with cancer also had fewer OX 8 labelled T 
lymphocytes (suppressor /cytotoxic) compared with age- matched rats 
treated with EDTA. Compared with normal rats, EDTA- treated rats had 
a greater proportion of OX 8 (suppressor /cytotoxic) cells. 
The effect of DMH carcinogenesis on T lymphocyte subsets has been 
studied in Wistar Furth rats (Ross et a1,1984). It was found that T 
lymphocyte subpopulations did not change until tumours had developed 
and even then differences were found only at 28 weeks after the 
first injection. Compared with six age- matched controls, six 
DMH- treated rats possessed a larger proportion of OX 8 
(suppressor /cytotoxic) labelled lymphocytes and a smaller proportion 
of W3/25 (helper) labelled cells. The helper /suppressor cell ratios 
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were compared and the difference between the mean ratios was 
significant. The results of the present study do not agree with 
this and the most obvious reason may have been the presence of 
secondary bacterial infections in the ulcerated ear tumours. 
The significance of the changes associated with EDTA injections is 
difficult to explain. The observation may simply be coincidental 
(P- 0.05). None of the rats treated with EDTA developed skin 
necrosis at the injection sites and only one of these rats developed 
sign of respiratory tract infections and was culled prematurely. 
The same infective problems which affected DMH- treated rats also 
affected the EDTA- treated rats, but to a lesser extent. The 
increase in OX 8 cells may reflect immunosuppression due to the 
repeated trauma of the injections. Alternatively it could be due to 
the effect of EDTA itself. There is no literature to support a 
direct toxic effect on stem cells or lymphocytes. 
Infection via a contaminated EDTA stock solution is a possibilty 
which cannot be excluded. Bacterial infection is less likely 
because the stock solution was sterilized by filtration prior to 
aliquoting and freezing, although no bacteriological cultures were 
performed on either the EDTA or DMH /EDTA solutions. 
A metabolic effect of EDTA is hypocalcaemia as EDTA chelates calcium 
ions (and probably other ions of similar valency). A series of 
sixteen weekly injections could, conceivably, cause chronic 
hypocalcaemia. EDTA has been used to treat Paget's disease of the 
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bone and it is recommended that calcium supplements are given 
concurrently. There are no reports of immunological side effects in 
vivo associated with this treatment. 
Schnaper studied the effects of EDTA on the suppressive of soluble 
immune response suppressor (SIRS) on murine plaque -forming cells in 
vitro (Schnaper, 1989). SIRS is an immunosuppressive protein which 
requires activation to SIRSox by peroxide. Purified hybridoma- 
derived SIRS was treated with chelating agents which included EDTA. 
Suppressive activity was reconstituted by subsequent treatment of 
SIRS with FeSO4, NiSO4, or MgSO4, but not by FeC13, MnSO4, CuSO4, 
ZnSO4, CaC12 or CrC13. These results indicated thatSIRS requires a 
divalent metal ion for activity. The effect of EDTA treatment in 
the rat model was associated with a change of the helper /suppressor 
ratio suggestive of immunosuppression and this clearly cannot be 
related to SIRS -related effect unless it affected some of these 
tracs elements. 
It is possible to form a hypothesis with regard to the possible role 
of hypocalcaemia in altered T lymphocyte subsets. An increase in 
the concentration of cytoplasmic free Ca2+ and the activation of 
protein kinase C appear to play prominent role in initiating 
lymphocyte responses (Weiss et al, 1986; Cambier et al, 1987). It 
is thought that these two intracellular signals are the result of 
receptor- induced hydrolysis of membrane polyphosphoinositides (PPI) 
(Kuno et al, 1986). The breakdown of PPI generates two second 
messengers - inositol 1,4,5 triphosphate (IP3) which releases Ca2+ 
from an intracellular source. Secondly, diacylglycerol (DG) is 
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prodeuced which activates protein kinase C (Kuno et al, 1986). 
However, it is thought that the second mechanism is associated with 
an influx of extra- cellullar Cat+ possibly through a plasma 
membrane channel (Kuno et al, 1987). Without going to deeply into 
this topic, it is possible that depletion of body calcium by the 
chelating action of EDTA could interfere in this immunoregulatory 
system and result in change in T lymphocyte populations. 
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7.3. BLOOD TRANSFUSION AND T CELL SUBSETS 
7.3.1 Transfusion in normal young rats 
In Experiments D1 and D2, normal 16 week old rats transfused with 
blood or saline showed a decrease in the proportion of T lymphocytes 
in peripheral blood. In these younger rats there was no effect on 
the helper or suppressor /cytotoxic populations of peripheral 
lymphocytes. It will be noted that four different statistical 
methods have been used to analyse the the two groups of results. 
These have clearly given rise to varying degrees of significance. 
The rationale for using the t test in this situation has already 
been discussed. 
7.3.2 Transfusion in normal aged rats 
In the older rats (Experiments D3 and D4) the total T lymphocyte 
proportions did not change following transfusion, whether it was 
blood or saline. In the older rats, allogeneic blood transfusion 
was associated with an increase in the OX 8 T lymphocyte proportion. 
In older rats transfused with saline only a small insignificant 
increase in OX 8 cells was seen, but the W3/25 (helper) lymphocytes 
appeared to increase in this group. 
Lennard et al (1986) reported that in WAG rats, allogeneic blood 
transfusions caused a "down regulation of the immune response by 
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altering the ratio of the immunoregulatory lymphocyte 
subpopulations ". The monoclonal antibodies used were W3/13, W3/25 
and OX 8 and the subsets were counted using flow cytometry. The 
present series of experiments involved rats of different strains and 
these results suggest that T lymphocyte helper and suppressor 
subpopulations in normal young rats are not influenced by allogeneic 
blood transfusion. This would appear to contradict the findings of 
Lennard et al. However, it has been demonstrated that in older rats 
allogeneic blood transfusion may cause T lymphocyte population 
changes which are indicative of an immunosuppressive state. It has 
been suggested that blood transfusion may have a detrimental effect 
in cancer patients. It is possible, therefore, that this effect 
may be greater in elderly patients with cancer than in younger 
patients. It should be interesting to investigate this theory 
further on a clinical basis. 
7.3.3 Transfusion in dimethylhydrazine -treated rats 
The effects of transfusion with allogeneic blood and saline were 
assessed in Sprague Dawley rats receiving dimethylhydrazine 
injections (Experiments El and E2). It will be recalled that 16 
week old rats transfused with blood or saline showed a decrease in 
the total T lymphocyte count following transfusion, but no 
significant change in T cell subsets. Age matched rats receiving 
weekly injections of dimethylhydrazine were transfused concurrently 
with the rats in Experiments D1 and D2. Rats undergoing chemical 
carcinogenesis did not demonstrate a drop in the proportion of T 
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lymphocytes in peripheral blood. When transfused with blood there 
was no change in the proportions of W3/25 and OX 8 cells in the 
peripheral blood. However, when these rats were transfused with 
saline, this resulted in a decrease in the proportion of lymphocytes 
labelled with W3/25 monoclonal antibody. In this group of rats 
there was a post -transfusion decrease in W3/13 labelled T 
lymphocytes. Although this was not statistically significant, it 
may have accounted for the observed post -transfusion (saline) 
decrease in helper cells. 
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7.4 INDOMETHACIN, BLOOD TRANSFUSION AND COLONIC 
CARCINOGENESIS 
Experiment F 
The aim of this experiment was to investigate the possibility that 
indomethacin, a prostaglandin synthetase inhibitor, might influence 
the enhancing effect of allogeneic blood transfusion on 
dimethylhydrazine colonic carcinogenesis. 
7.4.1 Experimental design 
Dimethylhydrazine was administered as weekly subcutaneous injections 
at a dose of 16 mg /kg body weight for a period of 14 weeks. In the 
previous experiments dimethylhydrazine was given for 16 weeks. The 
total dosage was decreased in the present experiment in order to 
reduce the incidence of advanced cancer which tended to cloud the 
overall results in the other series of experiments (Ross et al, 
1988: Appendix 1). Rats were also killed earlier at 28 weeks. This 
regime appeared to be effective. Noticeably, there were fewer rats 
which developed ear tumours and there was a smaller incidence of 
rats with small bowel tumours and metastatic disease. 
If further experiments were planned, it is suggested that a suitable 
regime would be 14 weekly injections of dimethylhydrazine (16 mg /kg 
body weight) with assessment by post mortem examination at 24 weeks. 
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This experiment included four experimental groups of rats, all of 
which were given the carcinogen. One group received no additional 
treatment. Two groups of rats received allogeneic blood transfusion 
and one of these was treated with oral indomethacin before, during 
and after transfusion. The fourth group, not transfused, was 
treated with indomethacin for an identical period. 
Ideally, two more groups could have been added. Both these would be 
transfused with saline and one would also receive indomethacin. 
These groups would have controlled for the possible effect of 
repeated anaesthesia and surgical trauma required to perform the 
transfusions. In the present experiment the group transfused with 
blood developed more tumours than the control group (6.7 versus 3.3; 
P<0.02). Previous experiments showed that up to 34 weeks after the 
start of tumour induction, the number of tumours per rat increased 
with time (Ross et al, 1989: Appendix 1). The slightly smaller 
number of tumours observed in the present experiment is compatible 
with this observation. It is also likely that an additional group 
transfused with saline would have a similar degree of carcinogenesis 
to the untreated control group. 
7.4.2. Microscopic tumour development 
This experiment confirms that allogeneic blood transfusion enhances 
colonic carcinogenesis to a degree which is similar to that observed 
in previous work (Ross et al, 1989: Appendix 1). Administration of 
indomethacin at a dose of about 1.8 mg /kg body weight per day for a 
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a period of four weeks does not influence carcinogenesis. 
some evidence, which has been reviewed, which suggests that 
long -term treatment with indomethacin may retard dimethylhydrazine 
carcinogenesis in rats (Pollard et al, 1977,1978 and 1983). 
Administration of indomethacin during the period of blood 
transfusion appears to reverse the enhancing effect of transfusion 
on carcinogenesis. In transfused rats given indomethacin, the 
number of microscopic tumours was the same as in the group which 
received indomethacin alone. 
The incidences of ear tumours, small bowel tumours and metastatic 
disease were similar in all four groups. 
Indomethacin is a prostaglandin synthetase inhibitor. It would be 
reasonable to suggest that it is possible that the blood transfusion 
effect seen in this model may be mediated by a mechanism involving 
prostaglandins. 
In experimental models, allogeneic blood transfusion has been shown 
to enhance graft survival and these effects can be negated by 
administration of indomethacin (Shelby et al, 1987). It is 
suggested that a prostaglandin- mediated immunosupressive effect of 
blood transfusion may be present in the present cancer model (which 
does not involve tumour transplantation) and that this effect may 
share similar or identical mechanisms as the known beneficial effect 
of blood transfusion on experimental graft survival. 
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7.6. BLOOD TRANSFUSION AND MACROPHAGE PROSTAGLANDINS 
7.6.1. Blood transfusion and macrophage arachidonic acid 
metabolism (Experiment G) 
The aim of this experiment was to determine the effect of allogeneic 
blood transfusion on macrophage synthesis of arachidonic acid 
metabolites. Secondly, the experiment was designed to test the 
hypothesis that storage conditions of transfused blood might 
influence the effects of macrophage PGE2 production. 
The experimental design was based on that described by Waymack et al 
who had shown that allogeneic blood transfusion resulted in 
increased PGE2 production by rat peritoneal macrophages (Waymack et 
al, 1987). A pilot study had been performed by the author 
previously and there were major differences between the results of 
this pilot study and those of Waymack (Beavis, Ross et al, 1989: 
Appendix 2). This pilot study did not demonstrate an increased PGE2 
production by rat peritoneal macrophages associated with allogeneic 
blood transfusion. Blood transfusion in the pilot series was 1.5 ml 
of blood instead of 1 ml and the rat strains differed. The pilot 
series used DA rats as blood donors and Sprague Dawley rats as 
recipients. In the Waymack series Lewis rats were used as 
recipients and Buffalo rats or A'Sogaloff Cancer Institute (ACI) 
rats were used as blood donors. Waymack used blood which had been 
mixed with citrate -phosphate- dextrose anticoagulant solution and 
Page 257 
stored the blood at 4 °C for 24 hours prior to transfusion. In the 
pilot series fresh heparinized blood was used. 
In previous experiments it was observed that removal of the medium 
from the plastic wells and repeated washing to remove non- adherent 
cells after one hour of incubation resulted in a high degree of cell 
loss. It has been shown that the amount of prostaglandin E2 
produced by non -adherent cells was minimal (see Methods Section). 
Therefore, in the current series of experiments this washing step 
was omitted. 
Waymack had cultured the elicited macrophages for a period of 24 
hours after the first hour prior to removal and replacement of 
medium. At 24 hours his control (3mL intravenous bolus infusion of 
Ringer's lactate solution) rat macrophages produced 740 pg PGE2 per 
106 macrophages. In the present series it was found that at 20 
hours the control (NaCl /CDP) Lewis peritoneal macrophages produced 
3863 pg PGE2 per 106 cells. This obvious difference could be 
explained by the disparity in the number of macrophages retrieved 
from the peritoneal lavage fluid. In this experiment 13.6x106 cells 
were retrieved of which 5.6x106 were macrophages as identified by 
the non -specific esterase stain technique. Waymack retrieved a mean 
of 9.9x106 macrophages per rat - he does not state the total cells 
retrieved, but states that macrophages were counted using an 
automated cell counter. This morphological method of enumerating 
macrophages may be less accurate than histocytochemical analysis. 
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The present results show that PGE2 production is increased by all 
categories of transfusion, but only reaching significance in the 
allogeneic stored and serum and syngeneic stored groups. The strains 
of rat used in the present series (Lewis RT11 and DA RT1a) differed 
from those of Waymack (Lewis RT11 and ACI RT1a), but were similar in 
terms of rat histocompatibilty status. In both series the rats used 
were inbred. 
As a short period (up to 90 minutes) elapsed before actual 
transfusion of "fresh" blood the same mechanism at play in the 
stored blood may have been responsible for the obvious (but not 
statistically significant) rise in PGE2 production seen in both 
groups transfused with fresh blood compared with both control 
groups. It would appear therefore that the effect of blood 
transfusion may be due to storage conditions of blood and that this 
effect is independent of the genetic properties of the transfused 
blood. Indeed, Waymack found a 40% increase in PGE2 synthesis after 
transfusion with syngeneic Lewis blood, but this did not reach 
statistical significance. However, they were able to demonstrate 
significant increases after transfusion with allogeneic blood. 
Transfusion with blood from Buffalo rats resulted in similar PGE2 
synthesis to that found after transfusion with ACI rat blood. This 
finding does not suggest a variation in results which depends on the 
strain of rat used as donors, further supporting the postulated role 
of non -genetic factors in this model. 
In the present model allogeneic serum had a much greater effect than 
syngeneic serum. This is difficult to explain because serum does 
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not contain cells bearing histocompatibilty antigens, although it is 
not known whether histocompatibility antigens are released into 
serum as blood clots. 
Known immunological effects of stored blood. 
There are very few reports which concern the immunological effects 
of relating to the storage conditions of transfused blood. 
Transfused whole blood is defined as: blood collected into an 
anticoagulant /preservative soloution and not processed in any way. 
It contains all the cellular and plasma constituents of blood, 
subject to changes on storage, with the exception of ionized calcium 
which is precipitated by citric acid in citrate -containing 
anticoagulants. Blood is stored at 4 to 8 °C and the following 
changes are known to take place during storage: 
Red cells - rapidly lose ATP and 2,3 -DPG on storage. ATP loss 
can be slowed by the addition of adenine to CPD solution. The 
clinical significance of 2,3 -DPG loss is uncertain at present, 
but it is reversible. 
White cells - granulocytes begin to lose their phagocytic and 
bactericidal properties within 4 -6 hours and are 
non -functional after 24 hours storage. However, they do not 
appear to lose their antigenic properties. 
Platelets - lose their haemostatic properties within 48 hours. 
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Coagulation factors V and VIII (also XI) have less than 50% of 
their initial activity within 48 -72 hours. 
Biochemical changes in stored blood include a fall in sodium 
concentration, a drop in pH, a rise in potassium 
concentration, a fall in glucose levels and a rise in the 
concentration of inorganic phosphate. 
Vliet et al studied the the in vitro suppressive effects of banked 
blood (Vliet et al, 1989). Recalcified and heat -treated plasma and 
supernatants of blood were added to mixed lymphocyte cultures 
composed of cells from normal subjects. They found that plasma from 
citrate -phosphate- dextrose solutions with adenine had the most 
marked inhibitory effects on the proliferative response of normal 
lymphocytes. Further experiments showed that this effect was not 
due to the anticoagulant /preservative solutions. These effects were 
seen from the first day to 28 days of storage. There were no 
changes in the lymphocyte subsets associated with storage although 
others have reported technical problems relating to the effects of 
low temperatures on lymphocyte cell membranes and to flow cytometric 
considerations (Van Lambalgen et al, 1985; Nicholson et al, 1984). 
It has also been shown in a rat model that the killing ability of 
natural killer cells was markedly inhibited by citrated rat plasma 
(McCulloch et al, 1988). This effect was similar in both allogeneic 
and syngeneic preparations. Conversely, 10% rat serum had no 
effect. The findings of Hormini et al, have been discussed in the 
Review section: they found that amongst various transfusions plasma 
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had the greatest enhancing effect on growth of transplanted tumours 
in mice (Hormini et al, 1983). 
The study by Carty et al has been mentioned previously: they studied 
the effect of transfusions of syngeneic blood, which had been stored 
for three weeks prior to use, on azoxymethane colonic carcinogenesis 
in Sprague Dawley rats, but found no effect (Carty ey al, 1989). 
However, their paper does not describe the type or amount of anti- 
coagulant/preservative used and this limits interpetation of their 
results in the current context. 
Page 262 
7.7. BLOOD TRANSFUSION AND CANCER 
- POSSIBLE EXPLANATIONS AND MECHANISMS 
Several authors have reviewed the topic of blood transfusion and 
colonic cancer, but there is no clear consensus regarding possible 
mechanisms. Fielding (1985) drew attention to the work of Medawar 
who demonstrated that blood transfusion is an immunostimulant in a 
"normal" host and that forty years later immunologists cannot 
readily explain the effects of blood transfusion in renal transplant 
recipients. George and Morello (1986) concluded that while studying 
the effects of blood transfusion the influence of the underlying 
disease state must be considered. They also pointed out that in 
experimental models blood transfusion has been shown to augment or 
increase tumour growth and that these differing effects may be due 
to use of differing strains of host and donor animals. Waymack and 
Alexander (1986) felt that the effects of blood transfusion were 
more likely to be due exposure to foreign antigen than due to a 
non- specific effect. 
7.7.1. Blood transfusion is an index of advanced disease 
Many of the retrospective clinical studies reviewed previously have 
indicated that patients who received blood transfusion may have had 
more advanced cancer. For example, in the study reported in this 
thesis transfused patients had a higher incidence of preoperative 
anaemia and a higher incidence of tumours adherent to other 
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structures. These are not major prognostic variables in relatively 
small studies. In larger series authors have attempted to take 
account of bias introduced by confounding prognostic variables. 
Parrott et al (1986) found a higher incidence of preoperative 
anaemia and longer operations in colorectal cancer patients who were 
transfused perioperatively. However, they were able to adjust for 
this and still demonstrate poorer survival in transfused patients. 
Tartter prospectively studied cell- mediated immunity in patients 
about to undergo resection of colorectal cancers (Tartter and 
Martinelli, 1987). It was found that the preoperative blood count, 
T lymphocyte subet numbers and percentages, and natural killer cell 
cytotoxicity were lower in patients who were subsequently 
transfused, although the differences were not statistically 
significant. If these findings were confirmed in a larger study, 
then this would support the theory that blood transfusion is a 
marker of disease severity. Therefore, the argument that transfused 
patients will receive more blood because of the site and intrinsic 
nature of their tumour and that they have a poorer prognosis because 
of their tumour will remain tenable until prospective studies prove 
otherwise. 
7.7.2. Comparison with transplantation 
At present, the exact mechanism responsible for the "transfusion 
effect ", which has been observed in renal transplant recipients, has 
yet to be defined. It is therefore premature to suggest that the 
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same mechanism or mechanisms are responsible for fact that 
transfused cancer patients have a poorer prognosis than 
non -transfused patients. 
There are major differences between colon cancer patients and renal 
transplant patients. Although both groups of patients are to some 
extent immunosuppressed due to their disease, transplant patients 
are pharmacologically immunosuppressed with steroids, azathioprine 
and cyclosporin. Cyclosporin has been introduced after the effects 
of blood transfusion were recognised and it is likely that the 
enhanced graft survival associated with cyclosporin will diminish 
the overall beneficial effect of blood transfusion in transplants. 
Secondly, transplant patients will be transfused prior to 
transplantation (i.e. before they are exposed to the antigenic 
stimulus). Both groups of patients can be transfused 
postoperatively and there is evidence, which has been reviewed, to 
suggest that in transplant recipients, postoperative or 
perioperative transfusion will also enhance survival. 
If the transplant effect operates through a nonspecific mechanism 
mediating immunosuppression, then it would be reasonable to assume 
that such an effect could act in cancer patients. 
If the transplant transfusion effect is specific and depends on 
histocompatibility antigens, then it is more difficult to envisage a 
similar mechanism for colonic cancer patients. Transplanted kidneys 
are recognised and are rejected because they express foreign 
Page 265 
histocompatibility antigens. Previous exposure to foreign antigens 
shared with the transplanted tissue can result in tolerance and 
enhanced graft survival. This has been demonstrated experimentally 
(Hutchinson and Morris, 1986). For this mechanism to work in cancer 
patients, there must be foreign histocompatibility antigens present 
on cancer cells to which the host immune response is modulated by 
previous or subsequent exposure to similar foreign antigen in 
transfused blood. The tumour cells have been presumably present for 
some time within the lesion before surgery, but we know that tumour 
cells are dispersed at the time of tumour resection. 
7.7.3. Tumour emboli and potential metastases 
Recurrence can develop locally or at distant sites. Suture line 
recurrence is a problem and it has been demonstrated that viable 
exfoliated tumour cells are present at the anastomotic site and 
these must be considered as a possible cause of local recurrence 
assuming that the tumour itself has been completely excised 
(Umpleby et al, 1984). Tumours are also dispersed via the blood 
stream. Engell (1955 and 1957), working in Copenhagen has 
extensively investigated this topic. He obtained venous blood 
samples during surgery from patients undergoing cancer resections. 
Out of 76 patients with rectal cancer, tumour cells were identified 
in venous blood in 41 cases. In cancer of the colon 22/31 patients 
had cancer cells present in venous blood. These findings did not 
appear to have a prognostic significance and cancer cells were found 
with a similar frequency in patients who survived without recurrence 
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as in those who developed recurrence. Interestingly, he could not 
demonstrate an increase in the number of circulating tumour cells 
following operative manipulation. The presence of tumour cells in 
blood during resection was found to be related mainly to 
histological differentiation and to a lesser degree with local 
extension. Salsbury et al (1965) found that the incidence of 
malignant cells in the common iliac vein during resection of the 
colon and rectum was much greater after high ligation of the 
inferior mesenteric vessels than before. This suggested that there 
could be a retrograde flow of venous blood into the systemic 
circulation via the middle rectal and pelvic veins even after 
ligation of the main venous drainage. 
Jeekel (1986) reported the early results of a clinical trial to 
assess the effects of a "no- touch" technique of colonic resection 
for carcinoma. The essence of this method was early ligation of the 
vascular pedicle and mesenteric structures before mobilisation of 
the colonic segment. In patients with sigmoid colon cancer treated 
conventionally, 20% developed liver metastases compared with only 7% 
of patients in the "no- touch" technique. 
In summary, there is evidence that with or without operative 
manipulation tumour cells are released into the circulation. These 
cells may form tumour emboli which could develop into metastatic 
deposits. It is these cells which may represent a source of 
antigenic stimulus during the perioperative period. The type of 
antigenic stimulus will clearly depend on the antigens expressed on 
the surface of the cancer cells. 
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7.7.4. Cytokines as mediators of the transfusion effect 
Prostaglandin E2 
Other work has indicated that prostaglandin E2 is involved in 
immunosuppression caused by blood transfusion and these have been 
discussed in the Review Section, but they are summarised here. 
Prostaglandin E levels have been found to be raised in dialysis 
patients who received multiple transfusions (Jackson et al, 1985; 
Roy et al, 1985; Lenhard et al, 1985). Injection of sheep red blood 
cells into mice resulted in increased immunosuppressive PGE 
production by splenic macrophages (Webb and Osheroff, 1976). 
More recently, Shelby has shown that indomethacin blocks the blood 
transfusion- induced immunosuppression associated with a prolonged 
graft survival in a rat heart transplant model (Shelby et al, 1987). 
It was also shown that anti -PGE antibody blocked transfusion 
associated immunosuppression by neutralising endogenous PGE2 in the 
experimental animals. 
Waymack's finding that blood transfusion increases PGE2 production 
by macrophages has already been discussed. 
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Interleukin 2 
There is now more recent evidence that the cytokine interleukin 2 
(IL -2) may be involved in transfusion- mediated immunosuppression. 
To determine the effect of blood transfusion on IL -1 and IL -2 
production and IL -2 receptor expression by mouse splenic cells, Wood 
et al studied cells which had been characterised as suppressive in 
terms of decreased cell- mediated lymphocytotoxicty and suppression 
of blastogenesis in mixed lymphocyte culture (Wood et al, 1988). 
The production of IL -1 by transfused mice was normal, but the 
production of IL -2 was significantly suppressed when measured at 2 
and 16 days after transfusion. IL -2 receptor expression was normal 
after transfusion. Furthermore, the addition of IL -2, but not IL -1, 
to cell- mediated lymphocytoxic assays restored the diminished 
response to normal levels. Further experiments suggested that the 
suppressor cells derived from the spleen were macrophages and not T 
lymphocytes. 
Another study tested the effect of blood transfusion on antigen 
presentation function of peritoneal macrophages and IL -2 production 
by splenocytes in mice (Stephan et al, 1988). Antigen presentation 
function was tested by using D10.G4.1 T lymphocyte clone and 
conalbumin - a specific antigen for for these cells - and measuring 
D10.G4.1 proliferation induced by processing of the antigen by 
peritoneal macrophages. In this model, blood transfusion had no 
effect on the antigen processing and presentation functions of 
macrophages. However, the splenic cell production of IL -2 was 
significantly reduced after only one transfusion. 
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In a rat renal transplant model in which allogeneic transfusion 
enhanced graft survival, Dallman et al found that in vivo 
administration of recombinant IL -2 caused acute rejction in 
transfused transplant recipients (Dallman et al, 1989). 
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7.8. SURFACE ANTIGEN EXPRESSION AND COLONIC CANCER 
Colonic cancer cells have been shown to express various antigens on 
their surface. Some of these are weekly antigenic tumour associated 
antigens such as carcino- embryonic antigen (CEA). They also express 
a variety of histocompatibility antigens and blood group antigens. 
This expression appears to be variable and there is some evidence 
that tumour cells are capable of expressing non -self antigens. 
7.8.1. Blood group antigens 
Blood group antigens are a group of carbohydrate stuctures which can 
be identified on erythrocyte, endothelium, epithelium, and body 
secretions. 
The main blood group antigens are known as A, B, and H. These 
antigens are glycolipids and glycoproetins which are found on the 
cell surface. The application of monoclonal antibodies to this 
field has boosted research into the potential roles of these 
carbohydrate antigens in cancer (Feizi, 1985). 
In humans most blood group antigens are expressed throughout the 
fetal colon, but are absent from the distal colon in the adult (Denk 
et al, 1974; Cooper et al, 1978). Yuan et al (1985) confirmed this 
using monoclonal antibodies directed against the various blood group 
antigens. They also demonstrated enhanced distal expression of 
antigen in the distal colon of patients with colorectal cancer. 
These findings confirmed the oncofetal gene nature of blood group 
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antigens in bowel cancer. 
One of the other important findings of this study was the high 
incidence of incompatible blood group antigen expression in cancer 
tissue. This was not seen in normal and fetal colonic tissue. This 
suggests that this is a cancer related phenomenon rather than being 
due to technical reasons (cross- reacting antibodies, for example). 
However, Schoentag et al (1987) were unable to demonstrate 
inappropriate blood group expression in a much larger series of 68 
patients with colorectal cancer. They also found that metastatic 
tumour cells tended to have similar blood group antigen expression 
to the cells derived from the primary tumour. Other workers have 
provided evidence that some epithelial tumours of O and B patients 
express genetically inappropriate A antigen specificities (Lloyd, 
1987). 
7.8.2. Major histocompatibility antigens 
Daar et al (1983) demonstrated that HLA -DR antigens are expressed 
heterogenously on malignant colonic epithelium. 
More recently, Moore et al (1986) analysed the major 
histocompatibility antigen status of epithelial cells from patients 
with colorectal neoplasms. They demonstrated that class I antigens 
were generally expressed on all normal and malignant epithelia. 
However, class II antigen expression was less marked with 30% of 
primary colorectal cancers having lost the capacity for class II 
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antigen expression. The process which stimulates expression of 
class II antigens is unknown at present. 
Our present knowledge does not yet allow us to suggest possible 
immunological effects caused by differences in major (or minor) 
histocompatibility antigen expression between the host tumour and 
the transfused blood. 
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7.9. CURRENT TRANSFUSION PRACTICE 
7.9.1. Surgery and anaesthesia 
The insistence of some doctors that a patient for operation must 
have a haemoglobin in the normal range is reputed to have been 
described by Wintrobe as a form of superstition (Raven, 1981). 
Fellin and Murphy (1987) reviewed the problems associated with 
preoperative anaemia. Under normal conditions oxygen extraction is 
only 25 -30% and because oxygen transport depends on a variety of 
factors such as oxygen saturation of haemoglobin and cardiac output, 
anaemia alone may not decrease oxygen delivery to tissues. They 
posed the question, "What is a safe level of haemoglobin... ? ". 
Although many authors suggested a minimum haemoglobin level of 9 to 
10 g /dl there little data to support this concept. On the contrary 
several studies had indicated that there was no increased risk 
associated with haemoglobin values between 5 and 10 g /dl, provided 
blood volume was normal. It was recognised that reduced blood 
volume did increase risk. 
Anaemia probably does not affect wound healing. Three studies of 
wound dehiscence of abdominal wounds did not find anaemia to be a 
major contributing factor (Alexander et al, 1966; Mann et al, 1962; 
Marsh et al, 1954). Guiney et al (1966) found that 50% of patients 
with disrupted abdominal wounds had a haemoglobin of less than 12 
g /dl, compared with 20% in the group of patients whose wounds healed 
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normally. Using a rabbit model, Heughan et al (1974) demonstrated 
that no significant change occurred in the oxygenation of 
experimental wounds in rabbits made anaemic by bleeding and 
retransfusing the separated plasma. In fact, in their model 
connective tissue synthesis was slightly greater at a haematocrit of 
30% compared with a haematocrit of 40 %. A rat model was used more 
recently by Foster et al (1985) to study the effect of hypovolaemia 
on healing of colonic anastomoses. They found that acute 
intraoperative loss of 10% circulating blood volume significantly 
impaired collagen concentration in bowel anastomoses although early 
anastomotic strength was not affected. 
Lavies et al, (1985) discussed the short term hazards of not giving 
blood. They felt that the harmful effects of postoperative anaemia 
were difficult to prove. One of the main compensatory mechanisms 
for postoperative anaemia is an increased cardiac output. Clearly, 
the population of patients with colorectal cancer are elderly and 
such a compensatory mechanism may be inadequate and cause heart 
failure to varying degrees. They concluded that autotransfusion 
either with blood donated preoperatively or normovolaemic 
haemodilution at the start of surgery may be considered and improved 
surgical technique and greater use of epidural or spinal anaesthesia 
may help. They also suggested that postoperative oxygen therapy 
might be indicated for much longer periods than at present. 
In a study of policies of preoperative and postoperative blood 
transfusion in patients undergoing colorectal resections in Wales, 
it was found that 56% of consultant surgeons would transfuse 
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patients who had a preoperative haemoglobin of less tha 11 g /dl and 
18% would transfuse with a haemoglobin of 11 g /dl (Foster and Ross, 
1988). Given a preoperative haemoglobin of 12 g /dl, 51% of surgeons 
would transfuse if the haemoglobin fell to 9 g /dl or less. This 
suggested to the investigators that surgeons are over -transfusing 
their patients, particularly as a large proportion of surgeons 
arbitarily transfuse preoperatively with no evidence of benefit. 
Furthermore, it was considered that transfusion was unnecessary in 
42% of transfused patients in a study of 476 patients who underwent 
surgery for colorectal cancer (Kiff and Kingston, 1988). 
Transfusion was only considered necessary if the haemoglobin was 
less than 10g /dL. Of patients who were transfused only one unit of 
blood, 89% had a haemoglobin level of greater than 10g /dL. 
Spence et al studied the cases of 107 Jehovah's Witnesses who had 
undergone major elective surgery (Spence et al, 1990). They 
concluded that mortality in elective surgery appeared to depend more 
on estimated blood loss than on preoperative haemoglobin levels, and 
that elective surgery could be performed safely in patients with a 
preoperative haemoglobin level as low as 6g /dL provided the 
estimated blood loss was less than 500mL. 
7.9.2. Blood products 
During the early 1970s blood transfusion services were developing 
methods for preparing various blood components. The main advance 
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was the use of plastic blood containers which allowed component 
separation to be performed under sterile conditions within closed 
systems. In 1975 in England and Wales 90% of blood issued to 
clinicians consisted of whole blood (Gunson et al, 1986). Red cell 
concentrates (blood prepared by the removal of plasma) are now the 
main type of blood issued. Currently, it is generally recommended 
that red cell concentrates are the product of choice to treat 
patients with blood loss not exceeding 20 -30 %. Thus, two or three 
units of red cell concentrate are given with crystalloid solution to 
make up volume. For patients with loss of blood volume exceeding 
20 -30% further volume replacement is made with whole blood which 
contains coagulation factors. 
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7.10. AUTOLOGOUS TRANSFUSION 
In patients undergoing surgery the main purpose of blood transfusion 
is to replace blood lost during the operation. Transfusion with 
autologous blood is an alternative to homolgous blood. Autologous 
blood may be withrawn from the patient preoperatively, or it may be 
transfused as it is shed. 
One of the earliest examples of autotransfusion was described by 
Duncan in 1886. He reported a case of lower limb trauma as a result 
of a railway injury. The injured leg required amputation. However, 
a large amount of blood was lost during the patient's transfer from 
Kirkcaldy to the Royal Infirmary of Edinburgh. The patient 
displayed the clinical signs of hypovolaemic shock; "he was pallid 
and collapsed, with a pulse, when perceptible, quick, irregular and 
fluttering ". Alcohol, ether injection, and elevation of the limbs 
failed to alleviate the situation. Intravenous injection of blood 
was indicated. Apparently, blood donors were readily obtainable in 
this large teaching hospital during the day, but not at night. 
During the subsequent amputation, blood was caught in a dish 
containing a solution of phosphate of soda. This was injected into 
the femoral vein of the stump. The patient recovered. 
Apparently, intraoperative autotransfusion was not accepted into 
clinical practice until 1921 when its use in a patient with a 
cerebellar tumour was reported (Grant, 1921). 
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7.10.1. Intraoperative autotransfusion 
More recent attempts at intraoperative autotransfusion have met with 
problems including haemolysis, coagulopathy, emboli, renal failure 
and pulmonary problems (McShane et al, 1987). There have also been 
problems associated with the collection and washing of red cells 
collected during surgery. There are now specifically designed 
devices which surmount these problems. 
McShane et al (1987) described one such device which was used with 
patients undergoing cardiac surgery involving cardiopulmonary 
bypass. The quality of blood salvaged at operation was compared with 
that of homologous donor blood. The saved blood had a higher 
haemoglobin concentration, a higher white cell count, a higher pH 
and a more physiological concentration of potassium than donated 
blood. This device produced good quality red blood cells of benefit 
to the patients. However, the saved blood had a high white cell 
count consisting almost entirely of neutrophils of which three 
quarters were damaged. It was suggested that these damaged white 
cells may release enzymes and contribute to the severity of adult 
respiratory distress syndrome in which leukocytes are thought to 
have an etiological role. The authors indicated that additional 
washing and centrifugation of collected blood might reduce this 
potential hazard. 
In cancer patients intraoperative autotransfusion could have the 
risk of disseminating tumour cells. Klimberg, et al, (1986) 
reported a series of patients undergoing open surgery for kidney, 
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bladder and prostate tumours. Only five of these patients 
subsequently developed metastatic disease and this was thought to be 
a low incidence for these types of patients. These findings do not 
support the theory that intraoperative autotransfusion increases the 
risk of tumour dissemination. However, there are now specially 
designed filtering devices which can remove large cells including 
leukocytes and tumour cells from the blood prior to transfusion back 
into the patient. 
Autologous blood deposit was described in a series of 235 cancer 
patients (Lichtiger et al, 1990). These patients underwent a 
variety of operations for a number of cancers (gastrointestinal, 
adrenal, genitourinary, bone and other sarcomas). Autologous blood 
was given to 77% of these patients without apparent sequelae. 
Intraoperative autotransfusion is feasible in cancer patients, but 
perhaps patients undergoing surgery for bowel cancer would be at 
risk of dissemination of peritoneal bacteria. In elective colonic 
resection this risk is presumably low until the bowel is divided. 
However, in emergency colonic surgery the risk of peritoneal 
contamination will be higher and probably prohibitive. In elective 
cases there is an opportunity to withdraw autologous blood 
preoperatively and the need for intraoperative retrieval of blood 
will be minimal. This is not the case in emergency surgery and so 
intraoperative autotransfusion will probably have little to do with 
colonic surgery in the future. 
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7.10.2. Autologous transfusion for elective surgery 
Where elective surgery is planned in advance, the patient may attend 
the hospital two to three weeks prior to the proposed date of their 
operation. At this point one unit (500 ml) of blood is removed by 
venesection and stored in a conventional blood bank. A second unit 
of blood may be removed prior to surgery. Such a regime would 
clearly reduce the need for donated blood. 
Nicholls et al (1986) reported a large study of autotransfusion in 
336 patients. Most of these patients were undergoing orthopaedic 
and vascular surgery. The mean age for men in this group was 65 
years and 63 years for women. In the larger group of men, the 
haemaoglobin concentration fell by 1.2 g /dl to 14.1 g /dl after 
donation of one unit of blood and to 13.3 g /dl after two units. 
After venesection supplemental iron was given to encourage a brisk 
reticulocytosis. Patients in this programme were excluded if they 
were older than 75 years or if they were considered anaemic 
(haemoglobin less than 14 g /dl in men, and less than 13 g /dl in 
women). 
The amount of blood not transfused seemed to depend on the operation 
performed. For patients having a total hip replacement and patients 
having a repair of abdominal aortic aneurysm, virtually all of the 
precollected blood was used. In lower limb vascular reconstruction 
only about 10% of autologous blood was used. A similar scheme for 
patients undergoing joint replacement was reported by James and 
Smith (1987). 
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This method of autologous transfusion could be applied to colorectal 
cancer patients. However, one would have to lower the haemoglobin 
level at which patients were excluded. In the retrospective study 
reported in this thesis, colorectal cancer patients who actually 
received a blood transfusion had a preoperative haemoglobin of 
around 12 g /dl. Preoperative venesection of two units of blood 
would lower the haemoglobin level to around 10 g /dl. At present 
this may not be acceptable to anaesthetists. The second problem 
would be the extra two week delay required to gather autologous 
blood. It is probable that the delay could be reduced by including 
blood donation in the lag between decision to operate and subsequent 
admission to hospital. In any case, the risks associated with such 
a delay are probably much less than those detrimental risks which 
are associated with blood transfusion. 
Preoperative venesection is obviously not feasible in patients 
admitted for emergency surgery. This group of patients will 
continue to depend on donated homologous blood. 
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7.11. IMMUNOMODULATION 
At the present time blood transfusion cannot be avoided in certain 
cases. If blood transfusion does cause immunosuppression in cancer 
patients, then is it possible to reverse this effect? Clearly this 
would involve altering the immune response to tumour cells. This 
process has been given the term of imrnunomodulation or 
immunotherapy. 
Immunotherapy for cancer patients is not a new idea and the history 
of immunotherapy has been well reviewed by Priestman (1982). Cole 
and Humphrey (1985) recognised that immunosuppression is produced by 
major cancer operations and that this type of patient requires 
immunological help. They reviewed work that had been carried out in 
this field. However, this work probably did not take into account 
the more recent possibility of transfusion induced 
immunosuppression, but it is clear that generally increased 
immunosuppression in cancer patients correlates with an increasingly 
poor prognosis. Various nonspecific immune stimulators, such as BCG 
and Corynebacterium parvum, have in some trials seem to produce a 
small advantage for the cancer patient, but other studies have been 
less convincing. 
Levamisole was one of the more promising agents (Amery et al, 1977), 
but this drug has untoward side effects. Windle et al (1987) found 
that a short postoperative course of levamisole together with a 
longer course of 5- fluoruracil reduced recurrence rates in patients 
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with colorectal cancer. This particular trial was stopped at an 
early staged because the early results suggested a possible 
detrimental effect on survival due to levamisole, although final 
analysis did not confirm this. 
Trauma, shock, sepsis, and blood transfusion are usually associated 
with a degree of immunosuppression. The mechanisms remain unclear, 
but much attention is currently being directed at the ability of the 
macrophage to cause suppression of cell- mediated immunity locally by 
increased synthesis of arachidon is acid metabolites (particularly 
prostaglandin E2). It has been debated whether, or not, it is safe 
to commence clinical trials with prostaglandin synthetase inhibitors 
to attempt to reverse these changes. Of these drugs indomethacin 
would appear to be the safest. One compelling argument against the 
introduction of this therapy is that we do not know what happens if 
prostaglandin synthesis is stopped completely. The beneficial 
effect may only be gained with relatively low doses of indomethacin 
and moderate doses may toxic in subjects with severe injury. In 
animals there is some unpublished evidence that splenomegaly results 
after treatment with indomethacin and this may represent a state of 
over stimulation. 
However, indomethacin has been used clinically in the past. Panje 
(1981) reported seven cases of patients with head and neck cancer 
which demonstrated that indomethacin taken in standard dosages 
caused regression and stabilization of the disease. In patients who 
had received radiotherapy for head and neck cancer, it has been 
found that indomethacin enhanced lymphoblast transformation in 
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response to antigen (Maca et al, 1982). 
Recent advances such as monoclonal antibodies, gene cloning, and 
cell cloning in relation to tumour immunology have been reviewed by 
Balch (1986). It is envisaged that these techniques will allow the 
complex immune mechanisms to be elucidated. Clinical trials 
involving specific rather than general immunomodulation will 
probably evolve in the years to come. 
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7.12. FUTURE RESEARCH 
Experimental 
The experimental research described in this thesis raises several 
questions. Older rats seem to be susceptible to immunomodulation as 
a result of blood transfusion whereas younger rats are not. The 
influence of age needs to be studied further using other indicators 
of immune function as the true significance of peripheral lymphocyte 
population changes remains unclear. 
The carcinogenesis model described will be useful, but it requires 
independent validation and must involve larger numbers of animals to 
confirm the abrogation of the transfusion effect with indomethacin. 
Blood transfusion- induced immunosuppression acting via a 
macrophage /prostaglandin pathway is emerging as one of the possible 
explanations of the detrimental effects associated with transfusion 
in cancer patients. If this mechanism is responsible and it can be 
reversed using prostaglandin synthetase inhibitors such as 
indomethacin, then clinical trials will ensue. Before this can 
happen the influence of prostaglandin synthetase inhibitors on other 




To clarify the immunological effects of blood transfusion in 
patients undergoing resection of colorectal cancer two types of 
studies should be undertaken. 
Firstly, the immune function must be studied during the 
perioperative period and secondly, the influence of transfusion on 
the survival of patients after curative surgery should be 
determined. 
In both studies randomisation will produce two groups of patients 
which are similar when the known major prognostic variables such as 
age, sex, site and stage of the tumour, are compared. One of these 
groups will receive blood transfusion according to standard practice 
and this transfusion will probably consist of whole blood and red 
cell concentrates. The second group must receive some form of blood 
volume replacement. 
If blood volume replacement consists of plasma expander, then 
ethical considerations arise. Ethical committees will have to 
decide whether or not it is safe to correct significant blood loss 
without transfusing blood. If such a regime is considered to be 
safe, then it is conceivable that valid objections may be raised to 
the "unnecessary" transfusion of patients and exposing them to the 
many known hazards of blood transfusion such as transmission of 
viral infection. For similar reasons it may be difficult to 
recruit patients to such a trial. Furthermore, increased awareness 
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amongst medical staff involved in the trial may result in a more 
conservative transfusion practice which will diminish the number of 
patients who actually receive blood. Lastly, this type of trial 
will produce three groups of patients: one group will receive no 
blood, the second group would receive an amount of blood (say one to 
three units) or a similar volume of plasma expander, and the third 
group would consist of patients who received four or more units of 
blood and patients who were initially randomised to receive plasma 
expander, but who required subsequent transfusion with blood. 
Clearly, the second group of patients would contain two subsets with 
similar tumours which could be compared. The third group which 
required relatively large transfusions could not be included in the 
survivorship studies. Blood volume replacement could also consist 
of autologous blood, but the numerical problems would still apply. 
The alternative trial would compare two transfusion regimes. The 
first would consist of conventional blood while the second would 
consist of washed and filtered blood. This latter process would 
remove the antigen bearing components of blood: the white blood 
cells and the platelets. The two blood products could be randomised 
before delivery to the ward or operating theatre. Thus, medical 
staff would be truly blind as to which blood product was being 
given. The third group in the previous trial could then be included 
in the survivorship studies. This would reduce the number of 
patients required to achieve a statistically significant result. 
The disadvantages of this trial include the financial and logistic 
implications for the blood transfusion services. However, 
widespread adoption of pretransplant transfusion for renal 
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transplant patients was based on retrospective and experimental 
studies and not on randomised, prospective clinical trials. 
Similarly, there may be a demand for blood free of 
histocompatability antigen and in the long -term it would be in the 
interests of the blood transfusion services to invest in trials in 




This thesis presents clinical evidence which suggests that blood 
transfusion is associated with decreased survival in patients with 
colorectal cancer. However, blood transfusion possibly represents 
an index of disease severity and current multicentre prospective 
studies will hopefully address this problem. 
In the Sprague Dawley rat, allogeneic blood transfusion was not 
associated with changes in peripheral T lymphocyte subsets in normal 
young rats. In older rats blood transfusion resulted in an increase 
in the proportion of OX 8 T lymphocytes. This suggests that older 
subjects may be more susceptible to the immunomodulatory effects of 
blood transfusion, although it is emphasised that this work did not 
include functional assays T subsets. 
Allogeneic blood transfusion enhanced colonic carcinogenesis in rats 
and treatment with indomethacin during the period of transfusion may 
reverse this effect. 
Rat peritoneal macrophage prostaglandin E2 was increased by blood 
transfusion and this appeared to be related to storage conditions of 
blood and was seen in both syngeneic and allogeneic blood in 
addition to genetic factors. Although prostaglandin E2 has been 
shown to have many immunosuppressive effects, one can only guess the 
role it plays in transfusion- mediated immunosuppression. It must be 
established what effects blood transfusion has on other macrophage 
products, eg: tumour necrosis factor, superoxide and interleukin 1. 
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On reviewing the many retrospective studies it was found that many 
did not control for variables related to blood transfusion which 
could affect disease recurrence (blood loss, duration of anaesthesia 
and surgery in particular). Overall, there is little agreement 
regarding the significance of blood transfusion in patients with 
colorectal cancer. Therefore, on the basis of these retrospective 
studies, one cannot recommend changes in transfusion practice. 
However, there is now increasing prospective clinical evidence to 
suggest that blood transfusion may indeed have an immunosuppressive 
effect in cancer patients. 
Autologous blood transfusion appears to be safe in cancer patients 
and stricter transfusion regimes may reduce the number of patients 
who receive allogeneic blood. The role of erythropoietin is yet to 
be established. There will remain a proportion of patients who will 
continue to require allogeneic transfusion either because they 
present as an emergency, or because haemorrhage is severe. Blood 
products containing large amounts of plasma may have the strongest 
immunosuppressive effects. 
Pharmacological immunomodulation, possibly using prostaglandin 
synthetase inhibitors, may be required to abrogate the detrimental 
effects of blood transfusion on the immune response. 
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Blood transfusion (BT) may cause immunosuppression which could have a detrimental effect in cancer 
patients. Previous experimental cancer models have used transplanted tumour cells rather than an autocht- 
honous tumour model. The aim of this research was to assess the effects of allogeneic blood transfusion 
on chemically induced colonic carcinogenesis in rats. At 28 weeks after commencing carcinogenesis with 
dimethylhydrazine rats transfused with allogeneic blood (n = 26) had a mean of 6.0 (SD = 2.7) macros- 
copic tumours per rat and rats transfused with NaCI (n = 23) had a mean of 4.1 (SD = 2.7) tumours per 
rat; p = 0.02. Some of these tumours arose in close proximity and converged, making it impossible to state 
that they were truly separate tumours. It is suggested that a lower dose of dimethylhydrazine is used to 
reduce the extent of cancer and that large numbers of rats may be required to achieve more highly 
significant results. 
KEY WORDS: Colon cancer, carcinogenesis, blood transfusion, T lymphocytes. 
INTRODUCTION 
Blood transfusion (BT) may cause immunosuppression which could have a detriment- 
al effect in burns and cancer patients.' Previous experimental cancer models have used 
transplanted tumour cells rather than an autochthonous tumour model. The aim of 
this research was to assess the effects of allogeneic blood transfusion on chemically 
induced colonic carcinogenesis in rats. 
MATERIALS AND METHODS 
Carcinogenesis 
The DMH was prepared in a concentration of 10mg /ml in 1 litre of 0.9% NaCl. To 
this was added 15 g of ethylene -diaminotetracetate (EDTA). This was done to prevent 
dehydrogenation which occurs rapidly in the presence of trace metals. The pH of the 
solution was brought to pH 7.0 with 1 M Na2CO3. 
Male Sprague Dawley rats were used throughout the experiments. They were fed 
on a standard pellet diet and tap water ad libitum. A group of 62 ten week old rats 
were given 16 weekly injections of dimethylhydrazine (DMH) at a dose of 16mg /kg.2 
After the eighth injection rats were transfused with either allogeneic blood or NaCl. 
'Correspondence to: Mr William B Ross, General Surgical Unit Il, D Block, Western General Hospital, 
Edinburgh EH4 2XU. 
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These rats were killed at 28 weeks and tumour development assessed. A further group 
of 22 rats also treated with DMH were killed at 36 weeks. A third group of 29 rats 
were not treated with DMH and these were randomised at eight weeks to receive 
transfusions of blood or NaCl. 
Assessment of Carcinogenesis 
The rats were killed at the appropriate time by ether anaesthesia. The animals were 
weighed and inspected for external signs of pathology. The most obvious signs were 
related to the development of tumours of the external auditory canal. A careful search 
was made of the visceral and parietal peritoneum for metastatic deposits. The small 
bowel was removed whole and placed in 0.9% NaCI. The liver and lungs were 
removed and weighed and sliced in sections to look for hepatic metastases. The large 
bowel was opened longitudinally and faecal material was washed off with fresh saline. 
The length of large bowel, which measured about 30 cm, was placed on a metal rule. 
The length was noted. The position and diameters of each macroscopic tumour were 
noted. Many tumours were related to the lymphoid patch found in the wall of the 
rectum and diagrams were made of these tumours. The diameters were measured 
using calipers. Magnification was obtained using a 1.5 binocular loupe. The large 
bowel was then wrapped like a swiss roll on a wooden rod and placed in 10% formalin 
(phosphate buffered) solution. Histological slides were prepared and stained with 
haematoxylin and eosin. The tumours were assessed and graded by an independent 
pathologist. 
T Lymphocyte Subset Analysis 
Animals were anaesthetised with ether and blood withdrawn from the tail vein. 
Ficoll -Hypaque density gradient columns were used to separate the lymphocytes. The 
interface between the Ficoll Hypaque and plasma contains monocytes and lym- 
phocytes and this interface was removed. These cells were washed twice in fresh RPMI 
and the cells suspended at 4 x 106 /ml. A portion of the isolated cells was used to 
prepare a slide for differential analysis, using a centrifuge to assess the purity of the 
lymphocyte preparation. Four samples were then prepared. In one of these tubes was 
placed 2 ml of PBS/ 10% fetal calf serum (FCS) to which 400 u] of the cell suspension 
were added. The tube was centrifuged at 1500 rpm for 10 minutes at 4 °C. The 
supernatant was discarded and 40Oµ] of PBS /10% FCS was added to the cell pellet. 
The cells were resuspended and 100 µl of this suspension were transferred into each 
of the three remaining test tubes which contained the monoclonal antibodies. The 
monoclonal antibodies used were: W3/13 for total T lymphocytes, W3/25 for helper 
T lymphocytes and OX8 for suppressor /cytotoxic lymphocytes.' 
The cells were then incubated with fluorescein isothiocyanate conjugated anti 
mouse IgG. Flow cytometric analysis was used to analyse the T lymphocyte subsets. 
The Becton Dickinson FACS 440 was used. For each sample of labelled cells the 
machine counted 5000 lymphocytes. It counted the number of these cells which 
fluoresced, therefore the proportion of labelled cells could be calculated. 
Blood Transfusion 
Male DA rats were used as blood donors throughout the series of experiments. These 
rats were normal and had not been used in previous experiments and had not 
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previously been used as blood donors. The donor animals were anaesthetised with 
ether and the thorax swabbed with chlorhexidine solution. Blood was withdrawn by 
cardiac puncture into a syringe containing a small amount of heparin to prevent the 
blood clotting. The concentration of heparin used was about 30 units/ml. This blood 
was transfused to the recipients within one hour. The recipient rats were anaesthetised 
lightly with ether. The volume injected was 1.5 ml in all cases. Three attempts were 
made to enter the tail vein and if venepuncture was unsuccessful a cut -down was 
performed on the jugular vein. 
Statistics 
The results of the T lymphocyte subset analysis are the mean (standard deviation) of 
fluorescent cells expressed as the proportion of the total cells counted (5000). The 
paired t -test formula was used to compare the differences between the mean propor- 
tions. 
RESULTS 
Allogeneic blood transfusion (compared with NaCI transfusion) did not alter T 
lymphocyte subsets either at one week or at 18 weeks after transfusion (Tables 1 and 
TABLE I 
Effect of allogeneic blood or NaCI transfusion on T lymphocytes subsets in 6- week -old rats which have 
been treated with dimethylhydrazine - paired data 
Monoclonal antibody 
A. Blood 
pre- transfusion, n = 
post- transfusion 
p value: t test 
B. NaC1 
pre -transfusion. n = 
post -transfusion 
p value: t test 0.12 0.024 0.69 
mean % cells labelled (SD) 



















Comparison of peripheral blood lymphocytes at 30 weeks 
Monoclonal antibody Mean % cells labelled (SD) 
W3 13 W3/25 OX8 
Transfusion group 
A. DMH- treated rats 
blood, n = 26 
saline, n = 23 
p value: t test 
B. untreated rats 
blood, n = 6 
saline, n = 9 
p value: t test 
66.3 (11.0) 34.9 (9.4) 





63.7 (8.1) 30.7 (11.5) 37.3 (6.3) 
71.6 (14.4) 25.0 (5.8) 40.1 (12.4) 
0.26 0.23 0.62 
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II). None of untreated rats developed tumours. All rats treated with DMH had 
developed colonic malignancy and some developed ear and small bowel tumours 
(Table III). The second set of 22 rats treated with dimethylhydrazine and had identical 
transfusions to the first and second sets. This third group was killed at 34 weeks. By 
this time 2'11 rats transfused with blood had died due to malignancy and 4/11 rats 
transfused with 0.9% saline had died due to malignancy. 
At 28 weeks rats transfused with blood (n = 26) had a mean of 6.0 (SD = 2.7) 
macroscopic tumours per rat and rats transfused with NaCl (n = 23) had a mean of 
4.1 (SD = 2.7) tumours per rat; p = 0.02. The specimens were analysed by an 
independent pathologist and histological features noted (Table IV). In some adjacent 
tumours, it was not possible to identify them as histologically separate. The second 
group of DMH- treated rats given BT (n = 9) and rats given NaCI (n = 7) killed at 
36 weeks had advanced malignancy, but had similar numbers of bowel tumours; 9.0 
(SD = 4.8) versus 10.6 (SD = 2.9): p = 0.5. 
DISCUSSION 
There are now several retrospective clinical studies which suggest that in patients with 
colorectal cancer, the receipt of perioperative blood transfusion is associated with a 
poorer prognosis. Other studies fail to demonstrate a statistically significant result, 
but present a clear trend which clearly suggests that transfused patients fare less well. 
These studies have been reviewed.' It is possible that transfused patients lost more 
blood because of the severity of their malignant disease, despite having, sanguinely, 
TABLE III 
Dimethylhydrazine carcinogenesis in Sprague Dawley rats transfused with allogeneic blood or 0.9% saline. 
comparison of macroscopic tumour distribution 
blood saline p* 
tumour 
colonic 26'26 23/23 NS 
small bowel 3/26 7/23 NS 
metastatic 7126 7/23 NS 
ear 5;'26 5'23 NS 
*chi squared test. 
TABLE IV 
Dimethylhydrazine carcinogenesis in Sprague Dawley rats transfused with allogeneic blood or 0.9% saline, 
comparison of histopathologic features 
Transfusion: 
adenoma: n, % 












30, 27% 23, 29% N.S. 
79, 73% 55, 71% N.S. 
14, 17% 12. 22% N.S. 
39, 51% 28, 51% N.S. 
26, 32% 15, 27% N.S. 
54, 70% 32, 58% N.S. 
39, 49% 24, 44% N.S. 
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had a curative, though sanguinous, resection. This conundrum will only be solved by 
the multicentre clinical trials which are now underway. 
Experimental work on the effects of blood transfusion on tumour behaviour yields 
conflicting conclusions. In 1954, George Davies Snell reported that pretreatment with 
some tissue preparations could produce tolerance of tumour transplants in host mice. 
This effect could be produced by allogeneic blood transfusion in a sarcoma transplant 
model.' However, since then various groups have used other animal models to test 
the effect of blood transfusion on tumour growth.' Using an athymic mouse model 
Francis et al. demonstrated that blood transfusion enhance the growth of transplan- 
ted melanoma cells and that this effect depended on the presence of the thymus gland 
and by implication that cell- mediated immunity must be involved in the mechanism.1ó 
A smaller number of studies present conflicting findings which suggest that blood 
transfusion does not enhance tumour growth.1 -19 There are also two studies which 
showed that blood transfusion decreased tumour growth, one of which showed that 
in mice allogeneic blood transfusion before and after inoculation with mammary 
cancer cells prolonged survival.'0" 
All of the studies cited used transplanted tumour cells. We have used an experi- 
mental model which does not involve tumour transplantation. This autochthonous 
cancer model is closer to the human colonic cancer disease, but it has some disadvan- 
tages which could be remedied with modification. We conclude that blood transfusion 
enhances the growth of chemically induced colonic tumours rather than increasing the 
number of tumours produced. This effect does not appear to involve changes in T 
lymphocyte subpopulations in the peripheral blood and we, therefore, question the 
value of this test in assessing blood transfusion immunomodulation. However, this 
model could be used to investigate the modulation of the immunosuppressive effects 
of blood transfusion in colonic cancer. It is suggested that a lower dose of dimethylhy- 
drazine is used to reduce the extent of cancer and that larger numbers of rats may be 
required to achieve more highly significant results. 
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Allogeneic blood transfusion has been associated with suppression of cell- mediated immunity and this 
possible effect may be mediated by increased production of prostaglandins by macrophages. The effect of 
allogeneic blood transfusion on macrophage arachidonic acid metabolite production was studied in the 
Sprague Dawley rat. In this strain of rat we found that blood transfusion did not influence arachidonic acid 
metabolite eicosanoid when compared with rats transfused with saline, although there appeared to be a 
decrease associated with anaesthesia and surgery which may have masked the effects of blood transfusion. 
Furthermore, stimulation of macrophages with calcium ionophore again failed to demonstrate an increased 
prostaglandin production after blood transfusion - an effect which had been observed previously by 
others. These results suggest that the influence of allogeneic blood transfusion on arachidonic acid 
metabolites may be limited to specific strains of animal. 
KEY WORDS: Blood transfusion. prostaglandins. Macrophages. 
INTRODUCTION 
Blood transfusion may cause immunosuppression which could have a detrimental 
effect in burns and cancer patients. We have established a rat model to study the effect 
of allogeneic blood transfusion on the growth of chemically induced colonic tu- 
mours.' The mechanism of this effect remains unclear, but recently attention has 
focused on the theory suggested by Waymack who suggests that immunosuppression 
caused by blood transfusion is mediated by an increase in macrophage prostaglandin 
synthesis.' The aim of our research was to analyse peritoneal macrophage arachidonic 
acid synthesis using both the donor and recipient strains used in the rat colon 
carcinogenesis model. 
MATERIALS AND METHODS 
In Experiment I male Sprague Dawley rats weighing 350 -400 g were divided into two 
groups. Rats in group one (n = 4) were not transfused and rats in group two (n = 5) 
were given a single intravenous transfusion of allogeneic blood. This was fresh 
heparinised whole blood obtained by cardiac puncture from DA rats. A volume of 
Correspondence to: Mr William B. Ross, Wards D5 -7, Western General Hospital, Crewe Road. 
Edinburgh EH4 2XU. 
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1.5 ml was injected into the tail vein of the recipient. In Experiment II rats were 
divided into three groups. Group (n = 4) one were not transfused, Group 2 (n = 5) 
were transfused with 1.5 ml of heparinised 0.9% NaCI, and Group 3 (n = 4) were 
given one intravenous transfusion of allogeneic blood. Eight days after transfusion, 
the peritoneal macrophages were harvested. In Experiment I macrophage prostaglan- 
din E2 synthesis was measured in resting cultured cells. In Experiment II, after 
incubation with various concentrations of the calcium ionophore A23187 (Cambridge 
Bioscience: Cambridge, UK), immunoreactive prostaglandin E2 (PGE2), and 6 -keto- 
prostaglandin F1 alpha, thromboxane B2 (TXB2), and leukotriene C4 concentrations 
were estimated. 
Macrophage harvesting 
Four days after transfusion, the peritoneal cavity of each animal was infused with 
3.4 ml of sterile brain -heart infusate (Oxford Ltd: Basingstoke, UK). The needle was 
introduced into the lower left quadrant of the abdomen in order to minimise the risk 
of perforating the caecum. Eight days after transfusion, the peritoneal macrophages 
were harvested. 
The rats were anaesthetised by the open ether method. The abdomen was shaved 
and the area washed once with 100% ethanol. The skin of the abdominal wall was 
removed by sharp dissection. The peritoneal cavities were lavaged by injecting 10 ml 
of sterile Phosphate Buffered Saline (PBS) pH 7.3, containing 5 mmol ethylene- diami- 
notetracetate (EDTA). The abdomen was greatly massaged for 2 minutes to ensure 
dispersion of the lavage fluid. An incision was made in the flank of the animal on the 
right side. A sterile glass Pasteur pipette was used to collect the peritoneal fluid. 
Approximately 8 ml of fluid was collected each time. 
Preparation of the macrophages for culture 
The peritoneal fluid was centrifuged at 300 g for 10 minutes at 10 °C. The supernatant 
was removed, and the cell pellet resuspended and washed twice in PBS. Contaminat- 
ing red blood cells were lysed hypotonically by adding 2 ml 0.2% NaCI for 1 minute 
followed by 2 ml of 1.6% NaCI for 1 minute. The leukocytes were resuspended in PBS 
to a known volume and the cell number counted using a Coulter Counter (Coulter 
Electronics Ltd: Luton, UK). 
The cells were resuspended in medium 199 with Earle's balanced salt solution, 
EBSS (Flow Laboratories: Herts. UK) supplemented with penicillin /streptomycin 
(Flow Laboratories) L- glutamine (Flow Laboratories) and 7.5% fetal calf serum 
(Flow Laboratories) to a final concentration of 106 cells per ml. 
Macrophage culture 
Two million cells were added to plastic tissue culture plates (Gibco Ltd: Uxbridge, 
UK) and they were incubated at 37 °C in an atmosphere of 5% carbon dioxide for one 
hour. The culture medium was removed and replaced with fresh M -I99. This process 
removed non -adherent cells leaving the adherent macrophages. The macrophage 
suspensions were then cultured for period of 18 hours. The entire medium was then 
removed and frozen at -70 °C prior to assay. 
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Quantization of arachidonic acid metabolites 
Radioimmunoassays (RIA) were employed for measurement of cyclooxygenase 
products PGI2 measured as 6- keto -PGF1 alpha, PGE2 as well as for leukotriene 
LTC4. 100 pl samples of macrophage supernatants, or of synthetic standard; 100 pl 
of specific antibody and 100µl [3H]- eicosanoid (Amersham International: Cardiff, 
UK) were incubated in 3.5 ml polypropylene test tubes (Sarstedt: Leicester, UK) at 
4 °C for 18 hours. The non -protein bound eicosanoids were precipitated by the 
addition of 250µl of dextran (T70, Pharmacia: Uppsala, Sweden) coated charcoal, 
(Norit SX1, BDH Chemicals: Poole, UK), both 1% (w /v) in Tris- Isogel buffer. 
followed by centrifugation at 250 g for 10 minutes, 4 °C. Supernatants were decanted 
and mixed with 3.5 ml of optiphase MP scintillant (LKB Instruments: Poole, UK) and 
the radioactivity measured in a Rakbeta liquid scintillation counter (LKB: Turku. 
Finland). 
The synthetic and measured eicosanoids were detected in the linear portion of the 
radioligand binding curve. Synthetically prepared prostaglandin standards were ob- 
tained from Sigma Ltd: Poole, UK. Leukotriene standard was also synthetically 
prepared and was a kind gift by Dr Brendt Spur. 
Statistics 
The t -test was used to compare the mean metabolite concentrations in the various 
experimental groups. 
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Time Course Experiments of PGE2 Release 
PGE2 was generated by resting cultured peritoneal macrophages in a time dependent 
manner reaching a mean maximum after 19 hours of incubation of 658 + 445pg!l0° 
cells (Figure 1). The release of PGE2 by macrophages from transfused animals 
followed a similar pattern and wasno different in quantitative terms or in comparison 
of the kinetics of generation. 
Arachidonic Acid Metabolism Following Ca lonophore Stimulation 
The results of calcium ionophore stimulation are shown in Figures 2 -5. The results 
show that maximal stimulation of thromboxane B2 and 6 keto prostaglandin F1 
alpha synthesis is reached with a calcium ionophore concentration of 0.5µM, while 
maximal synthesis of prostaglandin E2 and leukotriene C4 is achieved with calcium 
ionophore of 2.5 µM. In all cases increasing calcium ionophore concentration above 
these levels did not increase synthesis. There were no significant differences between 
the three groups when prostaglandin E2 was measured. When thromboxane B2 was 
assayed the synthesis of this was slightly reduced after transfusion with either saline 
or blood, although this did not reach statistical significance. A similar effect was seen 
after maximal stimulation of prostaglandin F1 alpha and leukotriene C4, the latter 
reaching statistical significance at calcium ionophore concentrations greater than 
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FIGURE 2 PGE2 production by stimulated rat peritoneal macrophages in culture. 
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FIGURE 4 Thromboxane B2 production by stimulated rat peritoneal macrophages in culture. 
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FIGURE 5 Leukotriene C4 production by stimulated rat peritoneal macrophages in culture. 
DISCUSSION 
The aim of this series of experiments was to determine the effect of allogeneic blood 
transfusion on macrophage synthesis of arachidonic acid metabolites. 
The experimental design was based on that described by Waymack where the effect 
of transfusions on the production of arachidonic acid metabolites by cultured macro- 
phages was studied.' Using a rat model they demonstrated that allogeneic blood 
transfusions decreased macrophage migration in response to inflammatory stimuli. 
This response was ellicited by injecting brain -heart infusate into the peritoneal cavity. 
Allogeneic blood transfusion was also associated with increased macrophage produc- 
tion of prostaglandin E2. Control groups given infusions of Ringer's lactate solution 
or syngeneic blood yielded more macrophages after peritoneal lavage and these 
harvested macrophages produced less prostaglandin E2 in culture. 
There were some differences in that the blood transfusion in the present series was 
1.5 ml of blood instead of 1 ml and the rat strains differed. The current series used DA 
rats as blood donors and Sprague Dawley rats as recipients. In the Waymack series 
Lewis rats were used as recipients and Buffalo rats or A'Sogaloff Cancer Institute 
(ACI) rats were used as blood donors. Waymack used blood which had been mixed 
with citrate- phosphate- dextrose anticoagulant solution and stored the blood at 4 °C 
for 24 hours prior to transfusion. In the present series fresh heparinised blood was 
used. 
Waymack had cultured the elicited macrophages for a period of 24 hours after the 
first hour prior to removal and replacement of medium. At 24 hours his normal rat 
macrophages produced 740 (SEM = 89) pg PGE per 10' macrophages. This corn- 
pares favourably with the present results: 563 (SD = 584) pg per 106 macrophages. 
It will be seen that there is a marked degree of variation in results as expressed by the 
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large standard deviation. Waymack's series of experiments consisted of relatively 
large numbers of rats to achieve statistical results: the experimental groups contained 
20 animals each. Waymack found a 40% increase in PGE synthesis after transfusion 
with syngeneic Lewis blood, but this did not reach statistical significance. However, 
they were able to demonstrate significant increases after transfusion with allogeneic 
blood. Transfusion with blood from buffalo rats resulted in similar PGE synthesis to 
that found after transfusion with ACI rat blood. This finding does not support the 
suggestion that a variation in results depends on the strain of rat used as donors. 
The current series of experiments did not show any significant differences, or even 
trends, which support the theory proposed by Waymack and his colleagues, i.e. that 
immunosuppression seen following transfusion appears to be related to an increased 
synthesis of prostaglandin E. The reason for this discrepancy may be explained by the 
variation in experimental techniques (in particular by the use of fresh blood instead 
of stored blood). Future investigation may explore the possibility that changes in 
donated blood arising as a consequence of storage may account for its effect on the 
recipient's immune system. 
Both Experiment I and those conducted by Waymack et al. measured arachidonic 
acid metabolites of macrophages at a baseline state of activation. The levels reported 
in both series are well below those found in inflammatory situations. 
The aim of Experiment II was to assess the response of macrophages to stimulation 
with calcium ionophore and to determine any differences between normal untreated 
rats and rats transfused with either allogeneic blood or saline. The results show that 
the levels of arachidonic acid metabolites were lower if rats had been transfused with 
either NaCl or blood. This was particularly striking with leukotriene C4. This is 
difficult to explain, but the transfused rats underwent one additional anaesthetic with 
ether and a venepuncture to administer the transfusion. This suggests that macro- 
phage synthesis of these metabolites is less readily stimulated in rats subjected to 
surgical trauma and repeated anaesthesia. In this situation, stimulation of prostaglan- 
din F1 alpha and leukotriene C4 was least in the macrophages of rats transfused with 
saline. Reduced leukotriene prodcution is thought to impair host defence mechanisms 
and increase the risk of bacterial infections. 
Relatively small numbers of rats were included in the various experimental groups 
and it is suggested that future research will be required to verify these findings. 
The macrophage is now known to have a key role in the regulation of cell- mediated 
immunity. Some of these effects are mediated by arachidonic acid metabolites secreted 
by the macrophage and this cell may play a central role in the immunosuppressive 
response to blood transfusion. 
In conclusion, our experiments have failed to support the theory that allogeneic 
blood transfusion is associated with an increase of prostaglandin production by 
peritoneal macrophages in the rat. However, we have demonstrated that prostaglan- 
din production by stimulated macrophages in this experimental model is influenced 
by operative trauma and/or ether anaeshtesia. 
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